(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/026968 A2

(51) International Patent Classification[7]: C12N 15/11

(21) International Application Number: PCT/CA01/01379

(22) International Filing Date:
27 September 2001 (27.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/672,717 28 September 2000 (28.09.2000) US

(71) Applicants: **UNIVERSITY OF OTTAWA** [CA/CA]; Suite 2213, 451 Smyth Road, Ottawa, Ontario K1H 8M5 (CA). **AEGERA THERAPEUTICS, INC.** [CA/CA]; 810 Chemin du Golf, Verdun, Quebec H3E 1A8 (CA).

(72) Inventors: **KORNELUK, Robert, G.**; 1901 Tweed Avenue, Ottawa, Ontario K1G 2L8 (CA). **LACASSE, Eric**; 1727 Featherston Drive, Ottawa, Ontario K1H 6P3 (CA). **BAIRD, Stephen**; 20 Julian Avenue, Ottawa, Ontario K1Y 0S5 (CA). **HOLCIK, Martin**; Apartment 9, 210 Stewart Street, Ottawa, Ontario K1N 6K2 (CA). **YOUNG, Sean**; 1903 West 14th Avenue, Vancouver, British Columbia V6J 2K1 (CA).

(74) Agents: **ROBINSON, J., Christopher** et al.; Smart & Biggar, Box 11560, Suite 2200, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *without international search report and to be republished upon receipt of that report*

(48) Date of publication of this corrected version:
15 August 2002

(15) Information about Correction:
see PCT Gazette No. 33/2002 of 15 August 2002, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/026968 A2

(54) Title: ANTISENSE IAP NUCLEIC ACIDS AND USES THEREOF

(57) Abstract: The present invention feature antisense IAP nucleic acids and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

# ANTISENSE IAP NUCLEIC ACIDS AND USES THEREOF

## Field of the Invention

The invention relates to antisense IAP nucleic acids and methods of using them to increase apoptosis.

## Background of the Invention

One way by which cells die is referred to as apoptosis, or programmed cell death. Apoptosis often occurs as a normal part of the development and maintenance of healthy tissues. The process may occur so rapidly that it is difficult to detect.

The apoptosis pathway is now known to play a critical role in embryonic development, viral pathogenesis, cancer, autoimmune disorders, and neurodegenerative diseases, as well as other events. The failure of an apoptotic response has been implicated in the development of cancer, autoimmune disorders, such as lupus erythematosis and multiple sclerosis, and in viral infections, including those associated with herpes virus, poxvirus, and adenovirus.

Baculoviruses encode proteins that are termed inhibitors of apoptosis (IAPs) because they inhibit the apoptosis that would otherwise occur when insect cells are infected by the virus. These proteins are thought to work in a manner that is independent of other viral proteins. The baculovirus IAP genes include sequences encoding a ring zinc finger-like motif (RZF), which is presumed to be directly involved in DNA binding, and two N-terminal domains that consist of a 70 amino acid repeat motif termed a BIR domain (Baculovirus IAP Repeat).

The role of apoptosis in cancer has only recently been appreciated. The identification of growth promoting "oncogenes" in the late 1970's gave rise to an almost universal focus on cellular proliferation that dominated research in cancer biology for many years. Long-standing dogma held that anti-cancer therapies preferentially targeted rapidly dividing cancer cells relative to "normal" cells. This explanation was not entirely satisfactory, since some slow growing tumors are easily treated, while many rapidly dividing tumor types are extremely resistant to anti-cancer therapies. Progress in the cancer field has now led to a new paradigm in cancer biology wherein neoplasia is viewed as a failure to execute normal pathways of programmed cell death. Normal cells receive continuous feedback from their neighbors through various growth factors, and commit "suicide" if removed from this context. Cancer cells somehow ignore these commands and continue inappropriate proliferation. Cancer therapies, including radiation and many chemotherapies, have traditionally been viewed as causing overwhelming cellular injury. New evidence suggests that cancer therapies actually work by triggering apoptosis.

Both normal cell types and cancer cell types display a wide range of susceptibility to apoptotic triggers, although the determinants of this resistance are only now under investigation. Many normal cell types undergo temporary growth arrest in response to a sub-lethal dose of radiation or cytotoxic chemical, while cancer cells in the vicinity undergo apoptosis. This provides the crucial treatment "window" of appropriate toxicity that allows successful anti-cancer therapy. It is therefore not surprising that resistance of tumor cells to apoptosis is emerging as a major category of cancer treatment failure.

Compared to the numerous growth-promoting oncogenes identified to date (>100), relatively few genes have been isolated that regulate

apoptosis. The Bcl-2 gene was first identified as an oncogene associated with the development of follicular lymphomas. In contrast to all other oncogenes identified to date, Bcl-2 displays no ability to promote cell proliferation, and instead has been demonstrated to suppress apoptosis by a variety of triggers. Elevated Bcl-2 expression is associated with a poor prognosis in neuroblastoma, prostate and colon cancer, and can result in a multidrug resistant phenotype *in vitro*. Although the study of Bcl-2 has helped revolutionize cancer paradigms, the vast majority of human malignancies do not demonstrate aberrant Bcl-2 expression.

In contrast to the findings with Bcl-2, mutation of the p53 tumor suppresser gene has been estimated to occur in up to 50% of human cancers and is the most frequent genetic change associated with cancer to date. The p53 protein plays a crucial role in surveying the genome for DNA damage. The cell type and degree of damage determines whether the cell will undergo growth arrest and repair, or initiate apoptosis. Mutations in p53 interfere with this activity, rendering the cell resistant to apoptosis by a wide range of cellular insults. Some progress has been made in understanding the molecular biology of p53, but many questions remain. p53 is known to function as a transcription factor, with the ability to positively or negatively regulate the expression of a variety of genes involved in cell cycle control, DNA repair, and apoptosis (including the anti-apoptotic Bcl-2 gene described above and the related pro-apoptotic gene Bax). The drug resistant phenotype conferred by p53 alterations has been linked to Bcl-2/Bax regulation, but this correlation does not hold for most cancer types, leaving open the possibility that other critical genes regulated by p53 remain to be identified.

## Summary of the Invention

We have discovered that inhibitor of apoptosis (IAP) protein overexpression is associated with a wide range of cancer types including ovarian cancer, adenocarcinoma, lymphoma, and pancreatic cancer. In addition, we have found that nuclear localization, fragmentation of the IAPs, and overexpression of the IAPs in the presence of p53 mutations correlate with a cancer diagnosis, a poor prognosis, and resistance to numerous chemotherapeutic cancer drugs. These discoveries provide diagnostic, prognostic, and therapeutic compounds and methods for the detection and treatment of proliferative diseases. One way in which the expression of an IAP in a cell can be decreased is by administering to the cell a negative regulator of the IAP apoptotic pathway, for example, an antisense nucleic acid.

In general, the invention features methods and reagents useful for inducing apoptosis in a cell. The methods and reagents of the invention are useful in treating cancers, and other proliferative diseases.

In a first aspect, the invention features an inhibitor of apoptosis (IAP) antisense nucleic acid that inhibits IAP biological activity, regardless of the length of the antisense nucleic acid. In preferred embodiments, the IAP is XIAP, HIAP1, or HIAP2. In other preferred embodiments, the antisense nucleic acid is mammalian, for example, mouse or human. In yet another embodiment, the antisense nucleic acid is between 8 and 30 nucleotides in length.

In still other further preferred embodiments, the XIAP antisense is chosen from any one of SEQ ID NOS: 1 through 96, and the HIAP1 antisense is chosen from any one of SEQ ID NOS: 97 through 194. Preferably the IAP biological activity is inhibition of apoptosis or inhibition of IAP RNA or polypeptide expression. The antisense nucleic acid may comprise at least one modified internucleoside linkage.

Preferably the modified internucleoside linkage is a phosphorothioate, a methylphosphonate, a phosphotriester, a phosphorodithioate, or a phosphoselenate linkage. In addition, the antisense nucleic acid may comprise at least one modified sugar moiety. Preferably this modified sugar moiety is a 2'-O methoxyethyl group or a 2'-O methyl group. In still another preferred embodiment, the antisense nucleic acid is a chimeric nucleic acid. Preferably the chimeric nucleic acid comprises DNA residues linked together by phosphorothioate linkages, and the DNA residues are flanked on each side by at least one 2'-O methyl RNA residue linked together by a phosphorothioate linkage. More preferably the DNA residues are flanked on each side by at least three 2'-O methyl RNA residues. In yet another embodiment, the antisense nucleic acid is a ribozyme.

In a second aspect, the invention features a method of enhancing apoptosis in a cell, involving administering to the cell a negative regulator of the IAP-dependent antiapoptotic pathway. In preferred embodiments the negative regulator is an antisense IAP nucleic acid, an antibody that specifically binds an IAP polypeptide, an IAP polypeptide comprising a ring zinc finger, said polypeptide having no more than two BIR domains, a nucleic acid encoding the ring zinc finger domain of an IAP polypeptide, or a compound that prevents cleavage of the IAP polypeptide.

In preferred embodiments of the second aspect of the invention, the cell is in a mammal diagnosed with a proliferative disease, for example, cancer. The cell may comprises a mucosa-associated lymphoid tissue (MALT), a tissue in which the IAP gene HIAP1 is frequently involved in a translocation, resulting in marginal zone cell lymphomas. The cell may also be a breast cancer cell, where increased HIAP1 expression is known to correlate with tumor progression. The cell may also be a cell in which NFkB expression or activity is increased, for example, cell of head and

neck carcinomas, adult T-cell lymphomas, nasopharyngeal carcinomas, and Hodgkin's disease. The cell may also be an acute myelogenous leukemia cell, where increased XIAP levels correlate with poor patient prognosis. In addition, the cell may be a small cell lung carcinoma cell, where increased levels of XIAP correlates with increased resistance to radiation treatment.

In preferred embodiments of the second aspect of the invention, the IAP is XIAP, HIAP1, or HIAP2. Preferably the antisense nucleic acid is mammalian, for example, mouse or human. In still other preferred embodiments, the XIAP antisense is chosen from any one of SEQ ID NOS: 1 through 96, and the HIAP1 antisense is chosen from any one of SEQ ID NOS: 97 through 194.

In still other embodiments of the second aspect of the invention, the antisense nucleic acid comprises at least one modified internucleoside linkage. Preferably the modified internucleoside linkage is a phosphorothioate, a methylphosphonate, a phosphotriester, a phosphorodithioate, or a phosphoselenate linkage. In addition, the antisense nucleic acid may comprise at least one modified sugar moiety. Preferably this modified sugar moiety is a 2'-O methoxyethyl group or a 2'-O methyl group. In still another preferred embodiment, the antisense nucleic acid is a chimeric nucleic acid. Preferably the chimeric nucleic acid comprises DNA residues linked together by phosphorothioate linkages, and the DNA residues are flanked on each side by at least one 2'-O methyl RNA residue linked together by a phosphorothioate linkage. More preferably the DNA residues are flanked on each side by at least three 2'-O methyl RNA residues. In still further embodiments, administration of the antisense nucleic acid sensitizes the cell to chemotherapy or radiotherapy. In addition, the cell may be *in vitro* or *in vivo*.

In a third aspect, the invention features a pharmaceutical composition comprising a mammalian IAP antisense nucleic acid. In one preferred embodiment, the mammalian antisense IAP nucleic acid is a human antisense nucleic acid. Preferably the antisense nucleic acid binds a target sequence of the human XIAP gene or mRNA, the human HIAP1 gene or mRNA, the human HIAP2 gene or mRNA, the murine XIAP gene or mRNA, the murine HIAP1 gene or mRNA, or the murine HIAP2 gene or mRNA. More preferably the composition comprises an antisense nucleic acid chosen from any one of SEQ ID NOS: 1 through 96 (XIAP) or SEQ ID NOS: 97 through 194 (HIAP1).

In another aspect, the invention features an IAP gene nucleic acid fragment or antisense RNA sequence for use in suppressing cell proliferation. Such nucleic acids of the invention and methods for using them may be identified according to a method involving: (a) providing a cell sample; (b) introducing by transformation into the cell sample a candidate IAP nucleic acid; (c) expressing the candidate IAP nucleic acid within the cell sample; and (d) determining whether the cell sample exhibits an altered apoptotic response, whereby decreased apoptosis identifies an anti-proliferative compound. Preferably the cell is a cancer cell.

In another aspect, the invention features a method of treating a patient diagnosed with a proliferative disease. In the method, apoptosis may be induced in a cell to control a proliferative disease either alone or in combination with other therapies by administering to the cell a negative regulator of the IAP-dependent or anti-apoptotic pathway. The negative regulator may be, but is not limited to, an IAP ring zinc finger, and an IAP polypeptide that includes a ring zinc finger and lacks at least one BIR domain. Alternatively, apoptosis may be induced in the cell by administering a nucleic acid encoding an IAP antisense RNA molecule

administered directly or via gene therapy (see U.S. Pat. No. 5,576,208 for general parameters that may be applicable in the selection of IAP antisense RNAs). In yet another method, the negative regulator may be a purified antibody, or a fragment thereof, that binds specifically to an IAP polypeptide. For example, in one preferred embodiment, the antibody may bind to an approximately 26 kDa cleavage product of an IAP polypeptide that includes at least one BIR domain but lacks a ring zinc finger domain.

In two additional aspects, the invention features a transgenic animal and methods of using the mammal for detection of anti-cancer therapeutics. Preferably the mammal overexpresses an IAP polypeptide and/or expresses an IAP antisense RNA or IAP fragment. In one embodiment, the animal also has a genetic predisposition to cancer or has cancer cells under conditions that provide for proliferation absent the transgenic construct encoding either the antisense RNA or fragment.

"Protein" or "polypeptide" or "polypeptide fragment" means any chain of more than two amino acids, regardless of post-translational modification (e.g., glycosylation or phosphorylation), constituting all or part of a naturally-occurring polypeptide or peptide, or constituting a non-naturally occurring polypeptide or peptide.

"Apoptosis" means the process of cell death wherein a dying cell displays a set of well-characterized biochemical hallmarks that include cell membrane blebbing, cell soma shrinkage, chromatin condensation, and DNA laddering. Cells that die by apoptosis include neurons (e.g., during the course of neurodegenerative diseases such as stroke, Parkinson's disease, and Alzheimer's disease), cardiomyocytes (e.g., after myocardial infarction or over the course of congestive heart failure), and cancer cells (e.g., after exposure to radiation or chemotherapeutic agents). Environmental stress (e.g., hypoxic stress) that is not alleviated may cause

a cell to enter the early phase of the apoptotic pathway, which is reversible (i.e., cells at the early stage of the apoptotic pathway can be rescued). At a later phase of apoptosis (the commitment phase), cells cannot be rescued, and, as a result, are committed to die.

Proteins and compounds known to stimulate and inhibit apoptosis in a diverse variety of cells are well known in the art. For example, intracellular expression and activation of the caspase (ICE) family induces or stimulates apoptotic cell death, whereas expression of the IAPs or some members of the Bcl-2 family inhibits apoptotic cell death. In addition, there are survival factors that inhibit cell death in specific cell types. For example, neurotrophic factors, such as NGF inhibit neuronal apoptosis.

In some situations it may be desirable to artificially stimulate or inhibit apoptotic cell death by gene therapy or by a compound that mimics a gene therapeutic effect. For example, a cell that is susceptible to apoptosis induced by disease or environmental stress may be made more resistant to apoptosis by introducing an expression vector encoding an anti-apoptotic protein (such as an IAP, a Bcl-2 family member, or a neurotrophin) into the cell. Conversely, a cancer cell may be made less resistant to apoptosis by introducing into it an expression vector encoding a pro-apoptotic protein (such as a caspase) or by introducing into it an antisense nucleic acid, for example, an IAP antisense nucleic acid, regardless of its length. In addition, placement of the encoded protein of interest under the translational regulation of a XIAP IRES ensures that copious quantities of the protein are produced, especially under cellular conditions during which most protein translation (i.e., cap-dependent protein translation) is down-regulated, e.g., when a cell is under environmental stress, and when a cell is at a threshold for entering the apoptotic pathway.

By "IAP gene" is meant a gene encoding a polypeptide having at least one BIR domain and a ring zinc finger domain that is capable of modulating (inhibiting or enhancing) apoptosis in a cell or tissue when provided by other intracellular or extracellular delivery methods (see, e.g., U.S. Patent No. 5,919,912, U.S.S.N. 08/576,965, and PCT/IB96/01022). In preferred embodiments, the IAP gene is a gene having about 50% or greater nucleotide sequence identity to at least one of the IAP amino acid encoding sequences of Figs. 1 through 6, or portions thereof. Preferably the region of sequence over which identity is measured is a region encoding at least one BIR domain and a ring zinc finger domain. Mammalian IAP genes include nucleotide sequences isolated from any mammalian source. Preferably the mammal is a human.

The term "IAP gene" is meant to encompass any member of the family of genes that encode inhibitors of apoptosis. An IAP gene may encode a polypeptide that has at least 20%, preferably at least 30%, and most preferably at least 50% amino acid sequence identity with at least one of the conserved regions of one of the IAP members described herein (i.e., either the BIR or ring zinc finger domains from human or murine XIAP, HIAP1, and HIAP2). Representative members of the IAP gene family include, without limitation, the human and murine XIAP, HIAP1, and HIAP2 genes.

By "IAP protein" or "IAP polypeptide" is meant a polypeptide, or fragment thereof, encoded by an IAP gene.

By "BIR domain" is meant a domain having the amino acid sequence of the consensus sequence: Xaal-Xaal-Xaal-Arg-Leu-Xaal-Thr-Phe-Xaal-Xaal-Trp-Pro-Xaa2-Xaal-Xaal-Xaa2-Xaa2-Xaal-Xaal-Xaal-Xaal-Leu-Ala-Xaal-Ala-Gly-Phe-Tyr-Tyr-Xaal-Gly-Xaal-Xaal-Asp-Xaal-Val-Xaal-Cys-Phe-Xaal-Cys-Xaal-Xaal- Xaal-Xaal-Xaal-Xaal-Trp-Xaal-Xaal-Xaal-Asp-Xaal-Xaal-Xaal- Xaal-Xaal-His-Xaal-Xaal-Xaal-Xaal-

Pro-Xaal-Cys-Xaal-Phe-Val, wherein Xaal is any amino acid and Xaa2 is any amino acid or is absent (SEQ ID NO: 216). Preferably the sequence is substantially identical to one of the BIR domain sequences provided for XIAP, HIAP1, or HIAP2 herein.

By "ring zinc finger" or "RZF" is meant a domain having the amino acid sequence of the consensus sequence: Glu-Xaal-Xaal-Xaal-Xaal-Xaal-Xaal-Xaa2-Xaal-Xaal-Xaal-Cys- Lys-Xaa3-Cys-Met-Xaal-Xaal-Xaal-Xaal-Xaal-Xaa3-Xaal-Phe-Xaal-Pro-Cys-Gly-His-Xaal-Xaal-Xaal-Cys-Xaal-Xaal-Cys-Ala- Xaal-Xaal-Xaal-Xaal-Xaal-Cys-Pro-Xaal-Cys, wherein Xaal is any amino acid, Xaa2 is Glu or Asp, and Xaa3 is Val or Ile (SEQ ID NO: 217).

Preferably the sequence is substantially identical to the RZF domains provided in U.S.S.N. 08/800,929, incorporated herein by reference, for the human or murine XIAP, HIAP1, or HIAP2.

By "enhancing apoptosis" is meant increasing the number of cells that apoptose in a given cell population. Preferably the cell population is selected from a group including ovarian cancer cells, breast cancer cells, pancreatic cancer cells, T cells, neuronal cells, fibroblasts, or any other cell line known to proliferate in a laboratory setting. It will be appreciated that the degree of apoptosis enhancement provided by an apoptosis-enhancing compound in a given assay will vary, but that one skilled in the art can determine the statistically significant change in the level of apoptosis that identifies a compound that enhances apoptosis otherwise limited by an IAP. Preferably "enhancing apoptosis" means that the increase in the number of cells undergoing apoptosis is at least 25%, more preferably the increase is 50%, and most preferably the increase is at least one-fold. Preferably the sample monitored is a sample of cells that normally undergo insufficient apoptosis (i.e., cancer cells). Methods for

detecting a changes in the level of apoptosis (i.e., enhancement or reduction) are described herein.

By "proliferative disease" is meant a disease that is caused by or results in inappropriately high levels of cell division, inappropriately low levels of apoptosis, or both. For example, cancers such as lymphoma, leukemia, melanoma, ovarian cancer, breast cancer, pancreatic cancer, and lung cancer are all examples of proliferative disease.

By "IAP biological activity" is meant any activity known to be caused *in vivo* or *in vitro* by an IAP polypeptide.

By "transformed cell" is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) an IAP polypeptide.

By "transgene" is meant any piece of DNA that is inserted by artifice into a cell, and becomes part of the genome of the organism that develops from that cell. Such a transgene may include a gene that is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.

By "transgenic" is meant any cell that includes a DNA sequence that is inserted by artifice into a cell and becomes part of the genome of the organism that develops from that cell. As used herein, the transgenic organisms are generally transgenic mammals (e.g., rodents, such as rats or mice) and the DNA (transgene) is inserted by artifice into the nuclear genome.

By "transformation" is meant any method for introducing foreign molecules, for example, an antisense nucleic acid, into a cell. Lipofection, calcium phosphate precipitation, retroviral delivery, electroporation, biolistic transformation, and penetratin are just a few of the teachings that may be used. For example, biolistic transformation is a method for

introducing foreign molecules into a cell using velocity driven microprojectiles such as tungsten or gold particles. Such velocity-driven methods originate from pressure bursts that include, but are not limited to, helium-driven, air-driven, and gunpowder-driven techniques. Biolistic transformation may be applied to the transformation or transfection of a wide variety of cell types and intact tissues including, without limitation, intracellular organelles (e.g., and mitochondria and chloroplasts), bacteria, yeast, fungi, algae, animal tissue, and cultured cells. In another example, a foreign molecule (e.g., an antisense nucleic acid) can be translocated into a cell using the penetratin system as described, for example, by Prochiantz (Nature Biotechnology 16: 819-820, 1998; and Derossi et al. (Trends Cell Biol. 8: 84-87, 1998). In this system a penetratin peptide contains a transduction sequence that carries the peptide and a conjugated partner, for example, a phosphorothioate antisense nucleic acid (that is cross-linked through a disulfide bridge to the peptide) across the plasma membrane into the cell. The disulfide band is reduced inside the cell, releasing the partner.

By "antisense," as used herein in reference to nucleic acids, is meant a nucleic acid sequence, regardless of length, that is complementary to the coding strand or mRNA of an IAP gene. Preferably the antisense nucleic acid is capable of enhancing apoptosis when present in a cell that normally does not undergo sufficient apoptosis. Preferably the increase is at least 10%, relative to a control, more preferably 25%, and most preferably 1-fold or more. Preferably an IAP antisense nucleic acid comprises from about 8 to 30 nucleotides. An IAP antisense nucleic acid may also contain at least 40, 60, 85, 120, or more consecutive nucleotides that are complementary to a IAP mRNA or DNA, and may be as long as a full-length IAP gene or mRNA. The antisense nucleic acid may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or

other modified backbones known in the art, or may contain non-natural internucleoside linkages.

By "ribozyme" is meant an RNA that has enzymatic activity, possessing site specificity and cleavage capability for a target RNA molecule. Ribozymes can be used to decrease expression of a polypeptide. Methods for using ribozymes to decrease polypeptide expression are described, for example, by Turner et al., (Adv. Exp. Med. Biol. 465:303-318, 2000) and Norris et al., (Adv. Exp. Med. Biol. 465:293-301, 2000).

By "substantially identical" is meant a polypeptide or nucleic acid exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). This software program matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

By "substantially pure polypeptide" is meant a polypeptide that has been separated from the components that naturally accompany it. Typically, the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably the polypeptide is an IAP polypeptide that is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, pure. A substantially pure IAP polypeptide may be obtained, for example, by extraction from a natural source (e.g., a fibroblast, neuronal cell, or lymphocyte) by expression of a recombinant nucleic acid encoding an IAP polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

A protein is substantially free of naturally associated components when it is separated from those contaminants that accompany it in its natural state. Thus, a protein that is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in *E. coli* or other prokaryotes.

By "substantially pure DNA" is meant DNA that is free of the genes that, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other

sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.

By "positioned for expression" is meant that the DNA molecule is positioned adjacent to a DNA sequence, that directs transcription and translation of the sequence (i.e., facilitates the production of, e.g., an IAP polypeptide, a recombinant protein or an RNA molecule).

By "reporter gene" is meant a gene whose expression may be assayed; such genes include, without limitation, glucuronidase (GUS), luciferase, chloramphenicol transacetylase (CAT), and Beta-galactosidase.

By "promoter" is meant a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements that are sufficient to render promoter-dependent gene expression controllable for cell type-specific, tissue-specific or that are inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene.

By "operably linked" is meant that a gene and one or more regulatory sequences are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequences.

By "conserved region" is meant any stretch of six or more contiguous amino acids exhibiting at least 30%, preferably 50%, and most preferably 70% amino acid sequence identity between two or more of the IAP family members, (e.g., between human HIAP1, HIAP2, and XIAP). Examples of preferred conserved regions include, without limitation, BIR domains and ring zinc finger domains.

By "detectably-labelled" is meant any means for marking and identifying the presence of a molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule. Methods for detectably-labelling a molecule are well known in the art and include,

without limitation, radioactive labelling (e.g., with an isotope such as $^{32}P$ or $^{35}S$) and nonradioactive labelling (e.g., chemiluminescent labeling or fluorescein labelling).

By "purified antibody" is meant an antibody that is at least 60%, by weight, free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody, e.g., an IAP-specific antibody. A purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.

By "specifically binds" is meant an antibody that recognizes and binds a protein but that does not substantially recognize and bind other molecules in a sample, e.g., a biological sample, that naturally includes protein.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

## Brief Description of the Drawings

Fig. 1 is the human XIAP cDNA sequence (SEQ ID NO: 218) and the XIAP polypeptide sequence (SEQ ID NO: 219).

Fig. 2 is the human HIAP1 cDNA sequence (SEQ ID NO: 220) and the HIAP1 polypeptide sequence (SEQ ID NO: 221).

Fig. 3 is the human HIAP2 cDNA sequence (SEQ ID NO: 222) and the HIAP2 polypeptide sequence (SEQ ID NO: 223). The sequence absent in the HIAP2 variant is boxed.

Fig. 4 is the murine XIAP (also referred to as "miap-3") cDNA sequence (SEQ ID NO: 224) and encoded murine XIAP polypeptide sequence (SEQ ID NO: 225).

Fig. 5 is the murine HIAP1 (also referred to as "miap-1") cDNA sequence (SEQ ID NO: 226) and the encoded murine HIAP1 polypeptide sequence (SEQ ID NO: 227).

Fig. 6 is the murine HIAP2 (also referred to as "miap-2") cDNA sequence (SEQ ID NO: 228) and the encoded murine HIAP2 polypeptide (SEQ ID NO: 229).

Figs.7A through 7L are graphs showing the effect of antisense XIAP oligonucleotides on XIAP protein expression, relative to total protein (Figs. 7A, 7C, 7E, 7G, 7I, and 7K). Figs. 7B, 7D, 7F, 7H, 7J, and 7L are the total protein concentration values for each oligonucleotide transfection compared to mock transfection results that were used to normalize the above XIAP protein results.

Figs. 8A through 8C are graphs showing the effects of various antisense XIAP oligonucleotides, alone or in combination, on XIAP RNA (Fig. 8A) and protein (Fig. 8B). Fig. 8C is a graph of the total protein concentration values for each oligonucleotide transfection compared to mock transfection results, which were used to normalize the XIAP protein results shown in Fig. 8B.

Figs. 9A through 9D are graphs of the effects of antisense XIAP oligonucleotides on cell viability (Figs. 9A, 9C, and 9D), and chemosensitization in the presence of adriamycin (Fig. 9B).

Fig. 10 is a graph showing the effects of HIAP1 antisense oligonucleotides on HIAP1 RNA levels.

Fig. 11A is a densitometric scan of a Western blot showing the effects of HIAP1 antisense oligonucleotides on a cell's ability to block cycloheximide-induced upregulation of HIAP1 protein.

Fig. 11 is a graph showing the effects of HIAP1 antisense oligonucleotides on a cell's ability to block cycloheximide-induced upregulation of HIAP1 protein.

Fig. 12 is a graph showing the effects of HIAP1 antisense oligonucleotides on cytotoxicity, as measured by total protein.

Fig. 13 is a graph showing the validation of the sequence specificity for HIAP1 antisense oligonucleotide APO 2.

Fig. 14 is a graph showing the effect of HIAP1 antisense oligonucleotides on the chemosensitization of drug-resistant SF295 glioblastomas.

Fig. 15 is the human XIAP sequence containing a 5' UTR, the coding region, and a 3' UTR (SEQ ID NO: 230).

Fig. 16 is the human HIAP1 sequence containing a 5' UTR, the coding region, and a 3' UTR (SEQ ID NO: 231).

## Detailed Description of the Invention

The present invention provides IAP antisense nucleic acid sequences that inhibit IAP biological activity, regardless of length, and methods for using them to induce apoptosis in a cell. The antisense nucleic acids of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a negative regulator of the IAP anti-apoptotic pathway other than antisense. Such negative regulators include, for example, an IAP polypeptide comprising a ring zinc finger having no more than two BIR domains, and a compound that prevents cleavage of an IAP polypeptide. Such negative regulators may also be used to form a pharmaceutical composition. These pharmaceutical compositions may be used to treat, ameliorate, improve, sustain, or prevent a proliferative disease, for example, cancer, or a symptom of a proliferative disease.

Administration

An IAP antisense nucleic acid, or other negative regulator of the IAP anti-apoptotic pathway may be administered within a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the compounds to patients suffering from a disease that is caused by excessive cell proliferation. Administration may begin before the patient is symptomatic. Any appropriate route of administration may be employed, for example, administration may be parenteral, intravenous, intraarterial, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, suppository, or oral administration. For example, therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations are found, for example, in "Remington's Pharmaceutical Sciences." Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for IAP modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example,

polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

The formulations can be administered to human patients in therapeutically effective amounts (e.g., amounts which prevent, eliminate, or reduce a pathological condition) to provide therapy for a disease or condition. The preferred dosage of therapeutic agent to be administered is likely to depend on such variables as the type and extent of the disorder, the overall health status of the particular patient, the formulation of the compound excipients, and its route of administration.

If desired, treatment with an IAP antisense nucleic acid, IAP fragments, or other negative regulator of the anti-apoptotic pathway may be combined with more traditional therapies for the proliferative disease such as surgery or chemotherapy.

For any of the methods of application described above, the therapeutic antisense IAP nucleic acid or other negative regulator of the IAP anti-apoptotic pathway is preferably applied to the site of the needed apoptosis event (for example, by injection). However, it may also be applied to tissue in the vicinity of the predicted apoptosis event or to a blood vessel supplying the cells predicted to require enhanced apoptosis.

The dosage of an antisense IAP nucleic acid, or a negative regulator of the IAP anti-apoptotic pathway, for example, an IAP fragment, IAP mutant protein or an IAP antibody depends on a number of factors, including the size and health of the individual patient, but, generally, between 0.1 mg and 100 mg inclusive are administered per day to an adult in any pharmaceutically acceptable formulation. In addition, treatment by any IAP-modulating gene therapy approach may be combined with more traditional therapies.

Antisense Therapy

Anti-cancer therapy may be accomplished by direct administration of a therapeutic antisense IAP nucleic acid to a cell that is expected to require enhanced apoptosis. The antisense nucleic acid may be produced and isolated by any one of many standard techniques. Administration of IAP antisense nucleic acids to malignant cells can be carried out by any of the methods for direct nucleic acid administration, as described herein.

Retroviral vectors, adenoviral vectors, adeno-associated viral vectors, or other viral vectors with the appropriate tropism for cells likely requiring enhanced apoptosis (for example, breast cancer and ovarian cancer cells) may be used as a gene transfer delivery system for a therapeutic antisense IAP gene construct. Numerous vectors useful for this purpose are generally known (Miller, Human Gene Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis and Anderson, BioTechniques 6:608-614, 1988; Tolstoshev and Anderson, Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 17:407-416, 1991; Miller et al., BioTechniques 7:980-990, 1989; Le Gal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995).

Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., U.S. Patent No. 5,399,346). Non-viral approaches may also be employed for the introduction of therapeutic DNA into cells otherwise predicted to undergo apoptosis. For example, IAPs may be introduced into a cell by lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neurosci. Lett. 117:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989; Staubinger et al., Meth. Enz. 101:512,

1983), the penetratin system (Allinquant et al., J. Cell Biol. 128:919-927, 1995; Prochiantz, Curr. Opin. Neurobiol. 6:629-634, 1996), asialorosonucoid-polylysine conjugation (Wu et al., J. Biol. Chem. 263:14621, 1988; Wu et al., J. Biol. Chem. 264:16985, 1989); or, less preferably microinjection under surgical conditions (Wolff et al., Science 247:1465, 1990).

In the therapeutic nucleic acid constructs described, nucleic acid expression can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element. For example, if desired, enhancers known to preferentially direct gene expression in ovarian cells, breast tissue, neural cells, T cells, or B cells may be used to direct expression. Enhancers include, without limitation, those that are characterized as tissue- or cell-specific in their expression. Alternatively, if a clone is used as a therapeutic construct, regulation may be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.

Therapeutic Products

For IAP related therapies one may employ the paradigms utilized for Bcl-2 and Ras antisense development, although accommodation of an IAP mutation is not required (in contrast to Ras antisense). Most useful are antisense constructs that enhance apoptosis at least 10%, preferably by enhancing degradation of the RNA in the nucleus.

*Manipulation of cancer chemotherapeutic drug resistance using an antisense oligonucleotide and fragment approaches*

We have documented that overexpression of the IAPs renders cell lines resistant to serum growth factor withdrawal, tumor necrosis factor alpha (TNF) and menadione exposure, all of which are treatments that normally induce apoptosis. Herein, we describe the extension of these studies to cancer cell lines using apoptotic triggers used in clinical situations, such as doxorubicin, adriamycin, and methotrexate. Our findings have led up to the design of antisense RNA therapeutics. Rapid screening of multiple cell lines for apoptotic response has been made feasible through the generation of a series of sense and antisense adenoviral IAP and expression vectors, as well as control lacZ viruses. One may now show enhanced drug resistance using the expression constructs. In addition, anti-sense adenovirus constructs may be developed and used to test reversal of the drug resistant phenotype of appropriate cell lines. We have designed a series of antisense oligonucleotides to various regions of each of the *iaps*. These oligonucleotides may be used to enhance drug sensitivity after testing in an assay system, i.e., with the adenoviral vectors system. Animal modeling of the effectiveness of antisense IAP oligonucleotides may also be employed as a step in testing and appropriate transgenic mammals for this are described in U.S.S.N. 08/800,929, incorporated herein by reference, and are also generally available in the art.

Characterization of IAP Activity and Intracellular Localization Studies

The ability of IAPs to modulate apoptosis can be defined *in vitro* systems in which alterations of apoptosis can be detected. Mammalian expression constructs carrying IAP cDNAs, which are either full-length, truncated, or antisense constructs can be introduced into cell lines, such as

CHO, NIH 3T3, HL60, Rat-1, or Jurkat cells. In addition, SF21 insect cells may be used, in which case the IAP gene is preferentially expressed using an insect heat shock promoter. Following transfection, apoptosis can be induced by standard methods, which include serum withdrawal, or application of staurosporine, menadione (which induces apoptosis via free radial formation), or anti-Fas antibodies. As a control, cells are cultured under the same conditions as those induced to undergo apoptosis, but either not transfected, or transfected with a vector that lacks an IAP insert. The ability of each IAP related construct to inhibit or enhance apoptosis upon expression can be quantified by calculating the survival index of the cells, i.e., the ratio of surviving transfected cells to surviving control cells. These experiments can confirm the presence of apoptosis inhibiting activity and, as discussed below, can also be used to determine the functional region(s) of an IAP that may be employed to achieve enhancement of apoptosis. These assays may also be performed in combination with the application of additional compounds in order to identify compounds that enhance apoptosis via IAP expression.

Apoptosis Assays

Specific examples of apoptosis assays are provided in the following references. Assays for apoptosis in lymphocytes are disclosed by: Li et al., "Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein", Science 268:429-431, 1995; Gibellini et al., "Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection", Br. J. Haematol. 89:24-33, 1995; Martin et al., "HIV-1 infection of human $CD4^+$ T cells *in vitro*. Differential induction of apoptosis in these cells." J. Immunol. 152:330-342, 1994; Terai et al., "Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1", J.

Clin. Invest. 87:1710-1715, 1991; Dhein et al., "Autocrine T-cell suicide mediated by APO-l/(Fas/CD95)", Nature 373:438-441, 1995; Katsikis et al., "Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals", J. Exp. Med. 1815:2029-2036, 1995; Westendorp et al., "Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120", Nature 375:497, 1995; and DeRossi et al., Virology 198:234-44, 1994.

Assays for apoptosis in fibroblasts are disclosed by: Vossbeck et al., "Direct transforming activity of TGF-beta on rat fibroblasts", Int. J. Cancer 61:92-97, 1995; Goruppi et al., "Dissection of c-myc domains involved in S phase induction of NIH3T3 fibroblasts", Oncogene 9:1537-1544, 1994; Fernandez et al., "Differential sensitivity of normal and Ha-ras transformed C3H mouse embryo fibroblasts to tumor necrosis factor: induction of bcl-2, c-myc, and manganese superoxide dismutase in resistant cells", Oncogene 9:2009-2017, 1994; Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines", EMBO J., 13:3286-3295, 1994; and Itoh et al., "A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen", J. Biol. Chem. 268:10932-10937, 1993.

Assays for apoptosis in neuronal cells are disclosed by: Melino et al., "Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells", Mol. Cell. Biol. 14:6584-6596, 1994; Rosenbaum et al., "Evidence for hypoxia-induced, programmed cell death of cultured neurons", Ann. Neurol. 36:864-870, 1994; Sato et al., "Neuronal differentiation of PC12 cells as a result of prevention of cell death by bcl-2", J. Neurobiol. 25:1227-1234, 1994; Ferrari et al., "N-acetylcysteine D- and L-stereoisomers prevents apoptotic death of neuronal cells", J. Neurosci. 1516:2857-2866, 1995; Talley et al., "Tumor necrosis factor alpha-induced apoptosis in human neuronal cells:

protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA", Mol. Cell Biol. 1585:2359-2366, 1995; and Walkinshaw et al., "Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.", J. Clin. Invest. 95:2458-2464, 1995.

Assays for apoptosis in insect cells are disclosed by: Clem et al., "Prevention of apoptosis by a baculovirus gene during infection of insect cells", Science 254:1388-1390, 1991; Crook et al., "An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif", J. Virol. 67:2168-2174, 1993; Rabizadeh et al., "Expression of the baculovirus p35 gene inhibits mammalian neural cell death", J. Neurochem. 61:2318-2321, 1993; Birnbaum et al., "An apoptosis inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs", J. Virol. 68:2521-2528, 1994; and Clem et al., "Control of programmed cell death by the baculovirus genes p35 and IAP", Mol. Cell. Biol. 14:5212-5222, 1994.

The following examples are to illustrate the invention. They are not meant to limit the invention in any way.

Example 1: Testing of antisense oligonucleotides

*1. Complete panel of adenovirus constructs.* The panel may consist of approximately four types of recombinant virus. A) Sense orientation viruses for each of the IAP open reading frames. These viruses are designed to massively overexpress the recombinant protein in infected cells. XIAP, HIAP1, HIAP2, and NAIP. B) Antisense orientation viruses in which the viral promoter drives the synthesis of an mRNA of opposite polarity to the *iap* mRNA, thereby shutting off host cell synthesis of the

targeted protein coding region. XIAP, HIAP1, HIAP2, and NAIP "antisense" constructs are used for production of such antisense IAPs. C) Sub-domain expression viruses. These constructs express only a partial IAP protein in infected cells. We have data indicating that deletion of the zinc finger of XIAP renders the protein more potent in protecting cell against apoptotic triggers. This data also indicates that expression of the zinc finger alone will indicate apoptosis by functioning as a dominant-negative repressor of XIAP function. XIAP- ZF and XIAP- BIR viruses are required. D) Control viruses. Functional analysis of the IAPs requires suitable positive and negative controls for comparison. Bcl-2 sense, Bcl-2 antisense, p53 sense, and Lac Z (negative control) viruses may be utilized.

*2. Confirmation of recombinant adenovirus function.* Verification of the sense adenovirus function involves infection of tissue culture cells and determination of protein expression levels. We have performed Western blot analysis of several of the recombinant adenoviruses, including NAIP, XIAP and XIAP- ZF. The remaining viruses may be readily assessed for protein expression using the polyclonal IAP antibodies. Functional analysis of the antisense viruses may be done at the RNA level using either Northern blots of total RNA harvested from infected tissue culture cells or ribonuclease protection assays. Western blot analysis of infected cells will be used to determine whether the expressed antisense RNA interferes with IAP expression in the host cell.

*3. Documentation that IAP overexpression results in increased drug resistance.* We have optimized cell death assays to allow high through-put of samples with minimal sample variation. Testing of the sense IAP adenoviruses for their ability to alter drug sensitivity of breast and pancreatic adenocarcinoma cell lines may be accomplished as follows.

Cancer cell lines are infected with the recombinant viruses, cultured for 5 days, then subdivided into 24 well plates. Triplicate cell samples each receive increasing concentrations of the anti-cancer drug under investigation. Samples are harvested at 24, 48, and 72 hours post-exposure, and assayed for the number of viable cells in the well. The dose response curve is then compared to uninfected and control virus (both positive and negative) infected cells. One may document a dramatic increase in the relative resistance of the cancer cell lines when infected with the sense viruses, confirming our hypothesis that overexpression of the IAP proteins contributes to the anti-apoptotic phenotype of cancer cells. Initial experiments utilize the drugs doxorubicin and adriamycin.

*4. Documentation that antisense IAP overexpression results in increased drug sensitivity.* Having confirmed that IAP overexpression renders cancer cells more resistant to chemotherapeutic drugs, one may examine whether the antisense adenoviruses render the same cells more sensitive. The effectiveness of antisense IAP viruses relative to antisense Bcl-2 virus will also be assessed as a crucial milestone.

*5. Identification of antisense oligonucleotides.* Concomitant to the adenovirus work, we have designed a series of antisense oligonucleotides to various regions of each of the IAPs. A generally accepted model of how antisense oligonucleotides function proposes that the formation of RNA/DNA duplexes in the nucleus activates cellular RnaseH enzymes which then enzymatically degrade the mRNA component of the hybrid. Virtually any region of the mRNA can be targeted, and therefore choosing an appropriate sequence to target is somewhat empirical.

6. *Optimization of oligonucleotides.* A secondary round of oligonucleotides may be made when effective target regions have been identified. These oligonucleotides target sequences in the immediate vicinity of the most active antisense oligonucleotides identified using methods such as those provided above. A second round of testing by Northern blot analysis may be required.

7. *Testing antisense oligonucleotides in vitro.* Following successful identification and optimization of targeting oligonucleotides, one may test these in the tissue culture model system using the optimal cell lines such as those described in the cancer survey described in U.S.S.N. 08/800,929, incorporated herein by reference. Experimental procedures may parallel those used in the recombinant antisense adenovirus work. Negative control oligonucleotides with miss-match sequences are used to establish base line or non-specific effects. Assisted transfection of the oligonucleotides using cationic lipid carriers may be compared to unassisted transfection. Confirmation of the effectiveness of specific antisense oligonucleotides prompts synthesis of oligonucleotides with modified phosphodiester linkages, such as phosphorothioate or methylimino substituted oligonucleotides. These may also be tested *in vitro*.

8. *Animal modeling of antisense oligonucleotide therapies.* Animal modeling of the effectiveness of the antisense IAP approach is described here. Cell lines are routinely assessed for their tumorigenic potential in "nude" mice, a hairless strain of mouse that is immunocompromised, and thus extremely susceptible to developing tumors. In the nude mouse assay, cancer cells are grown in tissue culture and then injected under the skin at multiple sites. The frequency with which these cells give rise to

palpable tumors within a defined period of time provides an index of the tumorigenic potential of the cell line in the absence of interference by a functional immune system. Preliminary assessment of an antisense IAP therapeutic involves injection of cancer cells infected with the recombinant adenoviruses (sense, antisense, and control viruses) under the skin, and the tumorigenic index compared to that of untreated cells. One may also use this model to assess the effectiveness of systemic administration of antisense oligonucleotides in increasing the efficacy of anti-cancer drugs in the nude mouse model. Phosphorothioate or methylimino substituted oligonucleotides will be assessed at this stage. This type of antisense oligo has demonstrated enhanced cell permeability and slower clearance rates from the body in experimental animal models.

Example 2: Antisense oligonucleotide (ODN) selection

We selected 96 or 98, mostly non-overlapping, 19-mer antisense oligonucleotide (ODN) sequences for XIAP and HIAP1, respectively, based on the selection criteria listed below. In the case of XIAP, we selected 96 sequences (each being 19 nucleobases in length) (SEQ ID NOS: 1 through 96; Table 1), from a region approximately 1 kb upstream of the start codon to approximately 1 kb downstream of the stop codon of the cDNA sequence (Fig. 15). This blanketed approximately 50% of the coding region, and immediate 5' and 3' UTR sequences (i.e., 96 19-mers span 1.8 kb of sequence, while the targeted region is approximately 3.5 kb in length, comprised of a coding region of 1.5 kb plus 1 kb at either side of UTR sequences).

**Table 1. XIAP Antisense Oligonucleotides**

| SEQ ID NO: | Code | Position in XIAP Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 1 | A1 | 2 | AAAATTCTAAGTACCTGCA |
| 2 | B1 | 21 | TCTAGAGGGTGGCTCAGGA |
| 3 | C1 | 44 | CAGATATATATGTAACACT |
| 4 | D1 | 78 | TGAGAGCCCTTTTTTTGTT |
| 5 | E1 | 110 | AGTATGAAATATTTCTGAT |
| 6 | F1 | 134 | ATTGGTTCCAATGTGTTCT |
| 7 | G1 | 160 | TTAGCAAAATATGTTTTAA |
| 8 | H1 | 185 | TGAATTAATTTTTAATATC |
| 9 | A2 | 238 | ATTCAAGGCATCAAAGTTG |
| 10 | B2 | 326 | GTCAAATCATTAATTAGGA |
| 11 | C2 | 370 | AATATGTAAACTGTGATGC |
| 12 | D2 | 411 | GCAGAATAAAACTAATAAT |
| 13 | E2 | 430 | GAAAGTAATATTTAAGCAG |
| 14 | F2 | 488 | TTACCACATCATTCAAGTC |
| 15 | G2 | 508 | CTAAATACTAGAGTTCGAC |
| 16 | H2 | 535 | ACACGACCGCTAAGAAACA |
| 17 | A3 | 561 | TATCCACTTATGACATAAA |
| 18 | B3 | 580 | GTTATAGGAGCTAACAAAT |
| 19 | C3 | 607 | AATGTGAAACACAAGCAAC |
| 20 | D3 | 638 | ACATTATATTAGGAAATCC |
| 21 | E3 | 653 | CTTGTCCACCTTTTCTAAA |
| 22 | F3 | 673 | ATCTTCTCTTGAAAATAGG |
| 23 | G3 | 694 | CCTTCAAAACTGTTAAAAG |
| 24 | H3 | 721 | ATGTCTGCAGGTACACAAG |
| 25 | A4 | 759 | ATCTATTAAACTCTTCTAC |

| SEQ ID NO: | Code | Position in XIAP Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 26 | B4 | 796 | ACAGGACTACCACTTGGAA |
| 27 | C4 | 815 | TGCCAGTGTTGATGCTGAA |
| 28 | D4 | 835 | GTATAAAGAAACCCTGCTC |
| 29 | E4 | 856 | CGCACGGTATCTCCTTCAC |
| 30 | F4 | 882 | CTACAGCTGCATGACAACT |
| 31 | G4 | 907 | GCTGAGTCTCCATATTGCC |
| 32 | H4 | 930 | ATACTTTCCTGTGTCTTCC |
| 33 | A5 | 950 | GATAAATCTGCAATTTGGG |
| 34 | B5 | 990 | TTGTAGACTGCGTGGCACT |
| 35 | C5 | 1010 | ACCATTCTGGATACCAGAA |
| 36 | D5 | 1029 | AGTTTTCAACTTTGTACTG |
| 37 | E5 | 1059 | ATGATCTCTGCTTCCCAGA |
| 38 | F5 | 1079 | AGATGGCCTGTCTAAGGCA |
| 39 | G5 | 1100 | AGTTCTCAAAAGATAGTCT |
| 40 | H5 | 1126 | GTGTCTGATATATCTACAA |
| 41 | A6 | 1137 | TCGGGTATATGGTGTCTGA |
| 42 | B6 | 1146 | CAGGGTTCCTCGGGTATAT |
| 43 | C6 | 1165 | GCTTCTTCACAATACATGG |
| 44 | D6 | 1192 | GGCCAGTTCTGAAAGGACT |
| 45 | E6 | 1225 | GCTAACTCTCTTGGGGTTA |
| 46 | F6 | 1246 | GTGTAGTAGAGTCCAGCAC |
| 47 | G6 | 1273 | AAGCACTGCACTTGGTCAC |
| 48 | H6 | 1294 | TTCAGTTTTCCACCACAAC |
| 49 | A7 | 1316 | ACGATCACAAGGTTCCCAA |
| 50 | B7 | 1337 | TCGCCTGTGTTCTGACCAG |
| 51 | C7 | 1370 | CCGGCCCAAAACAAAGAAG |

| SEQ ID NO: | Code | Position in XIAP Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 52 | D7 | 1393 | GATTCACTTCGAATATTAA |
| 53 | E7 | 1413 | TATCAGAACTCACAGCATC |
| 54 | F7 | 1441 | GGAAGATTTGTTGAATTTG |
| 55 | G7 | 1462 | TCTGCCATGGATGGATTTC |
| 56 | H7 | 1485 | AAGTAAAGATCCGTGCTTC |
| 57 | A8 | 1506 | CTGAGTATATCCATGTCCC |
| 58 | B8 | 1525 | GCAAGCTGCTCCTTGTTAA |
| 59 | C8 | 1546 | AAAGCATAAAATCCAGCTC |
| 60 | D8 | 1575 | GAAAGCACTTTACTTTATC |
| 61 | H8 | 1610 | ACTGGGCTTCCAATCAGTT |
| 62 | E8 | 1629 | GTTGTTCCCAAGGGTCTTC |
| 63 | F8 | 1650 | ACCCTGGATACCATTTAGC |
| 64 | G8 | 1669 | TGTTCTAACAGATATTTGC |
| 65 | A9 | 1688 | TATATATTCTTGTCCCTTC |
| 66 | B9 | 1696 | AGTTAAATGAATATTGTTT |
| 67 | C9 | 1725 | GACACTCCTCAAGTGAATG |
| 68 | D9 | 1745 | TTTCTCAGTAGTTCTTACC |
| 69 | E9 | 1759 | GTTAGTGATGGTGTTTTCT |
| 70 | F9 | 1782 | AGATGGTATCATCAATTCT |
| 71 | G9 | 1801 | TGTACCATAGGATTTTGGA |
| 72 | H9 | 1820 | CCCCATTCGTATAGCTTCT |
| 73 | A10 | 1849 | ATTATTTTCTTAATGTCCT |
| 74 | B10 | 1893 | CAAGTGATTTATAGTTGCT |
| 75 | C10 | 1913 | TAGATCTGCAACCAGAACC |
| 76 | D10 | 1945 | CATCTTGCATACTGTCTTT |
| 77 | E10 | 1997 | CCTTAGCTGCTCTTCAGTA |

| SEQ ID NO: | Code | Position in XIAP Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 78 | F10 | 2018 | AAGCTTCTCCTCTTGCAGG |
| 79 | G10 | 2044 | ATATTTCTATCCATACAGA |
| 80 | H10 | 2076 | CTAGATGTCCACAAGGAAC |
| 81 | A11 | 2096 | AGCACATTGTTTACAAGTG |
| 82 | B11 | 2123 | AGCACATGGGACACTTGTC |
| 83 | C11 | 2144 | CTTGAAAGTAATGACTGTG |
| 84 | D11 | 2182 | CCTACTATAGAGTTAGATT |
| 85 | E11 | 2215 | ATTCAATCAGGGTAATAAG |
| 86 | F11 | 2234 | AAGTCAGTTCACATCACAC |
| 87 | G11 | 2375 | CAGTAAAAAAAAATGGATAA |
| 88 | H11 | 2428 | TTCAGTTATAGTATGATGC |
| 89 | A12 | 2471 | TACACTTAGAAATTAAATC |
| 90 | B12 | 2630 | TCTCTATCTTTCCACCAGC |
| 91 | C12 | 2667 | AGAATCCTAAAACACAACA |
| 92 | D12 | 2709 | ATTCGCACAAGTACGTGTT |
| 93 | E12 | 2785 | TGTCAGTACATGTTGGCTC |
| 94 | F12 | 2840 | ACATAGTGTTTTGCCACTT |
| 95 | G12 | 2861 | CTTTGATCTGGCTCAGACT |
| 96 | H12 | 2932 | GAAACCACATTTAACAGTT |

Note that the three most 5' and the three most 3' nucleobases may comprise DNA residues, or RNA residues, such as 2'-O methyl RNA residues. For example, the antisense oligonucleotide sequence of SEQ ID NO: 3 may be CAGATATATATGTAACACT or CAGATATATATGTAACACU.

A similar approach was taken for designing antisense oligonucleotides against HIAP1. Ninety-eight 19-mer sequences were chosen, with some of the latter sequences picked using less stringent criteria than the originally defined selection criteria (listed below), to increase the number of candidate sequences to study (SEQ ID NOS: 97 through 194; Table 2). Of these 98 sequences targeted to the HIAP1 sequence of Fig. 16, 15 (SEQ ID NOS: 97 through 104, 107, 113, 136, 156, 157, 181, and 193) were selected to evaluate the efficacy of decreasing HIAP1 expression. These 15 candidate sequences consisted of 4 sequences targeting the coding region (SEQ ID NOS: 136, 156, 157,and 181), 1 sequence targeting the 3' UTR (SEQ ID NO: 193), and 7 sequences targeting the 5'UTR (SEQ ID NOS: 100 through 104, 107, and 113; one of the 7 oligonucleotides overlapped the start codon), and 3 other oligonucleotides (SEQ IDs 97 through 99) that were designed to target an intronic segment of the 5'UTR (the value of which is discussed in Example 7). These above-described 15 HIAP1 antisense oligonucleotides were synthesized and tested.

**Table 2. HIAP1 Antisense Oligonucleotides**

| SEQ ID NO | Code | Position in HIAP1 Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 97 | APO 1 | 1152 | TCATTTGAGCCTGGGAGGU |
| 98 | APO 2 | 1172 | CGGAGGCTGAGGCAGGAGA |
| 99 | APO 3 | 1207 | GGTGTGGTGGTACGCGCCT |
| 100 | APO 4 | 1664 | ACCCATGCACAAAACTACC |
| 101 | APO 5 | 1865 | AGAATGTGCCAGTAGGAGA |
| 102 | APO 6 | 2440 | TCTCACAGACGTTGGGCTT |
| 103 | APO 7 | 2469 | CCAGTGGTTTGCAAGCATG |
| 104 | APO 8 | 3695 | GAAATTTAGTGGCCAGGAA |
| 105 | | 4013 | AGAAATACACAATTGCACC |
| 106 | | 4032 | TACTGATACATTTTAAGGA |
| 107 | APO 9 | 4057 | TTCAACATGGAGATTCTAA |
| 108 | | 4076 | ATTTCTATGCATTTAGAGT |
| 109 | | 4121 | AATACTAGGCTGAAAAGCC |
| 110 | | 4142 | GGCTTTGCTTTTATCAGTT |
| 111 | | 4165 | TCTAGGGAGGTAGTTTTGT |

| SEQ ID NO | Code | Position in HIAP1 Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 112 | | 4189 | GGGAAGAAAAGGGACTAGC |
| 113 | APO 10 | 4212 | GTTCATAATGAAATGAATG |
| 114 | | 4233 | ATAAGAATATGCTGTTTTC |
| 115 | | 4265 | TTCAAACGTGTTGGCGCTT |
| 116 | | 4283 | ATGACAAGTCGTATTTCAG |
| 117 | | 4317 | AAGTGGAATACGTAGACAT |
| 118 | | 4338 | AGACAGGAACCCCAGCAGG |
| 119 | | 4357 | CGAGCAAGACTCCTTTCTG |
| 120 | | 4376 | AGTGTAATAGAAACCAGCA |
| 121 | | 4395 | TGACCTTGTCATTCACACC |
| 122 | | 4426 | TTATCCAGCATCAGGCCAC |
| 123 | | 4445 | ACTGTCTCCTCTTTTCCAG |
| 124 | | 4464 | TTTTATGCTTTTCAGTAGG |
| 125 | | 4489 | ACGAATCTGCAGCTAGGAT |
| 126 | | 4517 | CAAGTTGTTAACGGAATTT |
| 127 | | 4536 | TAGGCTGAGAGGTAGCTTC |
| 128 | | 4555 | GTTACTGAAGAAGGAAAAG |
| 129 | | 4574 | GAATGAGTGTGTGGAATGT |
| 130 | | 4593 | TGTTTTCTGTACCCGGAAG |
| 131 | | 4612 | GAGCCACGGAAATATCCAC |
| 132 | | 4631 | TGATGGAGAGTTTGAATAA |
| 133 | | 4656 | GATTTGCTCTGGAGTTTAC |
| 134 | | 4670 | GGCAGAAAATTCTTGATTT |
| 135 | | 4696 | GGACAGGGGTAGGAACTTC |
| 136 | APO 11 | 4714 | GCATTTTCGTTATTCATTG |
| 137 | | 4733 | CTGAAAAGTAAGTAATCTG |
| 138 | | 4759 | GGCGACAGAAAAGTCAATG |
| 139 | | 4812 | CCACTCTGTCTCCAGGTCC |
| 140 | | 4831 | CCACCACAGGCAAAGCAAG |
| 141 | | 4855 | TTCGGTTCCCAATTGCTCA |
| 142 | | 4874 | TTCTGACATAGCATTATCC |
| 143 | | 4893 | TGGGAAAATGTCTCAGGTG |
| 144 | | 4907 | TATAAATGGGCATTTGGGA |
| 145 | | 4926 | TGTCTTGAAGCTGATTTTC |
| 146 | | 4945 | GAAACTGTGTATCTTGAAG |
| 147 | | 4964 | TGTCTGCATGCTCAGATTA |
| 148 | | 4988 | GAATGTTTTAAAGCGGGCT |
| 149 | | 5007 | CACTAGAGGGCCAGTTAAA |
| 150 | | 5040 | CCGCACTTGCAAGCTGCTC |
| 151 | | 5070 | CATCATCACTGTTACCCAC |
| 152 | | 5095 | CCACCATCACAGCAAAAGC |
| 153 | | 5117 | TCCAGATTCCCAACACCTG |
| 154 | | 5130 | CCCATGGATCATCTCCAGA |
| 155 | | 5149 | AACCACTTGGCATGTTGAA |
| 156 | APO 12 | 5168 | CAAGTACTCACACCTTGGA |
| 157 | APO 13 | 5187 | CCTGTCCTTTAATTCTTAT |
| 158 | | 5206 | TGAACTTGACGGATGAACT |
| 159 | | 5225 | TAGATGAGGGTAACTGGCT |
| 160 | | 5244 | TGGATAGCAGCTGTTCAAG |
| 161 | | 5271 | CATTTTCATCTCCTGGGCT |

| SEQ ID NO | Code | Position in HIAP1 Sequence | Antisense Oligonucleotide Sequence |
|---|---|---|---|
| 162 | | 529 | TGGATAATTGATGACTCTG |
| 163 | | 5309 | GTCTTCTCCAGGTTCAAAA |
| 164 | | 5337 | TATTCATCATGATTGCATC |
| 165 | | 5366 | CATTTCCACGGCAGCATTA |
| 166 | | 5367 | CCAGGCTTCTACTAAAGCC |
| 167 | | 5416 | GCTAGGATTTTTCTCTGAA |
| 168 | | 5435 | TCTATAATTCTCTCCAGTT |
| 169 | | 5454 | ACACAAGATCATTGACTAG |
| 170 | | 5473 | TCTGCATTGAGTAAGTCTA |
| 171 | | 5492 | CTCTTCCCTTATTTCATCT |
| 172 | | 5515 | TCCTCAGTTGCTCTTTCTC |
| 173 | | 5560 | GCCATTCTATTCTTCCGGA |
| 174 | | 5579 | AGTCAAATGTTGAAAAAGT |
| 175 | | 5598 | CCAGGATTGGAATTACACA |
| 176 | | 5622 | ATTCCGGCAGTTAGTAGAC |
| 177 | | 5646 | TAACATCATGTTCTTGTTC |
| 178 | | 5675 | GTCTGTGTCTTCTGTTTAA |
| 179 | | 5684 | TTCTCTTGCTTGTAAAGAC |
| 180 | | 5703 | CTAAAATCGTATCAATCAG |
| 181 | APO 14 | 5723 | GGCTGCAATATTTCCTTTT |
| 182 | | 5742 | GAGAGTTTCTGAATACAGT |
| 183 | | 5761 | ACAGCTTCAGCTTCTTGCA |
| 184 | | 5780 | AAATAAATGCTCATATAAC |
| 185 | | 5821 | GAAACATCTTCTGTGGGAA |
| 186 | | 5841 | GTTCTTCCACTGGTAGATC |
| 187 | | 5862 | CTTCTTGTAGTCTCCGCAA |
| 188 | | 5890 | TTGTCCATACACACTTTAC |
| 189 | | 6097 | AACCAAATTAGGATAAAAG |
| 190 | | 6181 | ATGTTCATATGGTTTAGAT |
| 191 | | 6306 | TAAGTTTTACTTCACTTAC |
| 192 | | 6369 | ATGTTCCCGGTATTAGTAC |
| 193 | APO 15 | 6432 | GGGCTCAAGTAATTCTCTT |
| 194 | | 6455 | GCCCAGGATGGATTCAAAC |

*Oligonucleotide selection criteria*

The computer program OLIGO (previously distributed by National Biosciences Inc.) was used to define suitable antisense oligonucleotides based on the following criteria: 1) no more than 75% GC content, and no more than 75% AT content; 2) preferably no oligonucleotide with 4 or more consecutive G residues (due to reported toxic effects, although one was chosen as a toxicity control); 3) no oligonucleotides with the ability

to form stable dimers or hairpin structures; and 4) sequences around the translation start site are a preferred region. In addition, accessible regions of the mRNA were predicted with the help of the RNA secondary structure folding program mfold, by M. Zuker (website 1999-2000: http://mfold2.wustl.edu/~mfold/rna/form1.cgi). Sub-optimal folds with a free energy value within 5% of the predicted most stable fold of the mRNA were predicted using a window of 200 bases within which a residue can find a complimentary base to form a base pair bond. Open regions that did not form a base pair were summed together with each suboptimal fold and areas that consistently were predicted as open were considered more accessible to the binding of antisense oligonucleotides. Additional oligonucleotides that only partially fulfilled some of the above selection criteria (1-4), were also chosen as possible candidates if they recognized a predicted open region of the target mRNA.

Example 3: Antisense oligonucleotide synthesis

The antisense oligonucleotides were synthesized by IDT (Integrated DNA Technologies, USA) as chimeric, second-generation oligonucleotides, consisting of a core of phosphodiester DNA residues flanked on either side by two 2'-O methyl RNA residues with a phosphorothioate linkage between the flanking RNA residues. The oligonucleotides were provided in a 96-well plate, as well as matching tubes, with a minimum of 12 ODs of oligo DNA, which provided ample material for transfections (greater than a hundred assays in the 96-well format) when the detection method is a sensitive method, such as TaqMan quantitative PCR, or an ELISA. Once the positive hits were identified (see below), the antisense oligonucleotides were re-synthesized with 3, instead of 2, flanking RNA residues to further increase stability/nuclease resistance. In addition, for validation purposes, appropriate controls (such

as scrambled, 4-base mismatch, and reverse polarity oligonucleotides) were synthesized for some of the antisense targets that yielded the highest antisense activity.

Example 4: Screening assays and optimization of antisense oligonucleotide sequences

Our approach to identifying IAP antisense oligonucleotides was to screen the above-described antisense oligonucleotide libraries for specific decreases (knock-down) of the RNA and protein for the specific IAP gene targeted. Any number of standard assays may be used to detect RNA and protein levels in cells that have been administered an IAP antisense nucleic acid. For example, RNA levels can be measured using standard Northern blot analysis or RT-PCR techniques. In addition, protein levels can be measured, for example, by standard Western blot analyses or immunoprecipitation techniques. Alternatively, cells administered an antisense IAP nucleic acid may be examined for cell viability, according to methods described for example, in U.S. Patent No. 5,919,912, or U.S.S.Ns. 08/576,956, 08/800,929, incorporated herein by reference.

We used TaqMan quantitative PCR conditions (described below) to assay for changes in mRNA levels after antisense oligonucleotide treatment, as well as our ELISA method for XIAP and Western blotting (described below) for changes in HIAP1 protein levels, using a polyclonal anti-RIAP1 antibody (rat HIAP1 ortholog; AEgera Therapeutics, Inc.) in the latter case. Transfection conditions were optimized with LipofectAMINE PLUS (Life Technologies, Canada) on T24 bladder carcinoma cells, or lipofectin on SF-295 glioblastoma cells, using a fluorescein-tagged control sense oligo from XIAP spanning the start codon (mGmAG AAG ATG ACT GGT AAmC mA; SEQ ID NO:

195). The results were visualized and gauged by epi-fluorescence microscopy. In addition, in the case of T24 cells, transfections were further optimized based on the ability of a published antisense oligonucleotide to downregulate survivin expression (Li et al., Nat. Cell Biol. 1:461-466, 1999) (U/TGT GCT ATT CTG TGA AU/TU/T SEQ ID NO: 196). We optimized the transfection conditions based on the TaqMan results of survivin RNA knock-down detected with PCR primers and fluorescent probe, described in detail below. Optimal conditions for oligo uptake by the cells were found to be 940 nM oligonucleotide and 40 μL PLUS reagent and 0.8 μL LipofectAMINE in a total of 70 μL for 3 hours. We then applied these conditions to screen for XIAP protein knock-down using the oligo library against T24 cells.

HIAP1 knock-down was studied in SF-295 cells because these cells had easily detectable and discernable 70 kDa HIAP1 protein, while many cell lines do not express high levels of the protein, or are not distinguishable from the large amounts of the similarly sized 68 kDa HIAP2 protein. In fact, there are a number of published errors involving HIAP1 and HIAP2 in the literature because of naming errors in the databases, and because of the poor quality and high crossreactivity, of the various commercial antibodies to HIAP1/cIAP2. The best way to distinguish HIAP1 from HIAP2 is to perform an immunoprecipitation experiment with an IAP antibody (Aegera Therapeutics, Inc.), separate the proteins by 2-dimensional gel electrophoresis, and to then carry out mass spectroscopy analysis of the spots migrating in the 68 to 70 kDa range to verify the identity of the HIAP1 and HIAP2 bands, using standard methods known in the art. This method determines if HIAP1 and HIAP2 co-migrate at the 68 kDa position, and if the 70 kDa form of HIAP1 results from a splice variant or a post-translational modification.

*Real–time PCR*

RNA was extracted from cells lysed in RLT buffer (QIAGEn, Inc., Canada), and purified using QIAGEN RNeasy columns/kits. Real-time quantitative PCR was performed on a Perkin-Elmer ABI 7700 Prism PCR machine. RNA was reverse transcribed and amplified according to the TaqMan Universal PCR Master Mix protocol of PE Biosystems, using primers and probes designed to specifically recognize XIAP, HIAP1, survivin, or GAPDH. For human survivin, the forward primer was 5'-TCT GCT TCA AGG AGC TGG AA-3', the reverse primer was 5'-GAA AGG AAA GCG CAA CCG-3', and the probe was 5'-(FAM) AGC CAG ATG ACG ACC CCA TAG AGG AAC ATA(TAMRA)-3' (SEQ ID NOS: 197 through 199). For human HIAP1, the forward primer was 5'-TGG AGA TGA TCC ATG GGT TCA-3', the reverse primer was 5'-GAA CTC CTG TCC TTT AAT TCT TAT CAA GT-3', and the probe was 5'-(FAM) CTC ACA CCT TGG AAA CCA CTT GGC ATG(TAMRA)-3' (SEQ ID NOS: 200 through 202). For human XIAP, the forward primer was 5'-GGT GAT AAA GTA AAG TGC TTT CAC TGT-3', the reverse primer was 5'-TCA GTA GTT CTT ACC AGA CAC TCC TCA A-3', and the probe was 5'-(FAM) CAA CAT GCT AAA TGG TAT CCA GGG TGC AAA TAT C(TAMRA)-3' (SEQ ID NOS: 203 through 205). For human GAPDH, the forward primer was 5'-GAA GGT GAA GGT CGG AGT C-3', the reverse primer was 5'-GAA GAT GGT GAT GGG ATT C-3', and the probe was 5'-(JOE) CAA GCT TCC CGT TCT CAG CC(TAMRA)-3' (SEQ ID NOS: 206 through 208).

Relative quantitation of gene expression was performed as described in the PE Biosystems manual using GAPDH as an internal standard. The comparative Ct (cycle threshold) method was used for relative quantitation of IAP mRNA levels compared to GAPDH mRNA

levels. Briefly, real-time fluorescence measurements were taken at each PCR cycle and the threshold cycle (Ct) value for each sample was calculated by determining the point at which fluorescence exceeded a threshold limit of 30 times the baseline standard deviation. The average baseline value and the baseline SD are calculated starting from the third cycle baseline value and stopping at the baseline value three cycles before the signal starts to exponentially rise. The PCR primers and/or probes for ecific IAPs were designed to span at least one exon-intron boundary y 1 or more kb of genomic DNA, to reduce the possibility of amplifying and detecting genomic DNA contamination. The specificity of the signal, and possible contamination from DNA, were verified by me RNA samples with either DNase or RNase, prior to the reverse transcription and PCR reaction steps.

*XIAP ELISA and HIAP1 Western immunoblots*

A standard colorimetric XIAP ELISA assay was performed using an affinity-purified rabbit polyclonal antibody to XIAP (Aegera Therapeutics, Inc.) as a capture antibody, and was detected with a XIAP monoclonal antibody (MBL, Japan) and a biotinylated anti-mouse Ig antibody and horseradish peroxidase-conjugated streptavidin and TMB substrate. Alternatively, a polyclonal XIAP or HIAP1 antibody may be used to measure XIAP or HIAP1 protein levels, respectively.

HIAP1 was detected on a Western immunoblot using an affinity-purified anti-RIAP1 rabbit polyclonal antibody as a primary antibody and was detected by ECL (Amersham) on X-ray film with a secondary horseradish-peroxidase-conjugated anti-rabbit Ig antibody and a chemiluminescent substrate. The anti-RIAP1 polyclonal antibody is raised against a GST-fusion of the rat ortholog of HIAP1. This antibody cross-reacts with both human and murine HIAP1 and HIAP2.

Example 5: Antisense XIAP oligonucleotides decrease XIAP RNA and polypeptide expression

The XIAP synthetic library of 96 antisense oligonucleotides was first screened for decreases in XIAP protein levels. Specifically, T24 cells ($1.5 \times 10^4$ cells/well) were seeded in wells of a 96-well plate on day 1, and were cultured in antibiotic-free McCoy's medium for 24 hours. On day 2, the cells were transfected with XIAP antisense oligonucleotides as described above (oligonucleotides are labeled according to their plated position, i.e., A1 to H12, and include 2 repeats, A13 and B13 that contain lyophilized DNA pellets that stuck to the sealing membrane). Briefly, the oligos were diluted in 10 µl/well of serum-free, antibiotic-free McCoy's medium and then PLUS reagent was added. LipofectAMINE was diluted in 10 µl/well of serum-free, antibiotic-free McCoy's medium, and both mixes were incubated for 15 minutes at room temperature. The mixes were then combined and incubated for 15 minutes at room temperature.

In the meantime, the complete medium was removed from the cells and 50 µl/well of serum-free, antibiotic-free medium was added to the cells. The transfection mixes were added to the well, and the cells were incubated for 3 hours. Then 30 µl/well of serum-free, antibiotic-free medium and 100 µl/well of antibiotic-free complete medium, containing 2X fetal bovine serum were added to each well.

At day 3, XIAP RNA levels were measured using quantitative real-time PCR techniques, as described above. At day 4, XIAP protein levels were measured by ELISA (Figs. 7A, 7C, 7E, 7G, 7I, and 7K) , and total cellular protein was measured biochemically (Figs. 7B, 7D, 7F, 7H, 7J, and 7L; used to normalize the XIAP protein levels). The results were compared to a mock transfection sample (treated with the transfection agent but no oligonucleotide DNA was added, and then processed as for

the other samples). Time course experiments determined that the optimal time for protein knock-down to be around 12 to 24 hours.

The library was also screened for decreases in RNA levels, using TaqMan- specific PCR primers and fluorescent probes at the appropriate optimal time, using the primers and probes described above. Time course experiments determined mRNA to be optimally decreased at 6 to 9 hours. These results agree well with the protein results.

The first screen (although performed at a sub-optimal time point when XIAP levels are returning to normal, possibly due to an outgrowth of non-transfected cells) identified 16 antisense oligonucleotides (ODNs C2, E2, E3, F3, C4, D4, E4, F4, G4, C5, D5, B6, F6, D7, D8, F8) out of the total 96 antisense oligonucleotides tested that showed some decrease in XIAP protein levels relative to total protein, compared to mock (no ODN) transfection levels (Fig. 7A, 7C, 7E, 7G, 7I, and 7K). Interestingly, total protein was decreased for each of these 16 ODNs, which indicates a toxic or cytostatic effect of these ODNs (Fig. 7B, 7D, 7F, 7H, 7J, 7L). Note that ODNs B9 and C9 showed a clear drop in total protein but no relative drop in XIAP protein levels. These 16 hits were then validated more rigorously at more optimal time points XIAP protein and RNA knock-down results at 12 hours after the start of transfection.

The 16 antisense ODNs that showed some decrease in relative XIAP protein levels compared to mock transfection, were re-tested alone or in combination, with one control oligo (D2) included, for their ability to knock-down XIAP protein at a more optimal time point (12 hours) based on the above described time course studies (Fig. 8B). these ODNs were also examined for their ability to decrease XIAP mRNA levels at 12 hours, normalized against GAPDH levels, and compared to mock transfection. Total protein concentrations at 12 hours were also determined (Fig. 8C).

There was a good correlation between the ability of an antisense ODN to decrease XIAP protein levels (Fig. 8B) with its ability to decrease XIAP mRNA levels (Fig. 8A). In addition, there is no major loss of total protein at this early time point, and the decrease in XIAP mRNA and protein precede the decrease in total protein that is seen at later time points. The ODNs that showed greater than 50% loss of XIAP protein or mRNA levels alone, or in a combination of two ODNs added at a 0.5:0.5 ratio, were identified as the best ODNs and validated further. Of these 16 oligonucleotides, 10 of them (ODNs E2, E3, F3, E4, F4, G4, C5, B6, D7, F8) showed a consistent ability to decrease XIAP protein or RNA levels by more than 50%, depending on the transfection conditions used, or when used in combination, as for ODNs C5 and G4.

Interestingly, these 16 oligonucleotides that demonstrated antisense activity clustered in 4 different target regions of the XIAP mRNA, with adjacent ODNs showing some knock-down activity. No antisense activity was observed by oligonucleotides that target sequences between these regions or islands of sensitivity. Presumably, these regions represent open areas on the mRNA that are accessible to antisense ODNs inside the cell. Two antisense oligonucleotides,E3 and F3, target XIAP just upstream of the start codon in the intervening region between the IRES and the translation start site, and partially overlap the end of the IRES element. ODNs C2, D2, and E2 target a XIAP region upstream of the minimal IRES element, providing further evidence that the minimal IRES region is a highly structured region of RNA which is not readily accessible to antisense ODNs *in vivo*. All the other antisense ODN hits fall within the coding region, including a cluster of activity at positions 856-916 of the HIAP sequence of Fig. 15 (ODNs E4, F4, and G4) and smaller separate areas, as demonstrated by ODNs C5 and D5, for example.

Example 6: XIAP antisense oligonucleotides increase cytotoxicity and chemosensitization

We also investigated if XIAP antisense ODNs could chemosensitize the highly drug resistant T24 cells to traditional chemotherapeutic drugs, such as adriamycin or cisplatin. Antisense ODNs were chosen to represent some of the different XIAP target regions and were tested for their cytotoxic effects, alone or in combination with other ODNs or drugs. Five of the ten best XIAP antisense oligonucleotides were tested for their ability to kill or chemosensitize T24 bladder carcinoma cells, and were compared to the effects of three corresponding scrambled control ODNs.

T24 cells were transfected with XIAP antisense oligonucleotides, scrambled oligonucleotides, no oligonucleotides (mock transfected), or were left untreated. The cells were tested for viability 20 hours after transfection (with the exception of the untreated control) using the WST-1 tetrazolium dye assay in which WST-1 tetrazolium dye is reduced to a colored formazan product in metabolically active cells (Fig 9A). Alternatively, cell viability is tested using any one of the above described apoptosis methods.

The occurrence of cytoxicity induced by the antisense XIAP ODN E4 was examined by visually inspecting T24 cells that were left untreated, mock transfected, or transfected with E4 antisense ODNs, E4 scrambled ODNs, E4 reverse polarity, or E4 mismatched ODNs. Twenty hours after transfection, the cells were examined for morphology (Fig. 9D). Only the cell transfected with antisense E4 ODNs showed signs of toxicity.

To examine the effects of the oligonucleotides on the chemosensitization of the T24 cells to cisplatin or adriamycin, oligonucleotides were tested for their ability to further kill T24 cells in the presence of a fixed dose of adriamycin (0.5 μg/ml). Cells were first

transfected with the oligonucleotides, then adriamycin was added for another 20 hours. Viability was measured by WST-1 at the end of the 20 hour drug treatment (Fig. 9B). Values are shown as percentage viability compared to their ODN treatment alone results shown in Fig. 9C. Fig. 9C is essentially a repeat of Fig. 9A, but with the actual corresponding values used in calculating the results for the chemosensitization experiment in Fig. 9B.

All 5 oligonucleotides tested (ODNs F3, E4, G4, C5, D7, or the combinations of E4+C5, or G4+C5) killed the T24 cells, leaving only 10-15% surviving cells after 24 hours, as compared to the mock (no ODN) transfected cells, or to cells transfected with 3 corresponding scrambled controls to F3 (mCmAmG AGA TTT CAT TTA AmCmG mU; SEQ ID NO: 209), E4 (mCmUmA CgC TCg CCA TCg TmUmC mA; SEQ ID NO: 210) and C5 (mUmGmC CCA AGA ATA CTA GmUmC mA; SEQ ID NO: 211)(Figs. 9A and C). Therefore, the toxicity is sequence-specific to those ODNs that reduce XIAP levels, and not to a non-sequence specific toxicity due to ODNs of this chemistry in general, as three scrambled controls did not show any more toxicity compared to the mock transfected control. This cytotoxicity may result from the combined effect of XIAP protein knock-down (and the expected loss of anti-apoptotic protection afforded by XIAP) and the cytotoxicity of the transfection itself. Both mock (no ODN) and scrambled ODN transfections resulted in an approximately 40% decrease in survival as compared to untreated cells (Fig. 9A). This is not unexpected, as the opposite is true (i.e., overexpression of IAPs protect insect cells from cytofectin-mediated cell death, a liposomal transfection agent similar to the ones used in these studies (Jones et al., J. Biol. Chem. 275:22157-22165, 2000)

The addition of a fixed dose of adriamycin or cisplatin at the end of the 3 hour transfection period resulted in a further decrease in survival for

some of the tested oligonucleotides, a further 40% drop in survival after 20 hours for ODNs F3, D7 and G4+C5 combination (Fig. 9B), compared to their corresponding ODNs treated values (Fig. 9C). Note that the values in Fig. 9B (ODN plus drug) are compared to their corresponding ODN survival (ODN alone) in Fig. 9C, which is set a 100% for each ODN. Only the results for adriamycin chemosensitization are shown; however, similar results were obtained when the cells were chemosensitized with cisplatin. At the fixed doses used, the mock and scrambled control transfections did not show any increased loss of survival when either treated with adriamycin (Fig. 9B). Chemosensitization is only seen when XIAP levels are decreased by a specific antisense ODN.

Example 7: Antisense HIAP1 oligonucleotides decrease HIAP1 RNA and polypeptide expression

The smaller library of 15 HIAP1 antisense oligonucleotides was screened for protein knock-down by Western and for RNA knock-down by TaqMan, using the primers and probes described above, under two different conditions. Alternatively, HIAP1 RNA levels may be detected using standard Northern blot analyses or RT-PCR techniques. The antisense oligonucleotides were administered to cells under basal conditions or under cycloheximide-induction conditions (24 hour treatment with sub-toxic doses). We have discovered that cycloheximide (CHX) can lead to a 10- to 200-fold induction of HIAP1 mRNA depending on the cell line treated. This in turn leads to an increase in HIAP1 protein, as seen on a Western blot (70 kDa band). We have also discovered that this effect of CHX is via two distinct mechanisms of action. First, CHX activates NFkB, a known transcriptional inducer of HIAP1, by blocking the *de novo* synthesis of a labile protein, IkB, which

is an inhibitor of NFkB. This effect is mimicked by puromycin, another protein synthesis inhibitor, and by TNF-alpha, which induces a signaling cascade leading to the phosphorylation, ubiquination, and degradation of IkB. However, only CHX leads to a further stabilization of the HIAP1 mRNA, as seen by the decreased rate of disappearance of HIAP1 message in the presence of actinomycin D, to block *de novo* transcription, and CHX, as opposed to actinomycin D and puromycin or TNF-alpha combined.

SF295 glioblastoma cells were transfected with lipofectin and ODN (scrambled survivin, no oligo or mock, antisense APO1 to APO15) or left untreated. RNA was isolated from the cells 6 hours after transfection and the level of HIAP1 mRNA was measured by quantitative PCR (TaqMan analysis), normalized for GAPDH mRNA, with the value for the scrambled survivin ODN transfection set as 1.0.

The results of this experiment, a compilation of three separate experiments, are shown in Fig. 10. The scrambled survivin ODN, the mock transfection, and untreated (non-transfected) cells, all showed similar HIAP1 mRNA levels. Of the 15 antisense ODNs, 7 oligonucleotides (ODNs APO 1, -2, -7, -8, -9, -12, -15) showed an almost 50% decrease when compared to mock transfection or survivin scrambled control (mUmAmA GCT GTT CTA TGT GmUmU mC; SEQ ID NO: 212) ODN transfection (Fig. 10). Some of the ODNs led to an induction in HIAP1 mRNA, which may be a stress response to a non-specific toxic ODN. The antisense ODN, however, may still be effective at knocking down HIAP1 protein levels even if the message is increased if the ODN is able to interfere with the translation process.

The effect of HIAP1 antisense oligonucleotides on HIAP1 protein and mRNA expression was also examined in cells induced to express HIAP1. SF295 cells were transfected with ODNs, or were mock

transfected. The transfected cells were then treated with 10 μg/ml cycloheximide for 24 hours to induce 70 kDa HIAP1 mRNA and protein. Protein levels were measured by Western immunoblot analysis with an anti-RIAP1 polyclonal antibody, and normalized against actin protein in a re-probing of the same blots. Scans of the Western blot results are shown in Fig. 11A. The densitometric scan results were plotted against the mock results (set at 100%) in Fig. 11B. A line is drawn at 50% to easily identify the most effective antisense ODNs. The transfection process itself (e.g., mock or scrambled survivin) induces HIAP1 protein compared to the untreated sample as shown on the Western immunoblot.

Of the 15 tested ODNs, 6 of them (APO 1, -2, -7, -8, -12, and -15) showed the strongest activity, or had significant activity in both the protein and mRNA assays, and did not cause a stress-induced increase in HIAP1 mRNA, such as that seen with ODNs APO 4, -6, -11, -13, -14 (Fig. 10), and by control ODNs to APO 2 (mismatch or reverse polarity, see text below and Figs.12 and 13). Note that APO 6 also showed evidence of toxicity as seen by the general decrease in total protein (Fig. 12).

To further investigate the efficacy of HIAP1 antisense oligonucleotides under cycloheximide induction conditions, changes in HIAP1 mRNA were measured by TaqMan real time PCR 6 hours after transfection with ODN APO 2, which targets an Alu repeat within an intron of HIAP1 and results in the greatest block of CHX-induced upregulation of HIAP1 mRNA and protein. Controls for this experiment were three ODNs for APO 2: one scrambled sequence (same base composition but random order, AAG GGC GGC GGA GTG AGA C; SEQ ID NO: 213), one reverse polarity (same base composition, same sequential order but in the opposite direction, AGA GGA CGG AGT CGG

AGG C; SEQ ID NO: 214), and one mismatch sequence (containing 4 base mismatches out of 19 bases, CGG AGC GTG AGG ATG GAG A; SEQ ID NO: 215).

Transfection of the APO 2 antisense into cells resulted in a 50% decrease in mRNA compared to a scrambled survivin control and matched perfectly with the protein results, while the scrambled control for APO 2 (H1 sc apo 2 in Fig. 13) did not change HIAP1 mRNA levels at all (repeated twice here, and in two different experiments). However, the mismatch control ODN (H1 mm apo 2) and the reverse polarity control ODN (H1 RV apo 2) showed an induction of 6 to 7 fold in HIAP1 mRNA at 6 hours. These ODNs no longer targeted HIAP1, as expected, but may still target Alu repeats because of the degeneracy and repeat nature of these sequences. Therefore, it is possible that these two controls are toxic to the cell and cause a stress response that leads to the induction of HIAP1. This effect may also occur with the antisense APO 2 ODN, but in this case, the APO 2 ODN also causes the degradation of the induced HIAP1 mRNA which results in a relative decrease of HIAP1 mRNA, compared to a scrambled survivin control, as well as decreasing the relative fold induction of HIAP1 protein after transfection and CHX treatment, compared to scrambled survivin control ODN.

The 6 optimal antisense HIAP1 ODNs include two very effective antisense ODNs against an intronic sequence (APO 1, and -2; with APO 2 demonstrating the best activity). These oligonucleotides have some interesting properties that could be of great use therapeutically for cancer or autoimmune disorders. The oligonucleotides against an intronic sequence would likely only target pre-mRNA (very short-lived target) and not the mature, processed form of HIAP1. Typically, introns are not targeted for antisense except when one wants to alter splicing by targeting the intron-exon boundaries or the branching point. These usually result in

the skipping of an exon rather than RNase-mediated degradation of the message. Both mechanisms would likely be favorable for the enhancement of apoptosis, as the skipping would result in the loss of the exon encoding the first two important BIR domains of HIAP1. The APO-2 antisense oligo also targets an intron of survivin for 18 consecutive bases out of 19, but we did not see any loss of survivin protein; only HIAP1 was decreased after the oligo treatment, demonstrating the specificity of the HIAP1 antisense oligonucleotide. These antisense oligonucleotides hit Alu sequences in the HIAP1 intron and potentially in many other genes, and induce the cancer cells to die (see below), which may be as a result of down regulating HIAP1 and some other critical genes, and thus of therapeutic value if it is not too toxic to normal cells.

Cancer cells have reportedly more Alu-containing transcripts and may therefore be more sensitive to apoptosis induction with an Alu targeting antisense ODN. Furthermore, this killing effect of APO 1 and APO 2 ODNs may be due to the combined effect of both targeting Alu sequences and HIAP1 simultaneously. This dual effect would result in an effective way to prevent the normal stress response of HIAP1 induction through the NFkB pathway, when the cell is exposed to certain toxic agents. This stress response is most likely part of the cancer cell's anti-apoptotic program. By blocking HIAP1 expression, we counter this anti-apoptotic stress response and precipitate the cancer cell's demise.

Example 8: HIAP1 antisense oligonucleotides increase cytotoxicity and chemosensitization

The effect of HIAP1 antisense oligonucleotides on the chemosentization of SF295 cells was also evaluated. Cells were transfected with one of 3 different antisense ODNs (APO 7, APO 15, and Scrambled APO 2 (control)). Twenty-four hours after tranfection with the

ODNs, the cells were incubated with adriamycin for an additional 24 hours before assaying by for cell survival by assaying WST-1.

The WST-1 survival curves for SF295 cells transfected with the above-described HIAP1 ODNs and then treated with increasing concentrations of adriamycin are shown in Fig. 14. The two ODNs that resulted in a decrease in HIAP1 mRNA also showed a decrease in survival when treated with adriamycin compared to cells treated with an ODN which did not reduce HIAP1 mRNA levels. Therefore, reducing HIAP1 levels by antisense, or other means, can chemosensitize a glioblastoma cell line that is highly resistant to the cytotoxic action of many chemotherapeutic drugs.

Example 9: *In vivo* analyses of IAP antisense oligonucleotides

Antisense oligonucleotides that decrease expression of IAP in cell culture models can be tested in animals. For example, the antisense oligonucleotide can be tested in mice according to the method of Lopes de Menezes et al. (Clin. Cancer Res. 6: 2891-2902, 2000) or Klasa et al. (Clin. Cancer Res. 6: 2492-2500, 2000). Antisense and control ODNs are tested, for example, in sub-cutaneous human xenografts of breast cancer, colon cancer, lung cancer, squamous cell carcinoma or prostate cancer in SCID mice. The antisense oligonucleotides are also tested in an orthotopic model for the prostate, as well as in a disseminated non-Hodgkin's lymphoma model. The mouse's tolerance to cisplatin, taxol, doxorubicin, and cyclophosphamide is known for each of these models.

*In vivo* testing of the antisense oligonucleotides involves 15 intraperitoneal injections (once a day, on days 3 through 7, 10 through 14, and 17 through 21) of naked ODN of (5 mg/kg), with or without a chemotherapeutic drug. Alternatively, liposomal type carriers for the ODNs may also be employed. Oligos are injected shortly after tumors

cells have been seeded in the mouse, or when the tumor has established and grown to a size of 0.1-0.15 g. Tumor size is then monitored to determine if the ODN treatments or ODN plus drug treatments reduce the growth rate of the tumor, lead to regression, or have no effect at all. In another alternative, ODNs in liposomal formulation are injected directly into the tumors.

Example 10: Anti-IAP antibodies

In order to generate IAP-specific antibodies, an IAP coding sequence (e.g., amino acids 180-276) can be expressed as a C-terminal fusion with glutathione S-transferase (GST; Smith et al., Gene 67:31-40, 1988). The fusion protein can be purified on glutathione-Sepharose beads, eluted with glutathione, and cleaved with thrombin (at the engineered cleavage site), and purified to the degree required to successfully immunize rabbits. Primary immunizations can be carried out with Freund's complete adjuvant and subsequent immunizations performed with Freund's incomplete adjuvant. Antibody titres are monitored by Western blot and immunoprecipitation analyses using the thrombin-cleaved IAP fragment of the GST-IAP fusion protein. Immune sera are affinity-purified using CNBr-Sepharose-coupled IAP protein. Antiserum specificity is determined using a panel of unrelated GST proteins (including GSTp53, Rb, HPV-16 E6, and E6-AP) and GST-trypsin (which was generated by PCR using known sequences).

As an alternate or adjunct immunogen to GST fusion proteins, peptides corresponding to relatively unique hydrophilic regions of IAP may be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine. Antiserum to each of these peptides is similarly affinity-purified on peptides conjugated to BSA, and specificity is tested by ELISA and Western blotting, using peptide

conjugates, and by Western blotting and immunoprecipitation using IAP expressed as a GST fusion protein.

Alternatively, monoclonal antibodies may be prepared using the IAP proteins described above and standard hybridoma technology (see, e.g., Kohler et al., Nature 256:495, 1975; Kohler et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol. 6:292, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, New York, NY, 1981; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1994). Once produced, monoclonal antibodies are also tested for specific IAP recognition by Western blot or immunoprecipitation analysis (by the methods described in Ausubel et al., *supra*).

Antibodies that specifically recognize IAPs or fragments of IAPs, such as those described in U.S.S.N. 08/800,929, incorporated herein by reference, containing one or more BIR domains (but not a ring zinc finger domain), or that contain a ring zinc finger domain (but not a BIR domain) are considered useful in the invention. They may, for example, be used in an immunoassay to monitor IAP expression levels or to determine the subcellular location of an IAP or IAP fragment produced by a mammal. Antibodies that inhibit the 26 kDa IAP cleavage product described herein (which contains at least one BIR domain) may be especially useful in inducing apoptosis in cells undergoing undesirable proliferation.

Preferably antibodies of the invention are produced using IAP sequence that does not reside within highly conserved regions, and that appears likely to be antigenic, as analyzed by criteria such as those provided by the Peptide structure program (Genetics Computer Group Sequence Analysis Package, Program Manual for the GCG Package, Version 7, 1991) using the algorithm of Jameson and Wolf (CABIOS 4:181, 1988). Specifically, these regions, which are found between BIR1

and BIR2 of all IAPs, are: from amino acid 99 to amino acid 170 of HIAP1, from amino acid 123 to amino acid 184 of HIAP2, and from amino acid 116 to amino acid 133 of either XIAP or m-XIAP. These fragments can be generated by standard techniques, e.g., by the PCR, and cloned into the pGEX expression vector (Ausubel et al., *supra*). Fusion proteins are expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel et al. (*supra*). In order to minimize the potential for obtaining antisera that is non-specific, or exhibits low-affinity binding to IAP, two or three fusions are generated for each protein, and each fusion is injected into at least two rabbits. Antisera are raised by injections in series, preferably including at least three booster injections.

Example 11: Comparison of cell survival following transfection with full length vs. partial IAP constructs

In order to investigate the mechanism whereby human IAPs, including XIAP, HIAP1, and HIAP2, afford protection against cell death, expression vectors were constructed that contained either: (1) full-length IAP cDNA (as described in U.S.S.N. 08/800,929), (2) a portion of an IAP gene that encodes the BIR domains, but not the RZF, or (3) a portion of an IAP gene that encodes the RZF, but not the BIR domains. Human and murine XIAP cDNAs were tested by transient or stable expression in HeLa, Jurkat, and CHO cell lines. Following transfection, apoptosis was induced by serum withdrawal, application of menadione, or application of an anti-Fas antibody. Cell death was then assessed by trypan blue exclusion. As a control for transfection efficiency, the cells were co-transfected with a Beta-gal expression construct. Typically, approximately 20% of the cells were successfully transfected.

When CHO cells were transiently transfected, constructs containing full-length human or mouse XIAP cDNAs conferred modest but definite protection against cell death. In contrast, the survival of CHO cells transfected with constructs encoding only the BIR domains (i.e., lacking the RZF domain) was markedly enhanced 72 hours after serum deprivation. Furthermore, a large percentage of cells expressing the BIR domains were still viable after 96 hours, at which time no viable cells remained in the control, i.e. non-transfected, cell cultures, and less than 5% of the cells transfected with the vector only, i.e., lacking a cDNA insert, remained viable. Deletion of any of the BIR domains results in the complete loss of apoptotic suppression, which is reflected by a decrease in the percentage of surviving CHO cells to control levels within 72 hours of serum withdrawal.

Stable pools of transfected CHO cells, which were maintained for several months under G418 selection, were induced to undergo apoptosis by exposure to 10 μM menadione for 2 hours. Among the CHO cells tested were those that were stably transfected with: (1) full-length murine XIAP cDNA (miap), (2) full-length XIAP cDNA (XIAP), (3) full-length bcl-2 cDNA (Bcl-2), (4) cDNA encoding the three BIR domains (but not the RZF) of murine XIAP (BIR), and (5) cDNA encoding the RZF (but not BIR domains) of m-XIAP (RZF). Cells that were non-transfected (CHO) or transfected with the vector only (pcDNA3), served as controls for this experiment. Following exposure to 10 μM menadione, the transfected cells were washed with phosphate buffered saline (PBS) and cultured for an additional 24 hours in menadione-free medium. Cell death was assessed, as described above, by trypan blue exclusion. Less than 10% of the non-transfected or vector-only transfected cells remained viable at the end of the 24 hour survival period. Cells expressing the RZF did not fare significantly better. However, expression of full-length

murine XIAP, human XIAP, or bcl-2, and expression of the BIR domains, enhanced cell survival. When the concentration of menadione was increased from 10 μM to 20 μM (with all other conditions of the experiment being the same as when 10 μM menadione was applied), the percentage of viable CHO cells that expressed the BIR domain cDNA construct was higher than the percentage of viable cells that expressed either full-length murine XIAP or bcl-2.

Example 12: Analysis of the subcellular location of expressed RZF and BIR domains

The assays of cell death described above indicate that the RZF acts as a negative regulator of the anti-apoptotic function of IAPs. One way in which the RZF, and possibly other IAP domains, may exert their regulatory influence is by altering the expression of genes, whose products function in the apoptotic pathway.

In order to determine whether the subcellular locations of expressed RZF and BIR domains are consistent with roles as nuclear regulatory factors, COS cells were transiently transfected with the following four constructs, and the expressed polypeptide was localized by immunofluorescent microscopy: (1) pcDNA3-6myc-xiap, which encodes all 497 amino acids of SEQ ID NO:219, (2) pcDNA3-6myc-m-xiap, which encodes all 497 amino acids of mouse XIAP (SEQ ID NO:225), (3) pcDNA3-6myc-mxiap-BIR, which encodes amino acids 1 to 341 of m-xiap (SEQ ID NO:225), and (4) pcDNA3-6myc-mxiap-RZF, which encodes amino acids 342-497 of murine xiap (SEQ ID NO:225). The cells were grown on multi-well tissue culture slides for 12 hours, and then fixed and permeabilized with methanol. The constructs used (here and in the cell death assays) were tagged with a human Myc epitope tag at the N-terminus. Therefore, a monoclonal anti-Myc antibody and a secondary

goat anti-mouse antibody, which was conjugated to FITC, could be used to localize the expressed products in transiently transfected COS cells. Full-length XIAP and MIAP were located in the cytoplasm, with accentuated expression in the peri-nuclear zone. The same pattern of localization was observed when the cells expressed a construct encoding the RZF domain (but not the BIR domains). However, cells expressing the BIR domains (without the RZF) exhibited, primarily, nuclear staining. The protein expressed by the BIR domain construct appeared to be in various stages of transfer to the nucleus.

Other Embodiments

All publications and patent applications mentioned in this specification, including U.S. Patent No. 5,919,912 and U.S.S.Ns. 08/576,956 and 08/800,929 are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

## Claims

1. An inhibitor of apoptosis (IAP) antisense nucleic acid that inhibits IAP biological activity, regardless of length of said antisense nucleic acid.

2. The antisense IAP nucleic acid of claim 1, wherein said IAP is XIAP.

3. The antisense IAP nucleic acid of claim 1, wherein said IAP is HIAP1.

4. The antisense IAP nucleic acid of claim 1, wherein said IAP is HIAP2.

5. The antisense IAP nucleic acid of claim 1, wherein said antisense nucleic acid is mammalian.

6. The antisense IAP nucleic acid of claim 5, wherein said antisense nucleic acid is human.

7. The antisense nucleic acid of claim 1, wherein said antisense nucleic acid is between 8 and 30 nucleotides in length.

8. The antisense IAP nucleic acid of claim 2, wherein said antisense is chosen from any one of SEQ ID NOS: 1 through 96.

9. The antisense IAP nucleic acid of claim 3, wherein said antisense is chosen from any one of SEQ ID NOS: 97 through 194.

10. The antisense IAP nucleic acid of claim 1, wherein said IAP biological activity is inhibition of apoptosis.

11. The antisense IAP nucleic acid of claim 1, wherein said IAP biological activity is inhibition of IAP polypeptide expression.

12. The antisense IAP nucleic acid of claim 1, wherein said antisense nucleic acid comprises at least one modified internucleoside linkage.

13. The antisense IAP nucleic acid of claim 12, wherein said modified internucleoside linkage is selected from the group consisting of phosphorothioate, methylphosphonate, phosphotriester, phosphorodithioate, and phosphoselenate linkages.

14. The antisense IAP nucleic acid of claim 1, wherein said antisense nucleic acid comprises at least one modified sugar moiety.

15. The antisense IAP nucleic acid of claim 14, wherein said modified sugar moiety is a 2'-O methyl group.

16. The antisense IAP nucleic acid of claim 1, wherein said antisense nucleic acid is a chimeric nucleic acid.

17. The antisense IAP nucleic acid of claim 16, wherein said chimeric nucleic acid comprises DNA residues linked together by phosphorothioate linkages, said DNA residues flanked on each side by at least one 2'-O methyl RNA residues linked together by phosphorothioate linkages.

18. The antisense IAP nucleic acid of claim 17, wherein said DNA residues are flanked on each side by at least 3 2'-O methyl RNA residues.

19. The antisense nucleic acid of claim 1, wherein said antisense nucleic acid is a ribozyme.

20. A method of enhancing apoptosis in a cell, said method comprising administering a negative regulator of the IAP anti-apoptotic pathway to said cell.

21. The method of claim 20, wherein said negative regulator is an antisense IAP nucleic acid.

22. The method of claim 21, wherein said IAP is XIAP.

23. The method of claim 21, wherein said IAP is HIAP1.

24. The method of claim 21, wherein said IAP is HIAP2.

25. The method of claim 21, wherein said antisense nucleic acid is mammalian.

26 The method of claim 25, wherein said antisense nucleic acid is human.

27. The method of claim 22, wherein said antisense is chosen from any one of SEQ ID NOS: 1 through 96.

28. The method of claim 23, wherein said antisense is chosen from any one of SEQ ID NOS: 97 through 194.

29. The method of claim 21, wherein said antisense nucleic acid comprises at least one modified internucleoside linkage.

30. The method of claim 29, wherein said modified internucleoside linkage is selected from the group consisting of phosphorothioate, methylphosphonate, phosphotriester, phosphorodithioate, and phosphoselenate linkages.

31. The method of claim 21, wherein said antisense nucleic acid comprises at least one modified sugar moiety.

32. The method of claim 31, wherein said modified sugar moiety is a 2'-O methyl group.

33. The method of claim 21, wherein said antisense nucleic acid is a chimeric nucleic acid.

34. The method of claim 33, wherein said chimeric nucleic acid comprises DNA residues linked together by phosphorothioate linkages, said DNA residues flanked on each side by at least one 2'-O methyl RNA residues linked together by phosphorothioate linkages.

35. The method of claim 34, wherein said DNA residues are flanked on each side by at least 3 2'-O methyl RNA residues.

36. The method of claim 21, wherein said administration sensitizes said cell to chemotherapy.

37. The method of claim 21, wherein said administration sensitizes said cell to radiotherapy.

38. The method of claim 20, wherein said negative regulator is an antibody that specifically binds an IAP polypeptide.

39. The method of claim 20, wherein said negative regulator is an IAP polypeptide comprising a ring zinc finger, said polypeptide having no more than two BIR domains.

40. The method of claim 20, wherein said negative regulator is a nucleic acid encoding the ring zinc finger domain of an IAP polypeptide.

41. The method of claim 20, wherein said negative regulator is a compound that prevents cleavage of the IAP polypeptide.

42. The method of claim 20, wherein said cell is *in vitro*.

43. The method of claim 20, wherein said cell is *in vivo*.

44. The method of claim 43, wherein said cell is in a mammal diagnosed with a proliferative disease.

45. A pharmaceutical composition comprising a mammalian IAP antisense nucleic acid.

46. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the human XIAP gene or mRNA.

47. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the human HIAP1 gene or mRNA.

48. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the human HIAP2 gene or mRNA.

49. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the murine XIAP gene or mRNA.

50. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the murine HIAP1 gene or mRNA.

51. The pharmaceutical composition of claim 45, wherein said antisense nucleic acid binds a target sequence of the murine HIAP2 gene or mRNA.

52. The pharmaceutical composition of claim 45, wherein said mammalian antisense IAP nucleic acid is human antisense nucleic acid.

53. The pharmaceutical composition of claim 46, wherein said antisense is chosen from any one of SEQ ID NOS: 1 through 96.

54. The pharmaceutical composition of claim 47, wherein said antisense is chosen from any one of SEQ ID NOS: 97 through 194.

5

FIG. 1A

HUMAN xiap

```
                gaaaaggtggacaagtcctaatttcaagagaagatgactttaacagttttgaaggatct
             1  ----------+----------+----------+----------+----------+---- 60
a                                    M  T  F  N  S  F  E  G  S  -
                aaaacttgtgtacctgcagacatcaataaggaagaagaatttgtagaagagttaataga
            61  ----------+----------+----------+----------+----------+---- 120
a               K  T  C  V  P  A  D  I  N  K  E  E  E  F  V  E  E  F  N  R  -
                ttaaaaactttgctaatttccaagtggtagtcctgtttcagcatcaacactggcacga
           121  ----------+----------+----------+----------+----------+---- 180
a               L  K  T  F  A  N  F  P  S  G  S  P  V  S  A  S  T  L  A  R  -
                gcagggtttctttatactggtgaaggagataccgtgcggtgctttagttgtcatgcagct
           181  ----------+----------+----------+----------+----------+---- 240
a               A  G  F  L  Y  T  G  E  G  D  T  V  R  C  F  S  C  H  A  A  -
                gtagatagatggcaatatggagactcagcagttggaagacacaggaaagtatcccaaat
           241  ----------+----------+----------+----------+----------+---- 300
a               V  D  R  W  Q  Y  G  D  S  A  V  G  R  H  R  K  V  S  P  N  -
                tgcagatttatcaacggctttttatcttgaaaatagtgccacgcagtctacaaattctggt
           301  ----------+----------+----------+----------+----------+---- 360
a               C  R  F  I  N  G  F  Y  L  E  N  S  A  T  Q  S  T  N  S  G  -
```

FIG. 1B

HUMAN xiap

SUBSTITUTE SHEET (RULE 26)

FIG. 1C

HUMAN xiap






SUBSTITUTE SHEET (RULE 26)

FIG. 1D

HUMAN xiap

```
     gagtgtctggtaagaactactgagaaaacaccatcactaactagaagaattgatgatacc
1081 ---------+---------+---------+---------+---------+---------+ 1140

a        E  C  L  V  R  T  T  E  K  T  P  S  L  T  R  R  I  D  D  T  -

     atcttccaaaatcctatggtacaagaagctatacgaatggggttcagtttcaaggacatt
1141 ---------+---------+---------+---------+---------+---------+ 1200

a        I  F  Q  N  P  M  V  Q  E  A  I  R  M  G  F  S  F  K  D  I  -

     aagaaaataatggaggaaaaaattcagatatctgggagcaactataaatcacttgaggtt
1201 ---------+---------+---------+---------+---------+---------+ 1260

a        K  K  I  M  E  E  K  I  Q  I  S  G  S  N  Y  K  S  L  E  V  -

     ctggttgcagatctagtgaatgctcagaaagacagtatgcaagatgagtcaagtcagact
1261 ---------+---------+---------+---------+---------+---------+ 1320

a        L  V  A  D  L  V  N  A  Q  K  D  S  M  Q  D  E  S  S  Q  T  -

     tcattacagaaagagattagtactgaagagcagctaaggcgcctgcaagaggagaagctt
1321 ---------+---------+---------+---------+---------+---------+ 1380

a        S  L  Q  K  E  I  S  T  E  E  Q  L  R  R  L  Q  E  E  K  L  -

     tgcaaaatctgtatggatagaaatattgctatcgtttttgttccttgtggacatctagtc
1381 ---------+---------+---------+---------+---------+---------+ 1440

a        C  K  I  C  M  D  R  N  I  A  I  V  F  V  P  C  G  H  L  V  -
```

FIG. 1E

HUMAN xiap

```
     acttgtaaacaatgtgctgaagcagttgacaagtgtcccatgtgctacacagtcattact
1441 ---------+---------+---------+---------+---------+---------+ 1500

a         T  C  K  Q  C  A  E  A  V  D  K  C  P  M  C  Y  T  V  I  T   -

     ttcaagcaaaaaatttttatgtcttaatctaactctatagtaggcatgttatgttgttct
1501 ---------+---------+---------+---------+---------+---------+ 1560

a         F  K  Q  K  I  F  M  S  *                                   -

     tattaccctgattgaatgtgtgatgtgaactgactttaagtaatcaggattgaattccat
1561 ---------+---------+---------+---------+---------+---------+ 1620

a                                                                    -

     tagcatttgctaccaagtaggaaaaaaaatgtacatggcagtgttttagttggcaatata
1621 ---------+---------+---------+---------+---------+---------+ 1680

a                                                                    -

     atctttgaatttcttgatttttcagggtattagctgtattatccatttttttttactgtta
1681 ---------+---------+---------+---------+---------+---------+ 1740

a                                                                    -

     tttaattgaaaccatagactaagaataagaagcatcatactataactgaacacaatgtgt
1741 ---------+---------+---------+---------+---------+---------+ 1800

a                                                                    -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 1F

HUMAN xiap



FIG. 1G


HUMAN xiap
nagatatgttaagtgtaaaatgcaagtggcnnnacactatgtatagtctgagccagatca
2161 ----------+----------+----------+----------+----------+ 2220
a -
aagtatgtatgttnttaatatgcatagaacnanagatttggaaagatatacaccaaactg
2221 ----------+----------+----------+----------+----------+ 2280
a -
ttaaatgtggttctcttcgggagggggggattgggggagggggccccagaggggtttta
2281 ----------+----------+----------+----------+----------+ 2340
a -
naggggccttttcacttttcnactttttttcatttttgttctgttcgnatttttttataagtat
2341 ----------+----------+----------+----------+----------+ 2400
a -
gtanaccccnaagggttttatggnaactaacatcagtaacctaaccccccgtgactatcct
2401 ----------+----------+----------+----------+----------+ 2460
a -
gtnctcttccctagggagctgtnttgtttcccaccccaccaccctttcccctctgaacaaatgc
2461 ----------+----------+----------+----------+----------+ 2520
a -
ctgagtgctgggggcactttn
2521 ----------+----------+ 2540
a -

FIG. 2A


HUMAN hiap-1
TCCTTGAGATGTATCAGTATAGGATTTAGGATCTCCATGTTGGAACTCTAAATGCATAGA
1 ----------+----------+----------+----------+----------+----------+ 60
C -
AATGGAAATAATGGAAATTTTTCATTTTGGCTTTTCAGCCTAGTATTAAAACTGATAAAA
61 ----------+----------+----------+----------+----------+----------+ 120
C -
GCAAAGCCATGCACAAAACTACCTCCCTAGAGAAAGGCTAGTCCCTTTTCTTCCCCATTC
121 ----------+----------+----------+----------+----------+----------+ 180
C -
ATTTCATTATGAACATAGTAGAAAACAGCATATTCTTATCAAATTTGATGAAAAGCGCCA
181 ----------+----------+----------+----------+----------+----------+ 240
C M N I V E N S I F L S N L M K S A N -
ACACGTTTGAACTGAAATACGACTTGTCATGTGAACTGTACCGAATGTCTACGTATTCCA
241 ----------+----------+----------+----------+----------+----------+ 300
C T F E L K Y D L S C E L Y R M S T Y S T -
CTTTTCCTGCTGGGGTTCCTGTCTCAGAAAGGAGTCTTGCTCGTGCTGGTTTCTATTACA
301 ----------+----------+----------+----------+----------+----------+ 360
C F P A G V P V S E R S L A R A G F Y Y T -

SUBSTITUTE SHEET (RULE 26)

FIG. 2B

HUMAN hiap-1



FIG. 2C

HUMAN hiap-1

```
      CATGGCCATTGACTTTTCTGTCGCCAACAGATCTGGCACGAGCAGGCTTTTACTACATAG
  721 ---------+---------+---------+---------+---------+---------+ 780
C           W  P  L  T  F  L  S  P  T  D  L  A  R  A  G  F  Y  Y  I  G -
      GACCTGGAGACAGAGTGGCTTGCTTTGCCTGTGGTGGAAAATTGAGCAATTGGGAACCGA
  781 ---------+---------+---------+---------+---------+---------+ 840
C           P  G  D  R  V  A  C  F  A  C  G  G  K  L  S  N  W  E  P  K -
      AGGATAATGCTATGTCAGAACACCTGAGACATTTTCCCAAATGCCCATTTATAGAAAATC
  841 ---------+---------+---------+---------+---------+---------+ 900
C           D  N  A  M  S  E  H  L  R  H  F  P  K  C  P  F  I  E  N  Q -
      AGCTTCAAGACACTTCAAGATACACAGTTTCTAATCTGAGCATGCAGACACATGCAGCCC
  901 ---------+---------+---------+---------+---------+---------+ 960
C           L  Q  D  T  S  R  Y  T  V  S  N  L  S  M  Q  T  H  A  A  R -
      GCTTTAAAACATTCTTTAACTGGCCCTCTAGTGTTCTAGTTAATCCTGAGCAGCTTGCAA
  961 ---------+---------+---------+---------+---------+---------+ 1020
C           F  K  T  F  F  N  W  P  S  S  V  L  V  N  P  E  Q  L  A  S -
      GTGCGGGTTTTTATTATGTGGGTAACAGTGATGATGTCAAATGCTTTTGCTGTGATGGTG
 1021 ---------+---------+---------+---------+---------+---------+ 1080
C           A  G  F  Y  Y  V  G  N  S  D  D  V  K  C  F  C  C  D  G  G -
```



SUBSTITUTE SHEET (RULE 26)

FIG. 2D

HUMAN hiap-1

```
        GACTCAGGTGTTGGGAATCTGGAGATGATCCATGGGTTCAACATGCCAAGTGGTTTCCAA
1081    ---------+---------+---------+---------+---------+---------+ 1140

c         L  R  C  W  E  S  G  D  D  P  W  V  Q  H  A  K  W  F  P  R -

        GGTGTGAGTACTTGATAAGAATTAAAGGACAGGAGTTCATCCGTCAAGTTCAAGCCAGTT
1141    ---------+---------+---------+---------+---------+---------+ 1200

c         C  E  Y  L  I  R  I  K  G  Q  E  F  I  R  Q  V  Q  A  S  Y -

        ACCCTCATCTACTTGAACAGCTGCTATCCACATCAGACAGCCCAGGAGATGAAAATGCAG
1201    ---------+---------+---------+---------+---------+---------+ 1260

c         P  H  L  L  E  Q  L  L  S  T  S  D  S  P  G  D  E  N  A  E -

        AGTCATCAATTATCCATTTGGAACCTGGAGAAGACCATTCAGAAGATGCAATCATGATGA
1261    ---------+---------+---------+---------+---------+---------+ 1320

c         S  S  I  I  H  L  E  P  G  E  D  H  S  E  D  A  I  M  M  N -

        ATACTCCTGTGATTAATGCTGCCGTGGAAATGGGCTTTAGTAGAAGCCTGGTAAAACAGA
1321    ---------+---------+---------+---------+---------+---------+ 1380

c         T  P  V  I  N  A  A  V  E  M  G  F  S  R  S  L  V  K  Q  T -

        CAGTTCAGAGAAAAATCCTAGCAACTGGAGAGAATTATAGACTAGTCAATGATCTTGTGT
1381    ---------+---------+---------+---------+---------+---------+ 1440

c         V  Q  R  K  I  L  A  T  G  E  N  Y  R  L  V  N  D  L  V  L -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 2E

HUMAN hiap-1

```
        TAGACTTACTCAATGCAGAAGATGAAATAAGGGAAGAGGAGAGAGAAAGAGCAACTGAGG
    1441 ---------+---------+---------+---------+---------+---------+ 1500

c             D   L   L   N   A   E   D   E   I   R   E   E   E   R   E   R   A   T   E   E -

        AAAAAGAATCAAATGATTTATTATTAATCCGGAAGAATAGAATGGCACTTTTTCAACATT
    1501 ---------+---------+---------+---------+---------+---------+ 1560

c             K   E   S   N   D   L   L   L   I   R   K   N   R   M   A   L   F   Q   H   L -

        TGACTTGTGTAATTCCAATCCTGGATAGTCTACTAACTGCCGGAATTATTAATGAACAAG
    1561 ---------+---------+---------+---------+---------+---------+ 1620

c             T   C   V   I   P   I   L   D   S   L   L   T   A   G   I   I   N   E   Q   E -

        AACATGATGTTATTAAACAGAAGACACAGACGTCTTTACAAGCAAGAGAACTGATTGATA
    1621 ---------+---------+---------+---------+---------+---------+ 1680

c             H   D   V   I   K   Q   K   T   Q   T   S   L   Q   A   R   E   L   I   D   T -

        CGATTTTAGTAAAAGGAAATATTGCAGCCACTGTATTCAGAAACTCTCTGCAAGAAGCTG
    1681 ---------+---------+---------+---------+---------+---------+ 1740

c             I   L   V   K   G   N   I   A   A   T   V   F   R   N   S   L   Q   E   A   E -

        AAGCTGTGTTATATGAGCATTTATTTGTGCAACAGGACATAAAATATATTCCCACAGAAG
    1741 ---------+---------+---------+---------+---------+---------+ 1800

c             A   V   L   Y   E   H   L   F   V   Q   Q   D   I   K   Y   I   P   T   E   D -
```



SUBSTITUTE SHEET (RULE 26)

FIG. 2F

HUMAN hiap-1

```
        ATGTTTCAGATCTACCAGTGGAAGAACAATTGCGGAGACTACCAGAAGAAAGAACATGTA
1801    ---------+---------+---------+---------+---------+---------+ 1860

C         V  S  D  L  P  V  E  E  Q  L  R  R  L  P  E  E  R  T  C  K -

        AAGTGTGTATGGACAAAGAAGTGTCCATAGTGTTTATTCCTTGTGGTCATCTAGTAGTAT
1861    ---------+---------+---------+---------+---------+---------+ 1920

C         V  C  M  D  K  E  V  S  I  V  F  I  P  C  G  H  L  V  V  C -

        GCAAAGATTGTGCTCCTTCTTTAAGAAAGTGTCCTATTTGTAGGAGTACAATCAAGGGTA
1921    ---------+---------+---------+---------+---------+---------+ 1980

C         K  D  C  A  P  S  L  R  K  C  P  I  C  R  S  T  I  K  G  T -

        CAGTTCGTACATTTCTTTCATGAAGAAGAACCAAAACATCGTCTAAACTTTAGAATTAAT
1981    ---------+---------+---------+---------+---------+---------+ 2040

C         V  R  T  F  L  S  *                                        -

        TTATTAAATGTATTATAACTTTAACTTTTATCCTAATTTGGTTTCCTTAAAATTTTTATT
2041    ---------+---------+---------+---------+---------+---------+ 2100

C                                                                    -

        TATTTACAACTCAAAAAACATTGTTTTGTGTAACATATTTATATATGTATCTAAACCATA
2101    ---------+---------+---------+---------+---------+---------+ 2160

C                                                                    -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 2G


HUMAN hiap-1
TGAACATATATTTTTTAGAAACTAAGAGAATGATAGGCTTTTGTTCTTATGAACGAAAAA
2161 ----------+----------+----------+----------+----------+----------+ 2220
C -
GAGGTAGCACTACAAACACAATATTCAATCCAAATTTCAGCATTATTGAAATTGTAAGTG
2221 ----------+----------+----------+----------+----------+----------+ 2280
C -
AAGTAAAACTTAAGATATTTGAGTTAACCTTTAAGAATTTTTAAATATTTTGGCATTGTAC
2281 ----------+----------+----------+----------+----------+----------+ 2340
C -
TAATACCGGGAACATGAAGCCAGGTGTGGTGGTATGTACCTGTAGTCCCAGGCTGAGGCA
2341 ----------+----------+----------+----------+----------+----------+ 2400
C -
AGAGAATTACTTGAGCCCAGGAGTTTGAATCCATCCTGGGCAGCATACTGAGACCCTGCC
2401 ----------+----------+----------+----------+----------+----------+ 2460
C -
TTTAAAAACXAACAGXACCAAAXCCAAACACCAGGGACACATTTCTCTGTCTTTTTTGAT
2461 ----------+----------+----------+----------+----------+----------+ 2520
C -

FIG. 2H


HUMAN hiap-1
2521
CAGTGTCCTATACATCGAAGGTGTGCATATATGTTGAATCACATTTTAGGGACATGGTGT
2580
2581
TTTTATAAAGAATTCTGTGAGXAAAAATTTAATAAAGCAACCXAAATTACTCTTAAAAAA
2640
2641
AAAAAAAAAAAAAAAACTCGAGGGGCCCGTACCAAT
2676

FIG. 3A

HUMAN hiap-2



FIG. 3B

HUMAN hiap-2

```
     GACTTTTCCTGTGAACTCTACAGAATGTCTACATATTCAACTTTCCCCGCCGGGGTGCCT
361  ---------+---------+---------+---------+---------+---------+ 420

a        D  F  S  C  E  L  Y  R  M  S  T  Y  S  T  F  P  A  G  V  P  -

     GTCTCAGAAAGGAGTCTTGCTCGTGCTGGTTTTTATTATACTGGTGTGAATGACAAGGTC
421  ---------+---------+---------+---------+---------+---------+ 480

a        V  S  E  R  S  L  A  R  A  G  F  Y  Y  T  G  V  N  D  K  V  -

     AAATGCTTCTGTTGTGGCCTGATGCTGGATAACTGGAAACTAGGAGACAGTCCTATTCAA
481  ---------+---------+---------+---------+---------+---------+ 540

a        K  C  F  C  C  G  L  M  L  D  N  W  K  L  G  D  S  P  I  Q  -

     AAGCATAAACAGCTATATCCTAGCTGTAGCTTTATTCAGAATCTGGTTTCAGCTAGTCTG
541  ---------+---------+---------+---------+---------+---------+ 600

a        K  H  K  Q  L  Y  P  S  C  S  F  I  Q  N  L  V  S  A  S  L  -

     GGATCCACCTCTAAGAATACGTCTCCAATGAGAAACAGTTTTGCACATTCATTATCTCCC
601  ---------+---------+---------+---------+---------+---------+ 660

a        G  S  T  S  K  N  T  S  P  M  R  N  S  F  A  H  S  L  S  P  -

     ACCTTGGAACATAGTAGCTTGTTCAGTGGTTCTTACTCCAGCCTTCCTCCAAACCCTCTT
661  ---------+---------+---------+---------+---------+---------+ 720

a        T  L  E  H  S  S  L  F  S  G  S  Y  S  S  L  P  P  N  P  L  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 3C

HUMAN hiap-2

```
      AATTCTAGAGCAGTTGAAGACATCTCTTCATCGAGGACTAACCCCTACAGTTATGCAATG
  721 ---------+---------+---------+---------+---------+---------+ 780

a         N  S  R  A  V  E  D  I  S  S  S  R  T  N  P  Y  S  Y  A  M  -

      AGTACTGAAGAAGCCAGATTTCTTACCTACCATATGTGGCCATTAACTTTTTTGTCACCA
  781 ---------+---------+---------+---------+---------+---------+ 840

a         S  T  E  E  A  R  F  L  T  Y  H  M  W  P  L  T  F  L  S  P  -

      TCAGAATTGGCAAGAGCTGGTTTTTATTATATAGGACCTGGAGATAGGGTAGCCTGCTTT
  841 ---------+---------+---------+---------+---------+---------+ 900

a         S  E  L  A  R  A  G  F  Y  Y  I  G  P  G  D  R  V  A  C  F  -

      GCCTGTGGTGGGAAGCTCAGTAACTGGGAACCAAAGGATGATGCTATGTCAGAACACCGG
  901 ---------+---------+---------+---------+---------+---------+ 960

a         A  C  G  G  K  L  S  N  W  E  P  K  D  D  A  M  S  E  H  R  -

      AGGCATTTTCCCAACTGTCCATTTTTGGAAAATTCTCTAGAAACTCTGAGGTTTAGCATT
  961 ---------+---------+---------+---------+---------+---------+ 1020

a         R  H  F  P  N  C  P  F  L  E  N  S  L  E  T  L  R  F  S  I  -

      TCAAATCTGAGCATGCAGACACATGCAGCTCGAATGAGAACATTTATGTACTGGCCATCT
 1021 ---------+---------+---------+---------+---------+---------+ 1080

a         S  N  L  S  M  Q  T  H  A  A  R  M  R  T  F  M  Y  W  P  S  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 3D

HUMAN hiap-2

```
      AGTGTTCCAGTTCAGCCTGAGCAGCTTGCAAGTGCTGGTTTTTATTATGTGGGTCGCAAT
1081  ---------+---------+---------+---------+---------+---------+ 1140

a:        S  V  P  V  Q  P  E  Q  L  A  S  A  G  F  Y  Y  V  G  R  N  -

      GATGATGTCAAATGCTTTGGTTGTGATGGTGGCTTGAGGTGTTGGGAATCTGGAGATGAT
1141  ---------+---------+---------+---------+---------+---------+ 1200

a         D  D  V  K  C  F  G  C  D  G  G  L  R  C  W  E  S  G  D  D  -

      CCATGGGTAGAACATGCCAAGTGGTTTCCAAGGTGTGAGTTCTTGATACGAATGAAAGGC
1201  ---------+---------+---------+---------+---------+---------+ 1260

a         P  W  V  E  H  A  K  W  F  P  R  C  E  F  L  I  R  M  K  G  -

      CAAGAGTTTGTTGATGAGATTCAAGGTAGATATCCTCATCTTCTTGAACAGCTGTTGTCA
1261  ---------+---------+---------+---------+---------+---------+ 1320

a         Q  E  F  V  D  E  I  Q  G  R  Y  P  H  L  L  E  Q  L  L  S  -

      ACTTCAGATACCACTGGAGAAGAAAATGCTGACCCACCAATTATTCATTTTGGACCTGGA
1321  ---------+---------+---------+---------+---------+---------+ 1380

a         T  S  D  T  T  G  E  E  N  A  D  P  P  I  I  H  F  G  P  G  -

      GAAAGTTCTTCAGAAGATGCTGTCATGATGAATACACCTGTGGTTAAATCTGCCTTGGAA
1381  ---------+---------+---------+---------+---------+---------+ 1440

a         E  S  S  S  E  D  A  V  M  M  N  T  P  V  V  K  S  A  L  E  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 3E


HUMAN hiap-2
a
1441 ATGGGCTTTAATAGAGACCTGGTGAAACAAACAGTTCTAAGTAAAATCCTGACAACTGGA 1500
M G F N R D L V K Q T V L S K I L T T G -
a
1501 GAGAACTATAAAACAGTTAATGATATTGTGTCAGCACTTCTTAATGCTGAAGATGAAAAA 1560
E N Y K T V N D I V S A L L N A E D E K -
a
1561 AGAGAAGAGGAGAAGGAAAAACAAGCTGAAGAAATGGCATCAGATGATTTGTCATTAATT 1620
R E E E K K E E K Q A E E M A S D D L S L I -
a
1621 CGGAAGAACAGAATGGCTCTCTTTCAACAATTGACATGTGTGCTTCCTATCCTGGATAAT 1680
R K N R M A L F Q Q L T C V L P I L D N -
a
1681 CTTTTAAAGGCCAATGTAATTAATAACAGGAACATGATATTATTAAACAAAAAACACAG 1740
L L K A N V I N K Q E H D I I K Q K T Q -
a
1741 ATACCTTTACAAGCGAGAGAACTGATTGATACCATTTGGGTTAAAGGAAATGCTGCGGCC 1800
I P L Q A R E L I D T I W V K G N A A A -

FIG. 3F

HUMAN hiap-2

```
     AACATCTTCAAAAACTGTCTAAAAGAAATTGACTCTACATTGTATAAGAACTTATTTGTG
1801 ---------+---------+---------+---------+---------+---------+ 1860

a       N  I  F  K  N  C  L  K  E  I  D  S  T  L  Y  K  N  L  F  V   -

     GATAAGAATATGAAGTATATTCCAACAGAAGATGTTTCAGGTCTGTCACTGGAAGAACAA
1861 ---------+---------+---------+---------+---------+---------+ 1920

a       D  K  N  M  K  Y  I  P  T  E  D  V  S  G  L  S  L  E  E  Q   -

     TTGAGGAGGTTGCAAGAAGAACGAACTTGTAAAGTGTGTATGGACAAAGAAGTTTCTGTT
1921 ---------+---------+---------+---------+---------+---------+ 1980

a       L  R  R  L  Q  E  E  R  T  C  K  V  C  M  D  K  E  V  S  V   -

     GTATTTATTCCTTGTGGTCATCTGGTAGTATGCCAGGAATGTGCCCCTTCTCTAAGAAAA
1981 ---------+---------+---------+---------+---------+---------+ 2040

a       V  F  I  P  C  G  H  L  V  V  C  Q  E  C  A  P  S  L  R  K   -

     TGCCCTATTTGCAGGGGTATAATCAAGGGTACTGTTCGTACATTTCTCTCTTAAAGAAAA
2041 ---------+---------+---------+---------+---------+---------+ 2100

a       C  P  I  C  R  G  I  I  K  G  T  V  R  T  F  L  S  *       -

     ATAGTCTATATTTTAACCTGCATAAAAAGGTCTTTAAAATATTGTTGAACACTTGAAGCC
2101 ---------+---------+---------+---------+---------+---------+ 2160

a                                                                   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 3G

HUMAN hiap-2

```
                                                
```

FIG. 4A

MOUSE xiap

```
          GACACTCTGCTGGGCGGCGGGCCGCCCTCCTCCGGGACCTCCCCTCGGGAACCGTCGCCC
        1 ---------+---------+---------+---------+---------+---------+ 60

a                                                                       -

          GCGGCGCTTAGTTAGGACTGGAGTGCTTGGCGCGAAAAGGTGGACAAGTCCTATTTTCCA
       61 ---------+---------+---------+---------+---------+---------+ 120

a                                                                       -

          GAGAAGATGACTTTTAACAGTTTTGAAGGAACTAGAACTTTTGTACTTGCAGACACCAAT
      121 ---------+---------+---------+---------+---------+---------+ 180

a               M   T   F   N   S   F   E   G   T   R   T   F   V   L   A   D   T   N   -

          AAGGATGAAGAATTTGTAGAAGAGTTTAATAGATTAAAAACATTTGCTAACTTCCCAAGT
      181 ---------+---------+---------+---------+---------+---------+ 240

a           K   D   E   E   F   V   E   E   F   N   R   L   K   T   F   A   N   F   P   S   -

          AGTAGTCCTGTTTCAGCATCAACATTGGCGCGAGCTGGGTTTCTTTATACCGGTGAAGGA
      241 ---------+---------+---------+---------+---------+---------+ 300

a           S   S   P   V   S   A   S   T   L   A   R   A   G   F   L   Y   T   G   E   G   -

          GACACCGTGCAATGTTTCAGTTGTCATGCGGCAATAGATAGATGGCAGTATGGAGACTCA
      301 ---------+---------+---------+---------+---------+---------+ 360

a           D   T   V   Q   C   F   S   C   H   A   A   I   D   R   W   Q   Y   G   D   S   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 4B

MOUSE xiap






SUBSTITUTE SHEET (RULE 26)

FIG. 4C

MOUSE xiap

```
       CAATGCTTTTGTTGTGGGGGAAAACTGAAAAATTGGGAACCCTGTGATCGTGCCTGGTCA
   721 ---------+---------+---------+---------+---------+---------+ 780

a          Q  C  F  C  C  G  G  K  L  K  N  W  E  P  C  D  R  A  W  S  -

       GAACACAGGAGACACTTTCCCAATTGCTTTTTTGTTTTGGGCCGGAACGTTAATGTTCGA
   781 ---------+---------+---------+---------+---------+---------+ 840

a          E  H  R  R  H  F  P  N  C  F  F  V  L  G  R  N  V  N  V  R  -

       AGTGAATCTGGTGTGAGTTCTGATAGGAATTTCCCAAATTCAACAAACTCTCCAAGAAAT
   841 ---------+---------+---------+---------+---------+---------+ 900

a          S  E  S  G  V  S  S  D  R  N  F  P  N  S  T  N  S  P  R  N  -

       CCAGCCATGGCAGAATATGAAGCACGGATCGTTACTTTTGGAACATGGATATACTCAGTT
   901 ---------+---------+---------+---------+---------+---------+ 960

a          P  A  M  A  E  Y  E  A  R  I  V  T  F  G  T  W  I  Y  S  V  -

       AACAAGGAGCAGCTTGCAAGAGCTGGATTTTATGCTTTAGGTGAAGGCGATAAAGTGAAG
   961 ---------+---------+---------+---------+---------+---------+ 1020

a          N  K  E  Q  L  A  R  A  G  F  Y  A  L  G  E  G  D  K  V  K  -

       TGCTTCCACTGTGGAGGAGGGCTCACGGATTGGAAGCCAAGTGAAGACCCCTGGGACCAG
  1021 ---------+---------+---------+---------+---------+---------+ 1080

a          C  F  H  C  G  G  G  L  T  D  W  K  P  S  E  D  P  W  D  Q  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 4D

MOUSE xiap

```
          CATGCTAAGTGCTACCCAGGGTGCAAATACCTATTGGATGAGAAGGGGCAAGAATATATA
     1081 ---------+---------+---------+---------+---------+---------+ 1140

a         H  A  K  C  Y  P  G  C  K  Y  L  L  D  E  K  G  Q  E  Y  I   -

          AATAATATTCATTTAACCCATCCACTTGAGGAATCTTTGGGAAGAACTGCTGAAAAAACA
     1141 ---------+---------+---------+---------+---------+---------+ 1200

a         N  N  I  H  L  T  H  P  L  E  E  S  L  G  R  T  A  E  K  T   -

          CCACCGCTAACTAAAAAAATCGATGATACCATCTTCCAGAATCCTATGGTGCAAGAAGCT
     1201 ---------+---------+---------+---------+---------+---------+ 1260

a         P  P  L  T  K  K  I  D  D  T  I  F  Q  N  P  M  V  Q  E  A   -

          ATACGAATGGGATTTAGCTTCAAGGACCTTAAGAAAACAATGGAAGAAAAAATCCAAACA
     1261 ---------+---------+---------+---------+---------+---------+ 1320

a         I  R  M  G  F  S  F  K  D  L  K  K  T  M  E  E  K  I  Q  T   -

          TCCGGGAGCAGCTATCTATCACTTGAGGTCCTGATTGCAGATCTTGTGAGTGCTCAGAAA
     1321 ---------+---------+---------+---------+---------+---------+ 1380

a         S  G  S  S  Y  L  S  L  E  V  L  I  A  D  L  V  S  A  Q  K   -

          GATAATACGGAGGATGAGTCAAGTCAAACTTCATTGCAGAAAGACATTAGTACTGAAGAG
     1381 ---------+---------+---------+---------+---------+---------+ 1440

a         D  N  T  E  D  E  S  S  Q  T  S  L  Q  K  D  I  S  T  E  E   -
```



SUBSTITUTE SHEET (RULE 26)

FIG. 4E

MOUSE xiap








SUBSTITUTE SHEET (RULE 26)

FIG. 4F

MOUSE xiap



FIG. 5A

M-hiap-1

```
   GAATTCCGGGAGACCTACACCCCCGGAGATCAGAGGTCATTGCTGGCGTTCAGAGCCTAG
 1 ---------+---------+---------+---------+---------+---------+ 60
   GAAGTGGGCTGCGGTATCAGCCTAGCAGTAAAACCGACCAGAAGCCATGCACAAAACTAC
61 ---------+---------+---------+---------+---------+---------+ 120
   ATCCCCAGAGAAAGACTTGTCCCTTCCCCTCCCTGTCATCTCACCATGAACATGGTTCAA
121 ---------+---------+---------+---------+---------+---------+ 180
a                                                M  N  M  V  Q   -

   GACAGCGCCTTTCTAGCCAAGCTGATGAAGAGTGCTGACACCTTTGAGTTGAAGTATGAC
181 ---------+---------+---------+---------+---------+---------+ 240
a     D  S  A  F  L  A  K  L  M  K  S  A  D  T  F  E  L  K  Y  D   -

   TTTTCCTGTGAGCTGTACCGATTGTCCACGTATTCAGCTTTTCCCAGGGGAGTTCCTGTG
241 ---------+---------+---------+---------+---------+---------+ 300
a     F  S  C  E  L  Y  R  L  S  T  Y  S  A  F  P  R  G  V  P  V   -

   TCAGAAAGGAGTCTGGCTCGTGCTGGCTTTTACTACACTGGTGCCAATGACAAGGTCAAG
301 ---------+---------+---------+---------+---------+---------+ 360
a     S  E  R  S  L  A  R  A  G  F  Y  Y  T  G  A  N  D  K  V  K   -

   TGCTTCTGCTGTGGCCTGATGCTAGACAACTGGAAACAAGGGGACAGTCCCATGGAGAAG
361 ---------+---------+---------+---------+---------+---------+ 420
a     C  F  C  C  G  L  M  L  D  N  W  K  Q  G  D  S  P  M  E  K   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 5B

M-hiap-1

```
     CACAGAAAGTTGTACCCCAGCTGCAACTTTGTACAGACTTTGAATCCAGCCAACAGTCTG
 421 ---------+---------+---------+---------+---------+---------+ 480
a        H  R  K  L  Y  P  S  C  N  F  V  Q  T  L  N  P  A  N  S  L   -

     GAAGCTAGTCCTCGGCCTTCTCTTCCTTCCACGGCGATGAGCACCATGCCTTTGAGCTTT
 481 ---------+---------+---------+---------+---------+---------+ 540
a        E  A  S  P  R  P  S  L  P  S  T  A  M  S  T  M  P  L  S  F   -

     GCAAGTTCTGAGAATACTGGCTATTTCAGTGGCTCTTACTCGAGCTTTCCCTCAGACCCT
 541 ---------+---------+---------+---------+---------+---------+ 600
a        A  S  S  E  N  T  G  Y  F  S  G  S  Y  S  S  F  P  S  D  P   -

     GTGAACTTCCGAGCAAATCAAGATTGTCCTGCTTTGAGCACAAGTCCCTACCACTTTGCA
 601 ---------+---------+---------+---------+---------+---------+ 660
a        V  N  F  R  A  N  Q  D  C  P  A  L  S  T  S  P  Y  H  F  A   -

     ATGAACACAGAGAAGGCCAGATTACTCACCTATGAAACATGGCCATTGTCTTTTCTGTCA
 661 ---------+---------+---------+---------+---------+---------+ 720
a        M  N  T  E  K  A  R  L  L  T  Y  E  T  W  P  L  S  F  L  S   -

     CCAGCAAAGCTGGCCAAAGCAGGCTTCTACTACATAGGACCTGGAGATAGAGTGGCCTGC
 721 ---------+---------+---------+---------+---------+---------+ 780
a        P  A  K  L  A  K  A  G  F  Y  Y  I  G  P  G  D  R  V  A  C   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 5C

M-hiap-1

```
                TTTGCGTGCGATGGGAAACTGAGCAACTGGGAACGTAAGGATGATGCTATGTCAGAGCAC
          781 ---------+---------+---------+---------+---------+---------+ 840
a                 F  A  C  D  G  K  L  S  N  W  E  R  K  D  D  A  M  S  E  H  -

                CAGAGGCATTTCCCCAGCTGTCCGTTCTTAAAAGACTTGGGTCAGTCTGCTTCGAGATAC
          841 ---------+---------+---------+---------+---------+---------+ 900
a                 Q  R  H  F  P  S  C  P  F  L  K  D  L  G  Q  S  A  S  R  Y  -

                ACTGTCTCTAACCTGAGCATGCAGACACACGCAGCCCGTATTAGAACATTCTCTAACTGG
          901 ---------+---------+---------+---------+---------+---------+ 960
a                 T  V  S  N  L  S  M  Q  T  H  A  A  R  I  R  T  F  S  N  W  -

                CCTTCTAGTGCACTAGTTCATTCCCAGGAACTTGCAAGTGCGGGCTTTTATTATACAGGA
          961 ---------+---------+---------+---------+---------+---------+ 1020
a                 P  S  S  A  L  V  H  S  Q  E  L  A  S  A  G  F  Y  Y  T  G  -

                CACAGTGATGATGTCAAGTGTTTATGCTGTGATGGTGGGCTGAGGTGCTGGGAATCTGGA
         1021 ---------+---------+---------+---------+---------+---------+ 1080
a                 H  S  D  D  V  K  C  L  C  C  D  G  G  L  R  C  W  E  S  G  -

                GATGACCCCTGGGTGGAACATGCCAAGTGGTTTCCAAGGTGTGAGTACTTGCTCAGAATC
         1081 ---------+---------+---------+---------+---------+---------+ 1140
a                 D  D  P  W  V  E  H  A  K  W  F  P  R  C  E  Y  L  L  R  I  -

                AAAGGCCAAGAATTTGTCAGCCAAGTTCAAGCTGGCTATCCTCATCTACTTGAGCAGCTA
         1141 ---------+---------+---------+---------+---------+---------+ 1200
a                 K  G  Q  E  F  V  S  Q  V  Q  A  G  Y  P  H  L  L  E  Q  L  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 5D

M-hiap-1

```
     TTATCTACGTCAGACTCCCCAGAAGATGAGAATGCAGACGCAGCAATCGTGCATTTTGGC
1201 ---------+---------+---------+---------+---------+---------+ 1260
     L  S  T  S  D  S  P  E  D  E  N  A  D  A  A  I  V  H  F  G  -

     CCTGGAGAAAGTTCGGAAGATGTCGTCATGATGAGCACGCCTGTGGTTAAAGCAGCCTTG
1261 ---------+---------+---------+---------+---------+---------+ 1320
     P  G  E  S  S  E  D  V  V  M  M  S  T  P  V  V  K  A  A  L  -

     GAAATGGGCTTCAGTAGGAGCCTGGTGAGACAGACGGTTCAGTGGCAGATCCTGGCCACT
1321 ---------+---------+---------+---------+---------+---------+ 1380
     E  M  G  F  S  R  S  L  V  R  Q  T  V  Q  W  Q  I  L  A  T  -

     GGTGAGAACTACAGGACCGTCAGTGACCTCGTTATAGGCTTACTCGATGCAGAAGACGAG
1381 ---------+---------+---------+---------+---------+---------+ 1440
     G  E  N  Y  R  T  V  S  D  L  V  I  G  L  L  D  A  E  D  E  -

     ATGAGAGAGGAGCAGATGGAGCAGGCGGCCGAGGAGGAGGAGTCAGATGATCTAGCACTA
1441 ---------+---------+---------+---------+---------+---------+ 1500
     M  R  E  E  Q  M  E  Q  A  A  E  E  E  E  S  D  D  L  A  L  -

     ATCCGGAAGAACAAAATGGTGCTTTTCCAACATTTGACGTGTGTGACACCAATGCTGTAT
1501 ---------+---------+---------+---------+---------+---------+ 1560
     I  R  K  N  K  M  V  L  F  Q  H  L  T  C  V  T  P  M  L  Y  -
```



SUBSTITUTE SHEET (RULE 26)

FIG. 5E

M-hiap-1

```
        TGCCTCCTAAGTGCAAGGGCCATCACTGAACAGGAGTGCAATGCTGTGAAACAGAAACCA
  1561  ---------+---------+---------+---------+---------+---------+  1620
a       C  L  L  S  A  R  A  I  T  E  Q  E  C  N  A  V  K  Q  K  P   -

        CACACCTTACAAGCAAGCACACTGATTGATACTGTGTTAGCAAAAGGAAACACTGCAGCA
  1621  ---------+---------+---------+---------+---------+---------+  1680
a       H  T  L  Q  A  S  T  L  I  D  T  V  L  A  K  G  N  T  A  A   -

        ACCTCATTCAGAAACTCCCTTCGGGAAATTGACCCTGCGTTATACAGAGATATATTTGTG
  1681  ---------+---------+---------+---------+---------+---------+  1740
a       T  S  F  R  N  S  L  R  E  I  D  P  A  L  Y  R  D  I  F  V   -

        CAACAGGACATTAGGAGTCTTCCCACAGATGACATTGCAGCTCTACCAATGGAAGAACAG
  1741  ---------+---------+---------+---------+---------+---------+  1800
a       Q  Q  D  I  R  S  L  P  T  D  D  I  A  A  L  P  M  E  E  Q   -

        TTGCGGCCCCTCCCGGAGGACAGAATGTGTAAAGTGTGTATGGACCGAGAGGTATCCATC
  1801  ---------+---------+---------+---------+---------+---------+  1860
a       L  R  P  L  P  E  D  R  M  C  K  V  C  M  D  R  E  V  S  I   -

        GTGTTCATTCCCTGTGGCCATCTGGTCGTGTGCAAAGACTGCGCTCCCTCTCTGAGGAAG
  1861  ---------+---------+---------+---------+---------+---------+  1920
a       V  F  I  P  C  G  H  L  V  V  C  K  D  C  A  P  S  L  R  K   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 5F

M-hiap-1

```
      TGTCCCATCTGTAGAGGGACCATCAAGGGCACAGTGCGCACATTTCTCTCCTGAACAAGA
 1921 ---------+---------+---------+---------+---------+---------+ 1980
a     C  P  I  C  R  G  T  I  K  G  T  V  R  T  F  L  S  *        -

      CTAATGGTCCATGGCTGCAACTTCAGCCAGGAGGAAGTTCACTGTCACTCCCAGTTCCAT
 1981 ---------+---------+---------+---------+---------+---------+ 2040
      TCGGAACTTGAGGCCAGCCTGGATAGCACGAGACACCGCCAAACACACAAATATAAACAT
 2041 ---------+---------+---------+---------+---------+---------+ 2100
      GAAAAACTTTTGTCTGAAGTCAAGAATGAATGAATTACTTATATAATAATTTTAATTGGT
 2101 ---------+---------+---------+---------+---------+---------+ 2160
      TTCCTTAAAAGTGCTATTTGTTCCCAACTCAGAAAATTGTTTTCTGTAAACATATTTACA
 2161 ---------+---------+---------+---------+---------+---------+ 2220
      TACTACCTGCATCTAAAGTATTCATATATTCATATATTCAGATGTCATGAGAGAGGGTTT
 2221 ---------+---------+---------+---------+---------+---------+ 2280
      TGTTCTTGTTCCTGAAAAGCTGGTTTATCATCTGATCAGCATATACTGCGCAACGGGCAG
 2281 ---------+---------+---------+---------+---------+---------+ 2340
      GGCTAGAATCCATGAACCAAGCTGCAAAGATCTCACGCTAAATAAGGCGGAAAGATTTGG
 2341 ---------+---------+---------+---------+---------+---------+ 2400
      AGAAACGAAAGGAAATTCTTTCCTGTCCAATGTATACTCTTCAGACTAATGACCTCTTCC
 2401 ---------+---------+---------+---------+---------+---------+ 2460
      TATCAAGCCTTCTA
 2461 ---------+---- 2474
```

SUBSTITUTE SHEET (RULE 26)

FIG. 6A

M-hiap-2

```
    CTGTGGTGGAGATCTATTGTCCAAGTGGTGAGAAACTTCATCTGGAAGTTTAAGCGGTCA
  1 ---------+---------+---------+---------+---------+---------+ 60
    GAAATACTATTACTACTCATGGACAAAACTGTCTCCCAGAGACTCGCCCAAGGTACCTTA
 61 ---------+---------+---------+---------+---------+---------+ 120
    CACCCAAAAACTTAAACGTATAATGGAGAAGAGCACAATCTTGTCAAATTGGACAAAGGA
121 ---------+---------+---------+---------+---------+---------+ 180
b                        M  E  K  S  T  I  L  S  N  W  T  K  E  -

    GAGCGAAGAAAAAATGAAGTTTGACTTTTCGTGTGAACTCTACCGAATGTCTACATATTC
181 ---------+---------+---------+---------+---------+---------+ 240
b     S  E  E  K  M  K  F  D  F  S  C  E  L  Y  R  M  S  T  Y  S  -

    AGCTTTTCCCAGGGGAGTTCCTGTCTCAGAGAGGAGTCTGGCTCGTGCTGGCTTTTATTA
241 ---------+---------+---------+---------+---------+---------+ 300
b     A  F  P  R  G  V  P  V  S  E  R  S  L  A  R  A  G  F  Y  Y  -

    TACAGGTGTGAATGACAAAGTCAAGTGCTTCTGCTGTGGCCTGATGTTGGATAACTGGAA
301 ---------+---------+---------+---------+---------+---------+ 360
b     T  G  V  N  D  K  V  K  C  F  C  C  G  L  M  L  D  N  W  K  -

    ACAAGGGGACAGTCCTGTTGAAAAGCACAGACAGTTCTATCCCAGCTGCAGCTTTGTACA
361 ---------+---------+---------+---------+---------+---------+ 420
b     Q  G  D  S  P  V  E  K  H  R  Q  F  Y  P  S  C  S  F  V  Q  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 6B

M-hiap-2

```
     GACTCTGCTTTCAGCCAGTCTGCAGTCTCCATCTAAGAATATGTCTCCTGTGAAAAGTAG
 421 ---------+---------+---------+---------+---------+---------+ 480
b        T  L  L  S  A  S  L  Q  S  P  S  K  N  M  S  P  V  K  S  R  -

     ATTTGCACATTCGTCACCTCTGGAACGAGGTGGCATTCACTCCAACCTGTGCTCTAGCCC
 481 ---------+---------+---------+---------+---------+---------+ 540
b        F  A  H  S  S  P  L  E  R  G  G  I  H  S  N  L  C  S  S  P  -

     TCTTAATTCTAGAGCAGTGGAAGACTTCTCATCAAGGATGGATCCCTGCAGCTATGCCAT
 541 ---------+---------+---------+---------+---------+---------+ 600
b        L  N  S  R  A  V  E  D  F  S  S  R  M  D  P  C  S  Y  A  M  -

     GAGTACAGAAGAGGCCAGATTTCTTACTTACAGTATGTGGCCTTTAAGTTTTCTGTCACC
 601 ---------+---------+---------+---------+---------+---------+ 660
b        S  T  E  E  A  R  F  L  T  Y  S  M  W  P  L  S  F  L  S  P  -

     AGCAGAGCTGGCCAGAGCTGGCTTCTATTACATAGGGCCTGGAGACAGGGTGGCCTGTTT
 661 ---------+---------+---------+---------+---------+---------+ 720
b        A  E  L  A  R  A  G  F  Y  Y  I  G  P  G  D  R  V  A  C  F  -

     TGCCTGTGGTGGGAAACTGAGCAACTGGGAACCAAAGGATTATGCTATGTCAGAGCACCG
 721 ---------+---------+---------+---------+---------+---------+ 780
b        A  C  G  G  K  L  S  N  W  E  P  K  D  Y  A  M  S  E  H  R  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 6C

SUBSTITUTE SHEET (RULE 26)

FIG. 6D

M-hiap-2

```
      CACTTCAGACACCCCAGGAGAAGAAAATGCTGACCCTACAGAGACAGTGGTGCATTTTGG
1141  ---------+---------+---------+---------+---------+---------+ 1200
b          T   S   D   T   P   G   E   E   N   A   D   P   T   E   T   V   V   H   F   G   -

      CCCTGGAGAAAGTTCGAAAGATGTCGTCATGATGAGCACGCCTGTGGTTAAAGCAGCCTT
1201  ---------+---------+---------+---------+---------+---------+ 1260
b          P   G   E   S   S   K   D   V   V   M   M   S   T   P   V   V   K   A   A   L   -

      GGAAATGGGCTTCAGTAGGAGCCTGGTGAGACAGACGGTTCAGCGGCAGATCCTGGCCAC
1261  ---------+---------+---------+---------+---------+---------+ 1320
b          E   M   G   F   S   R   S   L   V   R   Q   T   V   Q   R   Q   I   L   A   T   -

      TGGTGAGAACTACAGGACCGTCAATGATATTGTCTCAGTACTTTTGAATGCTGAAGATGA
1321  ---------+---------+---------+---------+---------+---------+ 1380
b          G   E   N   Y   R   T   V   N   D   I   V   S   V   L   L   N   A   E   D   E   -

      GAGAAGAGAAGAGGAGAAGGAAAGACAGACTGAAGAGATGGCATCAGGTGACTTATCACT
1381  ---------+---------+---------+---------+---------+---------+ 1440
b          R   R   E   E   E   K   E   R   Q   T   E   E   M   A   S   G   D   L   S   L   -

      GATTCGGAAGAATAGAATGGCCCTCTTTCAACAGTTGACACATGTCCTTCCTATCCTGGA
1441  ---------+---------+---------+---------+---------+---------+ 1500
b          I   R   K   N   R   M   A   L   F   Q   Q   L   T   H   V   L   P   I   L   D   -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 6E

M-hiap-2

```
     TAATCTTCTTGAGGCCAGTGTAATTACAAAACAGGAACATGATATTATTAGACAGAAAAC
1501 ---------+---------+---------+---------+---------+---------+ 1560
b      N  L  L  E  A  S  V  I  T  K  Q  E  H  D  I  I  R  Q  K  T  -

     ACAGATACCCTTACAAGCAAGAGAGCTTATTGACACCGTTTTAGTCAAGGGAAATGCTGC
1561 ---------+---------+---------+---------+---------+---------+ 1620
b      Q  I  P  L  Q  A  R  E  L  I  D  T  V  L  V  K  G  N  A  A  -

     AGCCAACATCTTCAAAAACTCTCTGAAGGGAATTGACTCCACGTTATATGAAAACTTATT
1621 ---------+---------+---------+---------+---------+---------+ 1680
b      A  N  I  F  K  N  S  L  K  G  I  D  S  T  L  Y  E  N  L  F  -
       -
     TGTGGAAAAGAATATGAAGTATATTCCAACAGAAGACGTTTCAGGCTTGTCATTGGAAGA
1681 ---------+---------+---------+---------+---------+---------+ 1740
b      V  E  K  N  M  K  Y  I  P  T  E  D  V  S  G  L  S  L  E  E  -

     GCAGTTGCGGAGATTACAAGAAGAACGAACTTGCAAAGTGTGTATGGACAGAGAGGTTTC
1741 ---------+---------+---------+---------+---------+---------+ 1800
b      Q  L  R  R  L  Q  E  E  R  T  C  K  V  C  M  D  R  E  V  S  -

     TATTGTGTTCATTCCGTGTGGTCATCTAGTAGTCTGCCAGGAATGTGCCCCTTCTCTAAG
1801 ---------+---------+---------+---------+---------+---------+ 1860
b      I  V  F  I  P  C  G  H  L  V  V  C  Q  E  C  A  P  S  L  R  -
```

SUBSTITUTE SHEET (RULE 26)

FIG. 6F

M-hiap-2

```
      GAAGTGCCCCATCTGCAGGGGGACAATCAAGGGGACTGTGCGCACATTTCTCTCATGAGT
 1861 ---------+---------+---------+---------+---------+---------+ 1920
b      K  C  P  I  C  R  G  T  I  K  G  T  V  R  T  F  L  S  *     -

      GAAGAATGGTCTGAAAGTATTGTTGGACATCAGAAGCTGTCAGAACAAAGAATGAACTAC
 1921 ---------+---------+---------+---------+---------+---------+ 1980
      TGATTTCAGCTCTTCAGCAGGACATTCTACTCTCTTTCAAGATTAGTAATCTTGCTTTAT
 1981 ---------+---------+---------+---------+---------+---------+ 2040
      GAAGGGTAGCATTGTATATTTAAGCTTAGTCTGTTGCAAGGGAAGGTCTATGCTGTTGAG
 2041 ---------+---------+---------+---------+---------+---------+ 2100
      CTACAGGACTGTGTCTGTTCCAGAGCAGGAGTTGGGATGCTTGCTGTATGTCCTTCAGGA
 2101 ---------+---------+---------+---------+---------+---------+ 2160
      CTTCTTGGGATTTGGGAATTTGGGGAAAGCTTTGGAATCCAGTGATGTGGAGCTCAGAAA
 2161 ---------+---------+---------+---------+---------+---------+ 2220
      TCCTGGAACCAGTGACTCTGGTACTCAGTAGATAGGGTACCCTGTACTTCTTGGTGCTTT
 2221 ---------+---------+---------+---------+---------+---------+ 2280
      TCCAGTCTGGGAAATAAGGAGGAATCTGCTGCTGGTAAAAATTTGCTGGATGTGAGAAAT
 2281 ---------+---------+---------+---------+---------+---------+ 2340
      AGATGAAAGTGTTTCGGGTGGGGGCGTGCATCAGTGTAGTGTGTGCAGGGATGTATGCAG
 2341 ---------+---------+---------+---------+---------+---------+ 2400
      GCCAAACACTGTGTAG
 2401 ---------+------ 2416
```

SUBSTITUTE SHEET (RULE 26)

FIG. 7A


XIAP protein (ng/ mg)
70
60
50
40
30
20
10
0
Mock co.
A1
B1
C1
D1
E1
F1
G1
H1
A2
B2
C2
D2
E2
F2
G2
H2
asOligo well ID

FIG. 7B


Total protein (mg/ ml)
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Mock co.
A1
B1
C1
D1
E1
F1
G1
H1
A2
B2
C2
D2
E2
F2
G2
H2
asOligo well ID

FIG. 7C


XIAP protein (ng/ mg)
70
60
50
40
30
20
10
0
Mock co.
A3
B3
C3
D3
E3
F3
G3
H3
A4
B4
C4
D4
E4
F4
G4
H4
asOligo well ID

FIG. 7D


Total protein (mg/ ml)
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Mock co.
A3
B3
C3
D3
E3
F3
G3
H3
A4
B4
C4
D4
E4
F4
G4
H4
asOligo well ID

FIG. 7E


XIAP protein (ng/ mg)
60
50
40
30
20
10
0
Mock co.
A5
B5
C5
D5
E5
F5
G5
H5
A6
B6
C6
D6
E6
F6
G6
H6
as Oligo well ID

FIG. 7F


Total protein (mg/ ml)
0.6
0.5
0.4
0.3
0.2
0.1
0
Mock co.
A5
B5
C5
D5
E5
F5
G5
H5
A6
B6
C6
D6
E6
F6
G6
H6
asOligo well ID

FIG. 7G


XIAP protein (ng/ mg)
80
70
60
50
40
30
20
10
0
Mock co.
A7
B7
C7
D7
E7
F7
G7
H7
A8
B8
C8
D8
E8
F8
G8
H8
asOligo well ID

FIG. 7H


Total protein (mg/ ml)
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Mock co.
A7
B7
C7
D7
E7
F7
G7
H7
A8
B8
C8
D8
E8
F8
G8
H8
asOligo well ID

FIG. 7I


XIAP protein O.D./ total protein O.D.
25
20
15
10
5
0
Mock co
A9
B9
C9
D9
E9
F9
G9
H9
A10
B10
C10
D10
E10
F10
G10
H10
asOligo well ID

FIG. 7J


Total protein O.D.
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
Mock co
A9
B9
C9
D9
E9
F9
G9
H9
A10
B10
C10
D10
E10
F10
G10
H10
asOligo well ID

FIG. 7K


XIAP protein O.D./ total protein O.D.
30
25
20
15
10
5
0
Mock co.
A11
B11
C11
D11
E11
F11
G11
H11
A12
B12
C12
D12
E12
F12
G12
H12
A13
B13
asOligo well ID

FIG. 7L


Total protein O.D.
0.09
0.08
0.07
0.06
0.05
0.04
0.03
0.02
0.01
0
Mock co
A11
B11
C11
D11
E11
F11
G11
H11
A12
B12
C12
D12
E12
F12
G12
H12
A13
B13
asOligo well O.D.

FIG. 8A




FIG. 8B




FIG. 8C




O.D. 450
3.5
3
2.5
2
1.5
1
0.5
0
untransf. co
Mock co.
F3 scr.
E4 scr.
C5 scr.
F3
E4
G4
C5
D7
E4+C5
G4+C5
asOligo well ID

FIG. 9A

FIG. 9B


% Survival vs transfected control
180
160
140
120
100
80
60
45
20
0
Mock co.
F3 scr.
E4 scr.
C5 scr.
F3
E4
G4
C5
G4+C5
D7
E4+C5
E4+D7
asOligo well ID

FIG. 9C


O.D. 450
2.5
.2
1.5
1
0.5
0
Mock co.
F3 scr.
E4 scr.
C5 scr.
F3
E4
G4
C5
G4+C5
D7
E4+C5
G4+D7
asOligo well ID


E4 AS, 1 uM
E4 REV, 1 uM
Mock Control
E4 MM, 1 uM
Untransfected Control
E4 SCR, 1 uM

FIG. 9D


Survivin sc.
Untreated
Mock co.
H1 as apo 1
H1 as apo 2
H1 as apo 3
H1 as apo 4
H1 as apo 5
H1 as apo 6
H1 as apo 7
H1 as apo 8
H1 as apo 9
H1 as apo 10
H1 as apo 11
H1 as apo 12
H1 as apo 13
H1 as apo 14
H1 as apo 15
Antisense Oligos
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
Fold increase HIAP 1 relative to endogenous RNA

FIG. 10

FIG. 11A




FIG. 11B




% Ptn yield over s.c. cntr
150
100
50
0
S.C. Survivin
mock
apo 1
apo 2
apo 3
apo 4
apo 5
apo 6
apo 7
apo 8
apo 9
apo 10
apo 11
apo 12
apo 13
apo 14
apo 15
H1 anti-sense Oligos

FIG. 12


Fold increase HIAP 1 relative to endogenous RNA
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
6.01
6.84
Survivin s.c.
H1 mm apo 2
H1 RV apo 2
H1 sc apo 2
H1 sc apo 2
H1 as apo 2
Antisense Oligos

FIG. 13


h1sc apo2
h1as apo7
h1as apo15
% survival
0
20
40
60
80
100
120
140
160
0.01
0.1
1
10
50
Conc. in microg/ml

FIG. 14

FIG. 15A

1 TTGCAGGTAC TTAGAATTTT TCCTGAGCCA CCCTCTAGAG GGCAGTGTTA

51 CATATATATC TGTAATTATC CAGTTACAAC AAAAAAAGGG CTCTCATTCA

101 TGCATGAAAA TCAGAAATAT TTCATACTCT TAAAGAACAC ATTGGAACCA

151 ATATTATGAT TAAAACATAT TTTGCTAAGC AAAGAGATAT TAAAAATTAA

201 TTCATTAACA TTCTGAACAT TTTTTAACTT GTAAAAACAA CTTTGATGCC

251 TTGAATATAT AATGATTCAT TATAACAATT ATGCATAGAT TTTAATAATC

301 TGCATATTTT ATGCTTTCAT GTTTTTCCTA ATTAATGATT TGACATGGTT

351 AATAATTATA ATATATTCTG CATCACAGTT TACATATTTA TGTAAAATAA

401 GCATTTAAAA ATTATTAGTT TTATTCTGCC TGCTTAAATA TTACTTTCCT

451 CAAAAAGAGA AAACAAAAAT GCTAGATTTT ACTTTATGAC TTGAATGATG

501 TGGTAATGTC GAACTCTAGT ATTTAGAATT AGAATGTTTC TTAGCGGTCG

551 TGTAGTTATT TTTATGTCAT AAGTGGATAA TTTGTTAGCT CCTATAACAA

601 AAGTCTGTTG CTTGTGTTTC ACATTTTGGA TTTCCTAATA TAATGTTCTC

651 TTTTTAGAAA AGGTGGACAA GTCCTATTTT CAAGAGAAGA TGACTTTTAA

701 CAGTTTTGAA GGATCTAAAA CTTGTGTACC TGCAGACATC AATAAGGAAG

751 AAGAATTTGT AGAAGAGTTT AATAGATTAA AAACTTTTGC TAATTTTCCA

801 AGTGGTAGTC CTGTTTCAGC ATCAACACTG GCACGAGCAG GGTTTCTTTA

851 TACTGGTGAA GGAGATACCG TGCGGTGCTT TAGTTGTCAT GCAGCTGTAG

901 ATAGATGGCA ATATGGAGAC TCAGCAGTTG GAAGACACAG GAAAGTATCC

951 CCAAATTGCA GATTTATCAA CGGCTTTTAT CTTGAAAATA GTGCCACGCA

FIG. 15B

1001 GTCTACAAAT TCTGGTATCC AGAATGGTCA GTACAAAGTT GAAAACTATC

1051 TGGGAAGCAG AGATCATTTT GCCTTAGACA GGCCATCTGA GACACATGCA

1101 GACTATCTTT TGAGAACTGG GCAGGTTGTA GATATATCAG ACACCATATA

1151 CCCGAGGAAC CCTGCCATGT ATTGTGAAGA AGCTAGATTA AAGTCCTTTC

1201 AGAACTGGCC AGACTATGCT CACCTAACCC CAAGAGAGTT AGCAAGTGCT

1251 GGACTCTACT ACACAGGTAT TGGTGACCAA GTGCAGTGCT TTTGTTGTGG

1301 TGGAAAACTG AAAAATTGGG AACCTTGTGA TCGTGCCTGG TCAGAACACA

1351 GGCGACACTT TCCTAATTGC TTCTTTGTTT TGGGCCGGAA TCTTAATATT

1401 CGAAGTGAAT CTGATGCTGT GAGTTCTGAT AGGAATTTCC CAAATTCAAC

1451 AAATCTTCCA AGAAATCCAT CCATGGCAGA TTATGAAGCA CGGATCTTTA

1501 CTTTTGGGAC ATGGATATAC TCAGTTAACA AGGAGCAGCT TGCAAGAGCT

1551 GGATTTTATG CTTTAGGTGA AGGTGATAAA GTAAAGTGCT TTCACTGTGG

1601 AGGAGGGCTA ACTGATTGGA AGCCCAGTGA AGACCCTTGG
GAACAACATG

1651 CTAAATGGTA TCCAGGGTGC AAATATCTGT TAGAACAGAA
GGGACAAGAA

1701 TATATAAACA ATATTCATTT AACTCATTCA CTTGAGGAGT GTCTGGTAAG

1751 AACTACTGAG AAAACACCAT CACTAACTAG AAGAATTGAT GATACCATCT

1801 TCCAAAATCC TATGGTACAA GAAGCTATAC GAATGGGGTT CAGTTTCAAG

1851 GACATTAAGA AAATAATGGA GGAAAAAATT CAGATATCTG
GGAGCAACTA

1901 TAAATCACTT GAGGTTCTGG TTGCAGATCT AGTGAATGCT CAGAAAGACA

1951 GTATGCAAGA TGAGTCAAGT CAGACTTCAT TACAGAAAGA GATTAGTACT

2001 GAAGAGCAGC TAAGGCGCCT GCAAGAGGAG AAGCTTTGCA
AAATCTGTAT

FIG. 15C

2051 GGATAGAAAT ATTGCTATCG TTTTTGTTCC TTGTGGACAT CTAGTCACTT

2101 GTAAACAATG TGCTGAAGCA GTTGACAAGT GTCCCATGTG CTACACAGTC

2151 ATTACTTTCA AGCAAAAAAT TTTTATGTCT TAATCTAACT CTATAGTAGG

2201 CATGTTATGT TGTTCTTATT ACCCTGATTG AATGTGTGAT GTGAACTGAC

2251 TTTAAGTAAT CAGGATTGAA TTCCATTAGC ATTTGCTACC AAGTAGGAAA

2301 AAAAATGTAC ATGGCAGTGT TTTAGTTGGC AATATAATCT TTGAATTTCT

2351 TGATTTTTCA GGGTATTAGC TGTATTATCC ATTTTTTTTA CTGTTATTTA

2401 ATTGAAACCA TAGACTAAGA ATAAGAAGCA TCATACTATA ACTGAACACA

2451 ATGTGTATTC ATAGTATACT GATTTAATTT CTAAGTGTAA GTGAATTAAT

2501 CATCTGGATT TTTTATTCTT TTCAGATAGG CTTAACAAAT GGAGCTTTCT

2551 GTATATAAAT GTGGAGATTA GAGTTAATCT CCCCAATCAC ATAATTTGTT

2601 TTGTGTGAAA AAGGAATAAA TTGTTCCATG CTGGTGGAAA GATAGAGATT

2651 GTTTTTAGAG GTTGGTTGTT GTGTTTTAGG ATTCTGTCCA TTTTCTTTTA

2701 AAGTTATAAA CACGTACTTG TGCGAATTAT TTTTTTAAAG TGATTTGCCA

2751 TTTTTGAAAG CGTATTTAAT GATAGAATAC TATCGAGCCA ACATGTACTG

2801 ACATGGAAAG ATGTCAAAGA TATGTTAAGT GTAAAATGCA
AGTGGCAAAA

2851 CACTATGTAT AGTCTGAGCC AGATCAAAGT ATGTATGTTT TTAATATGCA

2901 TAGAACAAAA GATTTGGAAA GATATACACC AAACTGTTAA ATGTGGTTTC

2951 TCTTCGGGGA GGGGGGGATT GGGGGAGGGG CCCCATAGGG GTTTTATAGG

FIG. 16A

1 TTGCTCTGTC ACCCAGTTTG GAGTGCAGTT ATGCAGTCTC ACACTGCAAG

51 CTCTGCCTCA TGGGCTCAAG TGAACCTCCT GCCTCAGCCT CTCAAGTAGC

101 TGGGACCACA GGCAGGTGCC ACCATGTCTG GCTAATTTTT GAGTTTCTTT

151 GTAGAGATGG TGTTTTGCCA AGTCACCCAG TTTGAGGCTG GTCTCAAACA

201 CCTGGGCTCA AGCAATCCAT CTACCTCAGC CTCCCAAAGT GCTGGGATTA

251 CAGGAGTGAG CCATGGCATG AGGCCTTGTG GGGTGTCTCT TTTAAATGAA

301 AGCATACTCT GTTTACGTAT TTGATATGAA GGAATATCCT TCCTTTCCAC

351 AAAGACAAAA ATTATCCTAT TTTTCTCAAA ACATATGTCC TTTTTCTCTA

401 CTTTTCATTT TTGTTACTTT TGATGGACAC ATGTGTTACA TTGATTTCAC

451 TTTCTCATAA TTCTGCTGTA AGAAAAACAA TAGTGCCAGT TCAATGACAA

501 ATAGCAACAG TCTGTTATTG CTAGACTGTT ACTGTTAGTG GAGACTACCA

551 GAACAGTCAG TCCCAGTGTC AGGGAATCAA AGAGAACATG TTCCCTCTCT

601 AAAGGGCACA GCTGCTGCTC AGCTTTAGCT GATTGCTGCC CTGCAGGACT

651 ATAGGCCCAG TGTTGCTAGA TCTTTTGATG TTTCAAGAGA AGCTTGGAAT

701 CTAGAATGTG ATGGGAAGTC TCTTACATTT AAACATGTTG GCAATTAATG

FIG. 16B

751 GTAAGATTTA AAAATACTGT GGTCCAAGAA AAAAATGGAT TTGGAAACTG

801 GATTAAATTC AAATGAGGCA TGCAGATTAA TCTACAGCAT GGTACAATGT

851 GAATTTTCTG GTTTCTTTAA TTGCACTGTA ATTAGGTAAG ATGTTAGCTT

901 TGGGGAAGCT AAGTGCAGAG TATGCAGAAA CTATTATTTT TGTAAGTTTT

951 CTCTAAGTAT AAATAAATTT CAAAATAAAA ATAAAAACTT AGTAAAGAAC

1001 TATAATGCAA TTCTATGTAA GCCAAACATA ATATGTCTTC CAGTTTGAAA

1051 CCTCTGGGTT TTATTTTATT TTATTTTATT TTTGAGACAG AGTCTTGCTG

1101 TGTCACCCAG GCTGGAGTGT AGTGGCACTA TTTCGGCCCA CTGCAACCTC

1151 CACCTCCCAG GCTCAAATGA TTCTCCTGCC TCAGCCTCCG GAGTAGCTGG

1201 GATTACAGGC GCGTACCACC ACACCCAGCT AATTTTTGTA TTTTTAGTAG

1251 AGATGGGGTT TCACCATTTT GGCCAGGCTG GTTTTGAACT CCTGACCTCA

1301 AGTGATCCAC TTGTCTTGGC CTCCCAAAAT GCTGGGATTA CAGGCGTGAG

1351 CCACTGCACC AGGCAGAGGC CTCTGTTTTT TATCTCTTTT TGGCCTCTAC

1401 AGTGCCTAGT AAAGCACCTG ATACATGGTA AACGATCAGT AATTACTAGT

1451 ACTCTATTTT GGAGAAAATG ATTTTTTAAA AAGTCATTGT GTTCCATCCA

FIG. 16C

1501 TGAGTCGTTT GAGTTTTAAA ACTGTCTTTT TGTTTGTTTT TGAACAGGTT

1551 TACAAAGGAG GAAAACGACT TCTTCTAGAT TTTTTTTTCA GTTTCTTCTA

1601 TAAATCAAAA CATCTCAAAA TGGAGACCTA AAATCCTTAA AGGGACTTAG

1651 TCTAATCTCG GGAGGTAGTT TTGTGCATGG GTAAACAAAT TAAGTATTAA

1701 CTGGTGTTTT ACTATCCAAA GAATGCTAAT TTTATAAACA TGATCGAGTT

1751 ATATAAGGTA TACCATAATG AGTTTGATTT TGAATTTGAT TTGTGGAAAT

1801 AAAGGAAAAG TGATTCTAGC TGGGGCATAT TGTTAAAGCA TTTTTTTCAG

1851 AGTTGGCCAG GCAGTCTCCT ACTGGCACAT TCTCCCATTA TGTAGAATAG

1901 AAATAGTACC TGTGTTTGGG AAAGATTTTA AAATGAGTGA CAGTTATTTG

1951 GAACAAAGAG CTAATAATCA ATCCACTGCA AATTAAAGAA ACATGCAGAT

2001 GAAAGTTTTG ACACATTAAA ATACTTCTAC AGTGACAAAG AAAAATCAAG

2051 AACAAAGCTT TTTGATATGT GCAACAAATT TAGAGGAAGT AAAAAGATAA

2101 ATGTGATGAT TGGTCAAGAA ATTATCCAGT TATTTACAAG GCCACTGATA

2151 TTTTAAACGT CCAAAAGTTT GTTTAAATGG GCTGTTACCG CTGAGAATGA

2201 TGAGGATGAG AATGATGGTT GAAGGTTACA TTTTAGGAAA TGAAGAAACT

2251 TAGAAAATTA ATATAAAGAC AGTGATGAAT ACAAAGAAGA

FIG. 16D

TTTTTATAAC

2301 AATGTGTAAA ATTTTTGGCC AGGGAAAGGA ATATTGAAGT TAGATACAAT

2351 TACTTACCTT TGAGGGAAAT AATTGTTGGT AATGAGATGT GATGTTTCTC

2401 CTGCCACCTG GAAACAAAGC ATTGAAGTCT GCAGTTGAAA AGCCCAACGT

2451 CTGTGAGATC CAGGAAACCA TGCTTGCAAA CCACTGGTAA AAAAAAAAAA

2501 AAAAAAAAAA AAAGCCACAG TGACTTGCTT ATTGGTCATT GCTAGTATTA

2551 TCGACTCAGA ACCTCTTTAC TAATGGCTAG TAAATCATAA TTGAGAAATT

2601 CTGAATTTTG ACAAGGTCTC TGCTGTTGAA ATGGTAAATT TATTATTTTT

2651 TTTGTCATGA TAAATTCTGG TTCAAGGTAT GCTATCCATG AAATAATTTC

2701 TGACCAAAAC TAAATTGATG CAATTTGATT ATCCATCTTA GCCTACAGAT

2751 GGCATCTGGT AACTTTTGAC TGTTTTAAAA AATAAATCCA CTATCAGAGT

2801 AGATTTGATG TTGGCTTCAG AAACATTTAG AAAAACAAAA GTTCAAAAAT

2851 GTTTTCAGGA GGTGATAAGT TGAATAACTC TACAATGTTA GTTCTTTGAG

2901 GGGGACAAAA AATTTAAAAT CTTTGAAAGG TCTTATTTTA CAGCCATATC

2951 TAAATTATCT TAAGAAAATT TTTAACAAAG GGAATGAAAT ATATATCATG

3001 ATTCTGTTTT TCCAAAAGTA ACCTGAATAT AGCAATGAAG TTCAGTTTTG

FIG. 16E

3051 TTATTGGTAG TTTGGGCAGA GTCTCTTTTT GCAGCACCTG TTGTCTACCA

3101 TAATTACAGA GGACATTTCC ATGTTCTAGC CAAGTATACT ATTAGAATAA

3151 AAAAACTTAA CATTGAGTTG CTTCAACAGC ATGAAACTGA GTCCAAAAGA

3201 CCAAATGAAC AAACACATTA ATCTCTGATT ATTTATTTTA AATAGAATAT

3251 TTAATTGTGT AAGATCTAAT AGTATCATTA TACTTAAGCA ATCATATTCC

3301 TGATGATCTA TGGGAAATAA CTATTATTTA ATTAATATTG AAACCAGGTT

3351 TTAAGATGTG TTAGCCAGTC CTGTTACTAG TAAATCTCTT TATTTGGAGA

3401 GAAATTTTAG ATTGTTTTGT TCTCCTTATT AGAAGGATTG TAGAAAGAAA

3451 AAAATGACTA ATTGGAGAAA AATTGGGGAT ATATCATATT TCACTGAATT

3501 CAAAATGTCT TCAGTTGTAA ATCTTACCAT TATTTTACGT ACCTCTAAGA

3551 AATAAAAGTG CTTCTAATTA AAATATGATG TCATTAATTA TGAAATACTT

3601 CTTGATAACA GAAGTTTTAA AATAGCCATC TTAGAATCAG TGAAATATGG

3651 TAATGTATTA TTTTCCTCCT TTGAGTNAGG TCTTGTGCTT TTTNTTCCTG

3701 GCCACTAAAT NTCACCATNT CCAANAAGCA AANTAAACCT ATTCTGAATA

3751 TTTTTGCTGT GAAACACTTG NCAGCAGAGC TTTCCCNCCA TGNNAGAAGC

FIG. 16F

3801 TTCATGAGTC ACACATTACA TCTTTGGGTT GATTGAATGC CACTGAAACA

3851 TTTCTAGTAG CCTGGAGNAG TTGACCTACC TGTGGAGATG CCTGCCATTA

3901 AATGGCATCC TGATGGCTTA ATACACATCA CTCTTCTGTG NAGGGTTTTA

3951 ATTTTCAACA CAGCTTACTC TGTAGCATCA TGTTTACATT GTATGTATAA

4001 AGATTATACN AAGGTGCAAT TGTGTATTTC TTCCTTAAAA TGTATCAGTA

4051 TAGGATTTAG AATCTCCATG TTGAAACTCT AAATGCATAG AAATAAAAAT

4101 AATAAAAAAT TTTTCATTTT GGCTTTTCAG CCTAGTATTA AAACTGATAA

4151 AAGCAAAGCC ATGCACAAAA CTACCTCCCT AGAGAAAGGC TAGTCCCTTT

4201 TCTTCCCCAT TCATTTCATT ATGAACATAG TAGAAAACAG CATATTCTTA

4251 TCAAATTTGA TGAAAAGCGC CAACACGTTT GAACTGAAAT ACGACTTGTC

4301 ATGTGAACTG TACCGAATGT CTACGTATTC CACTTTTCCT GCTGGGGTTC

4351 CTGTCTCAGA AAGGAGTCTT GCTCGTGCTG GTTTCTATTA CACTGGTGTG

4401 AATGACAAGG TCAAATGCTT CTGTTGTGGC CTGATGCTGG ATAACTGGAA

4451 AAGAGGAGAC AGTCCTACTG AAAAGCATAA AAAGTTGTAT CCTAGCTGCA

4501 GATTCGTTCA GAGTCTAAAT TCCGTTAACA ACTTGGAAGC TACCTCTCAG

4551 CCTACTTTTC CTTCTTCAGT AACACATTCC ACACACTCAT

FIG. 16G

TACTTCCGGG

4601 TACAGAAAAC AGTGGATATT TCCGTGGCTC TTATTCAAAC TCTCCATCAA

4651 ATCCTGTAAA CTCCAGAGCA AATCAAGAAT TTTCTGCCTT GATGAGAAGT

4701 TCCTACCCCT GTCCAATGAA TAACGAAAAT GCCAGATTAC TTACTTTTCA

4751 GACATGGCCA TTGACTTTTC TGTCGCCAAC AGATCTGGCA CGAGCAGGCT

4801 TTTACTACAT AGGACCTGGA GACAGAGTGG CTTGCTTTGC CTGTGGTGGA

4851 AAATTGAGCA ATTGGGAACC GAAGGATAAT GCTATGTCAG AACACCTGAG

4901 ACATTTTCCC AAATGCCCAT TTATAGAAAA TCAGCTTCAA GACACTTCAA

4951 GATACACAGT TTCTAATCTG AGCATGCAGA CACATGCAGC CCGCTTTAAA

5001 ACATTCTTTA ACTGGCCCTC TAGTGTTCTA GTTAATCCTG AGCAGCTTGC

5051 AAGTGCGGGT TTTTATTATG TGGGTAACAG TGATGATGTC AAATGCTTTT

5101 GCTGTGATGG TGGACTCAGG TGTTGGGAAT CTGGAGATGA TCCATGGGTT

5151 CAACATGCCA AGTGGTTTCC AAGGTGTGAG TACTTGATAA GAATTAAAGG

5201 ACAGGAGTTC ATCCGTCAAG TTCAAGCCAG TTACCCTCAT CTACTTGAAC

5251 AGCTGCTATC CACATCAGAC AGCCCAGGAG ATGAAAATGC AGAGTCATCA

5301 ATTATCCATT TTGAACCTGG AGAAGACCAT TCAGAAGATG CAATCATGAT

FIG. 16H

5351 GAATACTCCT GTGATTAATG CTGCCGTGGA AATGGGCTTT AGTAGAAGCC

5401 TGGTAAAACA GACAGTTCAG AGAAAAATCC TAGCAACTGG AGAGAATTAT

5451 AGACTAGTCA ATGATCTTGT GTTAGACTTA CTCAATGCAG AAGATGAAAT

5501 AAGGGAAGAG GAGAGAGAAA GAGCAACTGA GGAAAAAGAA TCAAATGATT

5551 TATTATTAAT CCGGAAGAAT AGAATGGCAC TTTTTCAACA TTTGACTTGT

5601 GTAATTCCAA TCCTGGATAG TCTACTAACT GCCGGAATTA TTAATGAACA

5651 AGAACATGAT GTTATTAAAC AGAAGACACA GACGTCTTTA CAAGCAAGAG

5701 AACTGATTGA TACGATTTTA GTAAAAGGAA ATATTGCAGC CACTGTATTC

5751 AGAAACTCTC TGCAAGAAGC TGAAGCTGTG TTATATGAGC ATTTATTTGT

5801 GCAACAGGAC ATAAAATATA TTCCCACAGA AGATGTTTCA GATCTACCAG

5851 TGGAAGAACA ATTGCGGAGA CTACAAGAAG AAAGAACATG TAAAGTGTGT

5901 ATGGACAAAG AAGTGTCCAT AGTGTTTATT CCTTGTGGTC ATCTAGTAGT

5951 ATGCAAAGAT TGTGCTCCTT CTTTAAGAAA GTGTCCTATT TGTAGGAGTA

6001 CAATCAAGGG TACAGTTCGT ACATTTCTTT CATGAAGAAG AACCAAAACA

6051 TCGTCTAAAC TTTAGAATTA ATTTATTAAA TGTATTATAA CTTTAACTTT

FIG. 16I

6101 TATCCTAATT TGGTTTCCTT AAAATTTTTA TTTATTTACA
ACTCAAAAAA

6151 CATTGTTTTG TGTAACATAT TTATATATGT ATCTAAACCA
TATGAACATA

6201 TATTTTTTAG AAACTAAGAG AATGATAGGC TTTTGTTCTT
ATGAACGAAA

6251 AAGAGGTAGC ACTACAAACA CAATATTCAA TCAAAATTTC
AGCATTATTG

6301 AAATTGTAAG TGAAGTAAAA CTTAAGATAT TTGAGTTAAC
CTTTAAGAAT

6351 TTTAAATATT TTGGCATTGT ACTAATACCG GGAACATGAA
GCCAGGTGTG

6401 GTGGTATGTG CCTGTAGTCC CAGGCTGAGG CAAGAGAATT
ACTTGAGCCC

6451 AGGAGTTTGA ATCCATCCTG GGCAGCATAC TGAGACCCTG
CCTTTAAAAA

6501 CAAACAGAAC AAAAACAAAA CACCAGGGAC ACATTTCTCT
GTCTTTTTTG

6551 ATCAGTGTCC TATACATCGA AGGTGTGCAT ATATGTTGAA
TCACATTTTA

6601 GGGACATGGT GTTTTTATAA AGAATTCTGT GAGAAAAAAT
TTAATAAAGC

6651 AACCAAAAAA AAAAAAAAA

SEQUENCE LISTING

<110> University of Ottawa
Aegera Therapeutics, Inc.

<120> Antisense IAP Nucleic Acids and Uses Thereof

<130> 07891/025WO1

<150> US 09/672,717
<151> 2000-09-28

<160> 231

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 1
aaaattctaa gtacctgca 19

<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 2
tctagagggt ggctcagga 19

<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 3
cagatatata tgtaacact 19

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 4
tgagagccct ttttttgtt 19

<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 5
agtatgaaat atttctgat 19

<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 6
attggttcca atgtgttct 19

<210> 7
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 7
ttagcaaaat atgttttaa 19

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 8
tgaattaatt tttaatatc 19

<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 9
attcaaggca tcaaagttg 19

<210> 10
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 10
gtcaaatcat taattagga 19

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 11
aatatgtaaa ctgtgatgc 19

<210> 12
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 12
gcagaataaa actaataat 19

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 13
gaaagtaata tttaagcag 19

<210> 14
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 14
ttaccacatc attcaagtc 19

<210> 15
<211> 19
<212> DNA

<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 15
ctaaatacta gagttcgac 19

<210> 16
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 16
acacgaccgc taagaaaca 19

<210> 17
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 17
tatccactta tgacataaa 19

<210> 18
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 18
gttataggag ctaacaaat 19

<210> 19
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 19
aatgtgaaac acaagcaac 19

<210> 20
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> based on Homo sapiens

<400> 20
acattatatt aggaaatcc 19

<210> 21
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 21
cttgtccacc ttttctaaa 19

<210> 22
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 22
atcttctctt gaaaatagg 19

<210> 23
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 23
ccttcaaaac tgttaaaag 19

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 24
atgtctgcag gtacacaag 19

<210> 25
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 25

atctattaaa ctcttctac 19

<210> 26
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 26
acaggactac cacttggaa 19

<210> 27
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 27
tgccagtgtt gatgctgaa 19

<210> 28
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 28
gtataaagaa accctgctc 19

<210> 29
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 29
cgcacggtat ctccttcac 19

<210> 30
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 30
ctacagctgc atgacaact 19

<210> 31

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 31
gctgagtctc catattgcc 19

<210> 32
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 32
atactttcct gtgtcttcc 19

<210> 33
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 33
gataaatctg caatttggg 19

<210> 34
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 34
ttgtagactg cgtggcact 19

<210> 35
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 35
accattctgg ataccagaa 19

<210> 36
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 36
agttttcaac tttgtactg 19

<210> 37
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 37
atgatctctg cttcccaga 19

<210> 38
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 38
agatggcctg tctaaggca 19

<210> 39
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 39
agttctcaaa agatagtct 19

<210> 40
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 40
gtgtctgata tatctacaa 19

<210> 41
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 41
tcgggtatat ggtgtctga 19

<210> 42
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 42
cagggttcct cgggtatat 19

<210> 43
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 43
gcttcttcac aatacatgg 19

<210> 44
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 44
ggccagttct gaaaggact 19

<210> 45
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 45
gctaactctc ttggggtta 19

<210> 46
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 46
gtgtagtaga gtccagcac 19

<210> 47
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 47
aagcactgca cttggtcac 19

<210> 48
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 48
ttcagttttc caccacaac 19

<210> 49
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 49
acgatcacaa ggttcccaa 19

<210> 50
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 50
tcgcctgtgt tctgaccag 19

<210> 51
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 51
ccggcccaaa acaaagaag 19

<210> 52
<211> 19
<212> DNA

<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 52
gattcacttc gaatattaa 19

<210> 53
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 53
tatcagaact cacagcatc 19

<210> 54
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 54
ggaagatttg ttgaatttg 19

<210> 55
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 55
tctgccatgg atggatttc 19

<210> 56
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 56
aagtaaagat ccgtgcttc 19

<210> 57
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> based on Homo sapiens

<400> 57
ctgagtatat ccatgtccc 19

<210> 58
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 58
gcaagctgct ccttgttaa 19

<210> 59
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 59
aaagcataaa atccagctc 19

<210> 60
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 60
gaaagcactt tactttatc 19

<210> 61
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 61
actgggcttc caatcagtt 19

<210> 62
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 62

gttgttccca agggtcttc 19

<210> 63
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 63
accctggata ccatttagc 19

<210> 64
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 64
tgttctaaca gatatttgc 19

<210> 65
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 65
tatatattct tgtcccttc 19

<210> 66
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 66
agttaaatga atattgttt 19

<210> 67
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 67
gacactcctc aagtgaatg 19

<210> 68

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 68
tttctcagta gttcttacc 19

<210> 69
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 69
gttagtgatg gtgttttct 19

<210> 70
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 70
agatggtatc atcaattct 19

<210> 71
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 71
tgtaccatag gattttgga 19

<210> 72
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 72
ccccattcgt atagcttct 19

<210> 73
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 73
attattttct taatgtcct 19

<210> 74
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 74
caagtgattt atagttgct 19

<210> 75
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 75
tagatctgca accagaacc 19

<210> 76
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 76
catcttgcat actgtcttt 19

<210> 77
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 77
ccttagctgc tcttcagta 19

<210> 78
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 78
aagcttctcc tcttgcagg 19

<210> 79
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 79
atatttctat ccatacaga 19

<210> 80
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 80
ctagatgtcc acaaggaac 19

<210> 81
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 81
agcacattgt ttacaagtg 19

<210> 82
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 82
agcacatggg acacttgtc 19

<210> 83
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 83
cttgaaagta atgactgtg 19

<210> 84
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 84
cctactatag agttagatt 19

<210> 85
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 85
attcaatcag ggtaataag 19

<210> 86
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 86
aagtcagttc acatcacac 19

<210> 87
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 87
cagtaaaaaa aatggataa 19

<210> 88
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 88
ttcagttata gtatgatgc 19

<210> 89
<211> 19
<212> DNA

<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 89
tacacttaga aattaaatc 19

<210> 90
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 90
tctctatctt tccaccagc 19

<210> 91
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 91
agaatcctaa aacacaaca 19

<210> 92
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 92
attcgcacaa gtacgtgtt 19

<210> 93
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 93
tgtcagtaca tgttggctc 19

<210> 94
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> based on Homo sapiens

<400> 94
acatagtgtt ttgccactt 19

<210> 95
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 95
ctttgatctg gctcagact 19

<210> 96
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 96
gaaaccacat ttaacagtt 19

<210> 97
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 97
tcatttgagc ctgggaggu 19

<210> 98
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 98
cggaggctga ggcaggaga 19

<210> 99
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 99

ggtgtggtgg tacgcgcct 19

<210> 100
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 100
acccatgcac aaaactacc 19

<210> 101
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 101
agaatgtgcc agtaggaga 19

<210> 102
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 102
tctcacagac gttgggctt 19

<210> 103
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 103
ccagtggttt gcaagcatg 19

<210> 104
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 104
gaaatttagt ggccaggaa 19

<210> 105

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 105
agaaatacac aattgcacc 19

<210> 106
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 106
tactgataca ttttaagga 19

<210> 107
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 107
ttcaacatgg agattctaa 19

<210> 108
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 108
atttctatgc atttagagt 19

<210> 109
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 109
aatactaggc tgaaaagcc 19

<210> 110
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 110
ggctttgctt ttatcagtt 19

<210> 111
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 111
tctagggagg tagttttgt 19

<210> 112
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 112
gggaagaaaa gggactagc 19

<210> 113
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 113
gttcataatg aaatgaatg 19

<210> 114
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 114
ataagaatat gctgttttc 19

<210> 115
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 115
ttcaaacgtg ttggcgctt 19

<210> 116
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 116
atgacaagtc gtatttcag 19

<210> 117
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 117
aagtggaata cgtagacat 19

<210> 118
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 118
agacaggaac cccagcagg 19

<210> 119
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 119
cgagcaagac tcctttctg 19

<210> 120
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 120
agtgtaatag aaaccagca 19

<210> 121
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 121
tgaccttgtc attcacacc 19

<210> 122
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 122
ttatccagca tcaggccac 19

<210> 123
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 123
actgtctcct cttttccag 19

<210> 124
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 124
ttttatgctt ttcagtagg 19

<210> 125
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 125
acgaatctgc agctaggat 19

<210> 126
<211> 19
<212> DNA

<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 126
caagttgtta acggaattt 19

<210> 127
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 127
taggctgaga ggtagcttc 19

<210> 128
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 128
gttactgaag aaggaaaag 19

<210> 129
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 129
gaatgagtgt gtggaatgt 19

<210> 130
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 130
tgttttctgt acccggaag 19

<210> 131
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> based on Homo sapiens

<400> 131
gagccacgga aatatccac 19

<210> 132
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 132
tgatggagag tttgaataa 19

<210> 133
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 133
gatttgctct ggagtttac 19

<210> 134
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 134
ggcagaaaat tcttgattt 19

<210> 135
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 135
ggacaggggt aggaacttc 19

<210> 136
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 136

gcattttcgt tattcattg 19

<210> 137
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 137
ctgaaaagta agtaatctg 19

<210> 138
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 138
ggcgacagaa aagtcaatg 19

<210> 139
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 139
ccactctgtc tccaggtcc 19

<210> 140
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 140
ccaccacagg caaagcaag 19

<210> 141
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 141
ttcggttccc aattgctca 19

<210> 142

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 142
ttctgacata gcattatcc 19

<210> 143
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 143
tgggaaaatg tctcaggtg 19

<210> 144
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 144
tataaatggg catttggga 19

<210> 145
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 145
tgtcttgaag ctgattttc 19

<210> 146
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 146
gaaactgtgt atcttgaag 19

<210> 147
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 147
tgtctgcatg ctcagatta 19

<210> 148
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 148
gaatgtttta aagcgggct 19

<210> 149
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 149
cactagaggg ccagttaaa 19

<210> 150
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 150
ccgcacttgc aagctgctc 19

<210> 151
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 151
catcatcact gttacccac 19

<210> 152
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 152
ccaccatcac agcaaaagc 19

<210> 153
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 153
tccagattcc caacacctg 19

<210> 154
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 154
cccatggatc atctccaga 19

<210> 155
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 155
aaccacttgg catgttgaa 19

<210> 156
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 156
caagtactca caccttgga 19

<210> 157
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 157
cctgtccttt aattcttat 19

<210> 158
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 158
tgaacttgac ggatgaact 19

<210> 159
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 159
tagatgaggg taactggct 19

<210> 160
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 160
tggatagcag ctgttcaag 19

<210> 161
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 161
cattttcatc tcctgggct 19

<210> 162
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 162
tggataattg atgactctg 19

<210> 163
<211> 19
<212> DNA

<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 163
gtcttctcca ggttcaaaa 19

<210> 164
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 164
tattcatcat gattgcatc 19

<210> 165
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 165
catttccacg gcagcatta 19

<210> 166
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 166
ccaggcttct actaaagcc 19

<210> 167
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 167
gctaggattt ttctctgaa 19

<210> 168
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> based on Homo sapiens

<400> 168
tctataattc tctccagtt 19

<210> 169
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 169
acacaagatc attgactag 19

<210> 170
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 170
tctgcattga gtaagtcta 19

<210> 171
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 171
ctcttccctt atttcatct 19

<210> 172
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 172
tcctcagttg ctctttctc 19

<210> 173
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 173

gccattctat tcttccgga 19

<210> 174
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 174
agtcaaatgt tgaaaaagt 19

<210> 175
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 175
ccaggattgg aattacaca 19

<210> 176
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 176
attccggcag ttagtagac 19

<210> 177
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 177
taacatcatg ttcttgttc 19

<210> 178
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 178
gtctgtgtct tctgtttaa 19

<210> 179

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 179
ttctcttgct tgtaaagac 19

<210> 180
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 180
ctaaaatcgt atcaatcag 19

<210> 181
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 181
ggctgcaata tttcctttt 19

<210> 182
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 182
gagagtttct gaatacagt 19

<210> 183
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 183
acagcttcag cttcttgca 19

<210> 184
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 184
aaataaatgc tcatataac 19

<210> 185
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 185
gaaacatctt ctgtgggaa 19

<210> 186
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 186
gttcttccac tggtagatc 19

<210> 187
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 187
cttcttgtag tctccgcaa 19

<210> 188
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 188
ttgtccatac acactttac 19

<210> 189
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 189
aaccaaatta ggataaaag 19

<210> 190
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 190
atgttcatat ggtttagat 19

<210> 191
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 191
taagttttac ttcacttac 19

<210> 192
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 192
atgttcccgg tattagtac 19

<210> 193
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 193
gggctcaagt aattctctt 19

<210> 194
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 194
gcccaggatg gattcaaac 19

<210> 195
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<221> modified_base
<222> 1
<223> y=gm

<221> modified_base
<222> 18
<223> y=cm

<400> 195
yagaagatga ctggtaaya 19

<210> 196
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<221> misc_feature
<222> 1,17,18
<223> y=u or t

<400> 196
ygtgctattc tgtgaayy 18

<210> 197
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 197
tctgcttcaa ggagctggaa 20

<210> 198
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 198
gaaaggaaag cgcaaccg 18

<210> 199
<211> 30

<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 199
agccagatga cgaccccata gaggaacata 30

<210> 200
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 200
tggagatgat ccatgggttc a 21

<210> 201
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 201
gaactcctgt cctttaattc ttatcaagt 29

<210> 202
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 202
ctcacacctt ggaaaccact tggcatg 27

<210> 203
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 203
ggtgataaag taaagtgctt tcactgt 27

<210> 204
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 204
tcagtagttc ttaccagaca ctcctcaa 28

<210> 205
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 205
caacatgcta aatggtatcc agggtgcaaa tatc 34

<210> 206
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 206
gaaggtgaag gtcggagtc 19

<210> 207
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 207
gaagatggtg atgggattc 19

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 208
caagcttccc gttctcagcc 20

<210> 209
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> 1,17

<223> y= cm

<221> modified_base
<222> 3,18
<223> y=gm

<221> modified_base
<222> 19
<223> y=um

<223> based on Homo sapiens

<400> 209
yayagatttc atttaayyy 19

<210> 210
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> 1,18
<223> y=cm

<221> modified_base
<222> 2,17
<223> y=um

<223> based on Homo sapiens

<400> 210
yyacgctcgc catcgtyya 19

<210> 211
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> 3,18
<223> y=cm

<221> modified_base
<222> 1,17
<223> y=um

<221> modified_base
<222> 2,16
<223> y=gm

<223> based on Homo sapiens

<400> 211
yycccaagaa tactagyya 19

<210> 212

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> 1,17,18
<223> y=um

<221> modified_base
<222> 19
<223> y=cm

<223> based on Homo sapiens

<400> 212
yaagctgttc tatgtgyyy 19

<210> 213
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 213
aagggcggcg gagtgagac 19

<210> 214
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 214
agaggacgga gtcggaggc 19

<210> 215
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<400> 215
cggagcgtga ggatggaga 19

<210> 216
<211> 68
<212> PRT
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<221> VARIANT
<222> 1-3,6,9,10,14,15,18-20,24, 30,32,33,35,37,40, 42-47, 49-51, 53-57, 59-62, 64,66
<223> Xaa=any amino acid

<221> VARIANT
<222> 13, 16,17
<223> Xaa=any amino acid or is absent

<400> 216
Xaa Xaa Xaa Arg Leu Xaa Thr Phe Xaa Xaa Trp Pro Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Leu Ala Xaa Ala Gly Phe Tyr Tyr Xaa Gly Xaa
20 25 30
Xaa Asp Xaa Val Xaa Cys Phe Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Trp
35 40 45
Xaa Xaa Xaa Asp Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Pro Xaa
50 55 60
Cys Xaa Phe Val
65

<210> 217
<211> 46
<212> PRT
<213> Artificial Sequence

<220>
<223> based on Homo sapiens

<221> VARIANT
<222> 2-7,9-11,17-21,23,25, 30-32,34-35, 38-42 ,45
<223> Xaa=any amino acid

<221> VARIANT
<222> 8
<223> Xaa=Glu or Asp

<221> VARIANT
<222> 14,22
<223> Xaa=Val or Ile

<400> 217
Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Lys Xaa Cys Met
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Pro Cys Gly His Xaa Xaa Xaa
20 25 30
Cys Xaa Xaa Cys Ala Xaa Xaa Xaa Xaa Xaa Cys Pro Xaa Cys
35 40 45

<210> 218
<211> 2540
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature

<222> (1)...(2540)
<223> n=a,t,c, or g

<400> 218
gaaaaggtgg acaagtccta ttttcaagag aagatgactt ttaacagttt tgaaggatct 60
aaaacttgtg tacctgcaga catcaataag gaagaagaat ttgtagaaga gtttaataga 120
ttaaaaactt ttgctaattt tccaagtggt agtcctgttt cagcatcaac actggcacga 180
gcagggtttc tttatactgg tgaaggagat accgtgcggt gctttagttg tcatgcagct 240
gtagatagat ggcaatatgg agactcagca gttggaagac acaggaaagt atccccaaat 300
tgcagattta tcaacggctt ttatcttgaa aatagtgcca cgcagtctac aaattctggt 360
atccagaatg gtcagtacaa agttgaaaac tatctgggaa gcagagatca ttttgcctta 420
gacaggccat ctgagacaca tgcagactat cttttgagaa ctgggcaggt tgtagatata 480
tcagacacca tatacccgag gaaccctgcc atgtattgtg aagaagctag attaaagtcc 540
tttcagaact ggccagacta tgctcaccta accccaagag agttagcaag tgctggactc 600
tactacacag gtattggtga ccaagtgcag tgcttttgtt gtggtggaaa actgaaaaat 660
tgggaacctt gtgatcgtgc ctggtcagaa cacaggcgac actttcctaa ttgcttcttt 720
gttttgggcc ggaatcttaa tattcgaagt gaatctgatg ctgtgagttc tgataggaat 780
ttcccaaatt caacaaatct tccaagaaat ccatccatgg cagattatga agcacggatc 840
tttacttttg ggacatggat atactcagtt aacaaggagc agcttgcaag agctggattt 900
tatgctttag gtgaaggtga taaagtaaag tgctttcact gtggaggagg gctaactgat 960
tggaagccca gtgaagaccc ttgggaacaa catgctaaat ggtatccagg gtgcaaatat 1020
ctgttagaac agaagggaca agaatatata aacaatattc atttaactca ttcacttgag 1080
gagtgtctgg taagaactac tgagaaaaca ccatcactaa ctagaagaat tgatgatacc 1140
atcttccaaa atcctatggt acaagaagct atacgaatgg ggttcagttt caaggacatt 1200
aagaaaataa tggaggaaaa aattcagata tctgggagca actataaatc acttgaggtt 1260
ctggttgcag atctagtgaa tgctcagaaa gacagtatgc aagatgagtc aagtcagact 1320
tcattacaga aagagattag tactgaagag cagctaaggc gcctgcaaga ggagaagctt 1380
tgcaaaatct gtatggatag aaatattgct atcgtttttg ttccttgtgg acatctagtc 1440
acttgtaaac aatgtgctga agcagttgac aagtgtccca tgtgctacac agtcattact 1500
ttcaagcaaa aaatttttat gtcttaatct aactctatag taggcatgtt atgttgttct 1560
tattaccctg attgaatgtg tgatgtgaac tgactttaag taatcaggat tgaattccat 1620
tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt tggcaatata 1680
atctttgaat ttcttgattt ttcagggtat tagctgtatt atccattttt tttactgtta 1740
tttaattgaa accatagact aagaataaga agcatcatac tataactgaa cacaatgtgt 1800
attcatagta tactgattta atttctaagt gtaagtgaat taatcatctg gatttttttat 1860
tcttttcaga taggcttaac aaatggagct ttctgtatat aaatgtggag attagagtta 1920
atctccccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc catgctggtg 1980
gaaagataga gattgttttt agaggttggt tgttgtgttt taggattctg tccatttttct 2040
tgtaaaggga taaacacgga cgtgtgcgaa atatgtttgt aaagtgattt gccattgttg 2100
aaagcgtatt taatgataga atactatcga gccaacatgt actgacatgg aaagatgtca 2160
gagatatgtt aagtgtaaaa tgcaagtggc gggacactat gtatagtctg agccagatca 2220
aagtatgtat gttgttaata tgcatagaac gagagatttg gaaagatata caccaaactg 2280
ttaaatgtgg tttctcttcg gggaggggggg gattgggggga ggggccccag aggggtttta 2340
gaggggcctt ttcactttcg actttttttca ttttgttctg ttcggatttt ttataagtat 2400
gtagaccccg aagggtttta tgggaactaa catcagtaac ctaaccccccg tgactatcct 2460
gtgctcttcc tagggagctg tgttgtttcc cacccaccac ccttccctct gaacaaatgc 2520
ctgagtgctg gggcactttn 2540

<210> 219
<211> 497
<212> PRT
<213> Homo sapiens

<400> 219
Met Thr Phe Asn Ser Phe Glu Gly Ser Lys Thr Cys Val Pro Ala Asp
 1               5                  10                  15
Ile Asn Lys Glu Glu Glu Phe Val Glu Glu Phe Asn Arg Leu Lys Thr
            20                  25                  30

```
Phe Ala Asn Phe Pro Ser Gly Ser Pro Val Ser Ala Ser Thr Leu Ala
        35                  40                  45
Arg Ala Gly Phe Leu Tyr Thr Gly Glu Gly Asp Thr Val Arg Cys Phe
    50                  55                  60
Ser Cys His Ala Ala Val Asp Arg Trp Gln Tyr Gly Asp Ser Ala Val
65                  70                  75                  80
Gly Arg His Arg Lys Val Ser Pro Asn Cys Arg Phe Ile Asn Gly Phe
                85                  90                  95
Tyr Leu Glu Asn Ser Ala Thr Gln Ser Thr Asn Ser Gly Ile Gln Asn
            100                 105                 110
Gly Gln Tyr Lys Val Glu Asn Tyr Leu Gly Ser Arg Asp His Phe Ala
        115                 120                 125
Leu Asp Arg Pro Ser Glu Thr His Ala Asp Tyr Leu Leu Arg Thr Gly
    130                 135                 140
Gln Val Val Asp Ile Ser Asp Thr Ile Tyr Pro Arg Asn Pro Ala Met
145                 150                 155                 160
Tyr Cys Glu Glu Ala Arg Leu Lys Ser Phe Gln Asn Trp Pro Asp Tyr
                165                 170                 175
Ala His Leu Thr Pro Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr
            180                 185                 190
Gly Ile Gly Asp Gln Val Gln Cys Phe Cys Cys Gly Gly Lys Leu Lys
        195                 200                 205
Asn Trp Glu Pro Cys Asp Arg Ala Trp Ser Glu His Arg Arg His Phe
    210                 215                 220
Pro Asn Cys Phe Phe Val Leu Gly Arg Asn Leu Asn Ile Arg Ser Glu
225                 230                 235                 240
Ser Asp Ala Val Ser Ser Asp Arg Asn Phe Pro Asn Ser Thr Asn Leu
                245                 250                 255
Pro Arg Asn Pro Ser Met Ala Asp Tyr Glu Ala Arg Ile Phe Thr Phe
            260                 265                 270
Gly Thr Trp Ile Tyr Ser Val Asn Lys Glu Gln Leu Ala Arg Ala Gly
        275                 280                 285
Phe Tyr Ala Leu Gly Glu Gly Asp Lys Val Lys Cys Phe His Cys Gly
    290                 295                 300
Gly Gly Leu Thr Asp Trp Lys Pro Ser Glu Asp Pro Trp Glu Gln His
305                 310                 315                 320
Ala Lys Trp Tyr Pro Gly Cys Lys Tyr Leu Leu Glu Gln Lys Gly Gln
                325                 330                 335
Glu Tyr Ile Asn Asn Ile His Leu Thr His Ser Leu Glu Glu Cys Leu
            340                 345                 350
Val Arg Thr Thr Glu Lys Thr Pro Ser Leu Thr Arg Arg Ile Asp Asp
        355                 360                 365
Thr Ile Phe Gln Asn Pro Met Val Gln Glu Ala Ile Arg Met Gly Phe
    370                 375                 380
Ser Phe Lys Asp Ile Lys Lys Ile Met Glu Glu Lys Ile Gln Ile Ser
385                 390                 395                 400
Gly Ser Asn Tyr Lys Ser Leu Glu Val Leu Val Ala Asp Leu Val Asn
                405                 410                 415
Ala Gln Lys Asp Ser Met Gln Asp Glu Ser Ser Gln Thr Ser Leu Gln
            420                 425                 430
Lys Glu Ile Ser Thr Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Lys
        435                 440                 445
Leu Cys Lys Ile Cys Met Asp Arg Asn Ile Ala Ile Val Phe Val Pro
    450                 455                 460
Cys Gly His Leu Val Thr Cys Lys Gln Cys Ala Glu Ala Val Asp Lys
465                 470                 475                 480
Cys Pro Met Cys Tyr Thr Val Ile Thr Phe Lys Gln Lys Ile Phe Met
                485                 490                 495
```

Ser

<210> 220
<211> 2676
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(2676)
<223> n=a,t,c, or g

<400> 220
tccttgagat gtatcagtat aggatttagg atctccatgt tggaactcta aatgcataga 60
aatggaaata atggaaattt ttcattttgg cttttcagcc tagtattaaa actgataaaa 120
gcaaagccat gcacaaaact acctccctag agaaaggcta gtccctttc ttccccattc 180
atttcattat gaacatagta gaaaacagca tattcttatc aaatttgatg aaaagcgcca 240
acacgtttga actgaaatac gacttgtcat gtgaactgta ccgaatgtct acgtattcca 300
cttttcctgc tggggttcct gtctcagaaa ggagtcttgc tcgtgctggt ttctattaca 360
ctggtgtgaa tgacaaggtc aaatgcttct gttgtggcct gatgctggat aactggaaaa 420
gaggagacag tcctactgaa aagcataaaa agttgtatcc tagctgcaga ttcgttcaga 480
gtctaaattc cgttaacaac ttggaagcta cctctcagcc tacttttcct tcttcagtaa 540
cacattccac acactcatta cttccgggta cagaaaacag tggatatttc cgtggctctt 600
attcaaactc tccatcaaat cctgtaaact ccagagcaaa tcaagaattt tctgccttga 660
tgagaagttc ctacccctgt ccaatgaata acgaaaatgc cagattactt acttttcaga 720
catggccatt gacttttctg tcgccaacag atctggcacg agcaggcttt tactacatag 780
gacctggaga cagagtggct tgctttgcct gtggtggaaa attgagcaat tgggaaccga 840
aggataatgc tatgtcagaa cacctgagac attttcccaa atgcccattt atagaaaatc 900
agcttcaaga cacttcaaga tacacagttt ctaatctgag catgcagaca catgcagccc 960
gctttaaaac attctttaac tggccctcta gtgttctagt taatcctgag cagcttgcaa 1020
gtgcgggttt ttattatgtg ggtaacagtg atgatgtcaa atgcttttgc tgtgatggtg 1080
gactcaggtg ttgggaatct ggagatgatc catgggttca acatgccaag tggtttccaa 1140
ggtgtgagta cttgataaga attaaaggac aggagttcat ccgtcaagtt caagccagtt 1200
accctcatct acttgaacag ctgctatcca catcagacag cccaggagat gaaaatgcag 1260
agtcatcaat tatccatttg gaacctggag aagaccattc agaagatgca atcatgatga 1320
atactcctgt gattaatgct gccgtggaaa tgggctttag tagaagcctg gtaaaacaga 1380
cagttcagag aaaaatccta gcaactggag agaattatag actagtcaat gatcttgtgt 1440
tagacttact caatgcagaa gatgaaataa gggaagagga gagagaaaga gcaactgagg 1500
aaaaagaatc aaatgattta ttattaatcc ggaagaatag aatggcactt tttcaacatt 1560
tgacttgtgt aattccaatc ctggatagtc tactaactgc cggaattatt aatgaacaag 1620
aacatgatgt tattaaacag aagacacaga cgtctttaca agcaagagaa ctgattgata 1680
cgatttttagt aaaaggaaat attgcagcca ctgtattcag aaactctctg caagaagctg 1740
aagctgtgtt atatgagcat ttatttgtgc aacaggacat aaaatatatt cccacagaag 1800
atgtttcaga tctaccagtg gaagaacaat tgcggagact accagaagaa agaacatgta 1860
aagtgtgtat ggacaaagaa gtgtccatag tgtttattcc ttgtggtcat ctagtagtat 1920
gcaaagattg tgctccttct ttaagaaagt gtcctatttg taggagtaca atcaagggta 1980
cagttcgtac atttctttca tgaagaagaa ccaaaacatc gtctaaactt tagaattaat 2040
ttattaaatg tattataact ttaacttta tcctaatttg gtttccttaa aatttttatt 2100
tatttacaac tcaaaaaaca ttgttttgtg taacatattt atatatgtat ctaaaccata 2160
tgaacatata ttttttagaa actaagagaa tgataggctt ttgttcttat gaacgaaaaa 2220
gaggtagcac tacaaacaca atattcaatc caaatttcag cattattgaa attgtaagtg 2280
aagtaaaact taagatattt gagttaacct ttaagaattt taaatatttt ggcattgtac 2340
taataccggg aacatgaagc caggtgtggt ggtatgtacc tgtagtccca ggctgaggca 2400
agagaattac ttgagcccag gagtttgaat ccatcctggg cagcatactg agaccctgcc 2460
tttaaaaacn aacagnacca aanccaaaca ccagggacac atttctctgt ctttttgat 2520
cagtgtccta tacatcgaag gtgtgcatat atgttgaatc acattttagg gacatggtgt 2580

ttttataaag aattctgtga gnaaaaattt aataaagcaa ccaaattact cttaaaaaaa 2640
aaaaaaaaaa aaaaaactcg aggggcccgt accaat 2676

<210> 221
<211> 604
<212> PRT
<213> Homo sapiens

<400> 221

```
Met Asn Ile Val Glu Asn Ser Ile Phe Leu Ser Asn Leu Met Lys Ser
 1               5                  10                  15
Ala Asn Thr Phe Glu Leu Lys Tyr Asp Leu Ser Cys Glu Leu Tyr Arg
            20                  25                  30
Met Ser Thr Tyr Ser Thr Phe Pro Ala Gly Val Pro Val Ser Glu Arg
        35                  40                  45
Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys Val
    50                  55                  60
Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Arg Gly Asp
65                  70                  75                  80
Ser Pro Thr Glu Lys His Lys Lys Leu Tyr Pro Ser Cys Arg Phe Val
                85                  90                  95
Gln Ser Leu Asn Ser Val Asn Asn Leu Glu Ala Thr Ser Gln Pro Thr
            100                 105                 110
Phe Pro Ser Ser Val Thr His Ser Thr His Ser Leu Leu Pro Gly Thr
        115                 120                 125
Glu Asn Ser Gly Tyr Phe Arg Gly Ser Tyr Ser Asn Ser Pro Ser Asn
    130                 135                 140
Pro Val Asn Ser Arg Ala Asn Gln Glu Phe Ser Ala Leu Met Arg Ser
145                 150                 155                 160
Ser Tyr Pro Cys Pro Met Asn Asn Glu Asn Ala Arg Leu Leu Thr Phe
                165                 170                 175
Gln Thr Trp Pro Leu Thr Phe Leu Ser Pro Thr Asp Leu Ala Arg Ala
            180                 185                 190
Gly Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys
        195                 200                 205
Gly Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Asn Ala Met Ser Glu
    210                 215                 220
His Leu Arg His Phe Pro Lys Cys Pro Phe Ile Glu Asn Gln Leu Gln
225                 230                 235                 240
Asp Thr Ser Arg Tyr Thr Val Ser Asn Leu Ser Met Gln Thr His Ala
                245                 250                 255
Ala Arg Phe Lys Thr Phe Phe Asn Trp Pro Ser Ser Val Leu Val Asn
            260                 265                 270
Pro Glu Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Asn Ser Asp
        275                 280                 285
Asp Val Lys Cys Phe Cys Cys Asp Gly Gly Leu Arg Cys Trp Glu Ser
    290                 295                 300
Gly Asp Asp Pro Trp Val Gln His Ala Lys Trp Phe Pro Arg Cys Glu
305                 310                 315                 320
Tyr Leu Ile Arg Ile Lys Gly Gln Glu Phe Ile Arg Gln Val Gln Ala
                325                 330                 335
Ser Tyr Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Ser Pro
            340                 345                 350
Gly Asp Glu Asn Ala Glu Ser Ser Ile Ile His Leu Glu Pro Gly Glu
        355                 360                 365
Asp His Ser Glu Asp Ala Ile Met Met Asn Thr Pro Val Ile Asn Ala
    370                 375                 380
Ala Val Glu Met Gly Phe Ser Arg Ser Leu Val Lys Gln Thr Val Gln
```

```
385                 390                 395                 400
Arg Lys Ile Leu Ala Thr Gly Glu Asn Tyr Arg Leu Val Asn Asp Leu
                405                 410                 415
Val Leu Asp Leu Leu Asn Ala Glu Asp Glu Ile Arg Glu Glu Glu Arg
            420                 425                 430
Glu Arg Ala Thr Glu Glu Lys Glu Ser Asn Asp Leu Leu Leu Ile Arg
        435                 440                 445
Lys Asn Arg Met Ala Leu Phe Gln His Leu Thr Cys Val Ile Pro Ile
    450                 455                 460
Leu Asp Ser Leu Leu Thr Ala Gly Ile Ile Asn Glu Gln Glu His Asp
465                 470                 475                 480
Val Ile Lys Gln Lys Thr Gln Thr Ser Leu Gln Ala Arg Glu Leu Ile
                485                 490                 495
Asp Thr Ile Leu Val Lys Gly Asn Ile Ala Ala Thr Val Phe Arg Asn
            500                 505                 510
Ser Leu Gln Glu Ala Glu Ala Val Leu Tyr Glu His Leu Phe Val Gln
        515                 520                 525
Gln Asp Ile Lys Tyr Ile Pro Thr Glu Asp Val Ser Asp Leu Pro Val
    530                 535                 540
Glu Glu Gln Leu Arg Arg Leu Pro Glu Glu Arg Thr Cys Lys Val Cys
545                 550                 555                 560
Met Asp Lys Glu Val Ser Ile Val Phe Ile Pro Cys Gly His Leu Val
                565                 570                 575
Val Cys Lys Asp Cys Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg
            580                 585                 590
Ser Thr Ile Lys Gly Thr Val Arg Thr Phe Leu Ser
        595                 600
```

<210> 222
<211> 2580
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(2580)
<223> n=a,t,c, or g

<400> 222
ttaggttacc tgaaagagtt actacaaccc caaagagttg tgttctaagt agtatcttgg 60
taattcagag agatactcat cctacctgaa tataaactga gataaatcca gtaaagaaag 120
tgtagtaaat tctacataag agtctatcat tgatttcttt ttgtggtgga aatcttagtt 180
catgtgaaga aatttcatgt gaatgtttta gctatcaaac agtactgtca cctactcatg 240
cacaaaactg cctcccaaag acttttccca ggtccctcgt atcaaaacat taagagtata 300
atggaagata gcacgatctt gtcagattgg acaaacagca acaaacaaaa aatgaagtat 360
gacttttcct gtgaactcta cagaatgtct acatattcaa ctttccccgc cggggtgcct 420
gtctcagaaa ggagtcttgc tcgtgctggt ttttattata ctggtgtgaa tgacaaggtc 480
aaatgcttct gttgtggcct gatgctggat aactggaaac taggagacag tcctattcaa 540
aagcataaac agctatatcc tagctgtagc tttattcaga atctggtttc agctagtctg 600
ggatccacct ctaagaatac gtctccaatg agaaacagtt ttgcacattc attatctccc 660
accttggaac atagtagctt gttcagtggt tcttactcca gccttcctcc aaaccctctt 720
aattctagag cagttgaaga catctcttca tcgaggacta acccctacag ttatgcaatg 780
agtactgaag aagccagatt tcttacctac catatgtggc cattaacttt tttgtcacca 840
tcagaattgg caagagctgg tttttattat ataggacctg gagatagggt agcctgcttt 900
gcctgtggtg ggaagctcag taactgggaa ccaaaggatg atgctatgtc agaacaccgg 960
aggcattttc ccaactgtcc atttttggaa aattctctag aaactctgag gtttagcatt 1020
tcaaatctga gcatgcagac acatgcagct cgaatgagaa catttatgta ctggccatct 1080

agtgttccag ttcagcctga gcagcttgca agtgctggtt tttattatgt gggtcgcaat 1140
gatgatgtca aatgctttgg ttgtgatggt ggcttgaggt gttgggaatc tggagatgat 1200
ccatgggtag aacatgccaa gtggtttcca aggtgtgagt tcttgatacg aatgaaaggc 1260
caagagtttg ttgatgagat tcaaggtaga tatcctcatc ttcttgaaca gctgttgtca 1320
acttcagata ccactggaga agaaaatgct gacccaccaa ttattcattt tggacctgga 1380
gaaagttctt cagaagatgc tgtcatgatg aatacacctg tggttaaatc tgccttggaa 1440
atgggcttta atagagacct ggtgaaacaa acagttctaa gtaaaatcct gacaactgga 1500
gagaactata aaacagttaa tgatattgtg tcagcacttc ttaatgctga agatgaaaaa 1560
agagaagagg agaaggaaaa acaagctgaa gaaatggcat cagatgattt gtcattaatt 1620
cggaagaaca gaatggctct ctttcaacaa ttgacatgtg tgcttcctat cctggataat 1680
cttttaaagg ccaatgtaat taataaacag gaacatgata ttattaaaca aaaaacacag 1740
ataccttac aagcgagaga actgattgat accatttggg ttaaaggaaa tgctgcggcc 1800
aacatcttca aaaactgtct aaaagaaatt gactctacat tgtataagaa cttatttgtg 1860
gataagaata tgaagtatat tccaacagaa gatgtttcag gtctgtcact ggaagaacaa 1920
ttgaggaggt tgcaagaaga acgaacttgt aaagtgtgta tggacaaaga agtttctgtt 1980
gtatttattc cttgtggtca tctggtagta tgccaggaat gtgccccttc tctaagaaaa 2040
tgccctattt gcaggggtat aatcaagggt actgttcgta catttctctc ttaaagaaaa 2100
atagtctata ttttaacctg cataaaaagg tctttaaaat attgttgaac acttgaagcc 2160
atctaaagta aaaagggaat tatgagtttt tcaattagta acattcatgt tctagtctgc 2220
tttggtacta ataatcttgt ttctgaaaag atggtatcat atatttaatc ttaatctgtt 2280
tatttacaag ggaagattta tgtttggtga actatattag tatgtatgtg tacctaaggg 2340
agtagcgtcn ctgcttgtta tgcatcattt caggagttac tggatttgtt gttctttcag 2400
aaagctttga anactaaatt atagtgtaga aaagaactgg aaaccaggaa ctctggagtt 2460
catcagagtt atggtgccga attgtctttg gtgcttttca cttgtgtttt aaaataagga 2520
tttttctctt atttctcccc ctagtttgtg agaaacatct caataaagtg ctttaaaaag 2580

<210> 223
<211> 618
<212> PRT
<213> Homo sapiens

<400> 223
Met His Lys Thr Ala Ser Gln Arg Leu Phe Pro Gly Pro Ser Tyr Gln
1 5 10 15
Asn Ile Lys Ser Ile Met Glu Asp Ser Thr Ile Leu Ser Asp Trp Thr
20 25 30
Asn Ser Asn Lys Gln Lys Met Lys Tyr Asp Phe Ser Cys Glu Leu Tyr
35 40 45
Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala Gly Val Pro Val Ser Glu
50 55 60
Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys
65 70 75 80
Val Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Leu Gly
85 90 95
Asp Ser Pro Ile Gln Lys His Lys Gln Leu Tyr Pro Ser Cys Ser Phe
100 105 110
Ile Gln Asn Leu Val Ser Ala Ser Leu Gly Ser Thr Ser Lys Asn Thr
115 120 125
Ser Pro Met Arg Asn Ser Phe Ala His Ser Leu Ser Pro Thr Leu Glu
130 135 140
His Ser Ser Leu Phe Ser Gly Ser Tyr Ser Ser Leu Pro Pro Asn Pro
145 150 155 160
Leu Asn Ser Arg Ala Val Glu Asp Ile Ser Ser Ser Arg Thr Asn Pro
165 170 175
Tyr Ser Tyr Ala Met Ser Thr Glu Glu Ala Arg Phe Leu Thr Tyr His
180 185 190
Met Trp Pro Leu Thr Phe Leu Ser Pro Ser Glu Leu Ala Arg Ala Gly

```
        195                 200                 205
Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys Gly
    210                 215                 220
Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Asp Ala Met Ser Glu His
225                 230                 235                 240
Arg Arg His Phe Pro Asn Cys Pro Phe Leu Glu Asn Ser Leu Glu Thr
                245                 250                 255
Leu Arg Phe Ser Ile Ser Asn Leu Ser Met Gln Thr His Ala Ala Arg
            260                 265                 270
Met Arg Thr Phe Met Tyr Trp Pro Ser Ser Val Pro Val Gln Pro Glu
        275                 280                 285
Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Arg Asn Asp Asp Val
    290                 295                 300
Lys Cys Phe Gly Cys Asp Gly Gly Leu Arg Cys Trp Glu Ser Gly Asp
305                 310                 315                 320
Asp Pro Trp Val Glu His Ala Lys Trp Phe Pro Arg Cys Glu Phe Leu
                325                 330                 335
Ile Arg Met Lys Gly Gln Glu Phe Val Asp Glu Ile Gln Gly Arg Tyr
            340                 345                 350
Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Thr Thr Gly Glu
        355                 360                 365
Glu Asn Ala Asp Pro Pro Ile Ile His Phe Gly Pro Gly Glu Ser Ser
    370                 375                 380
Ser Glu Asp Ala Val Met Met Asn Thr Pro Val Val Lys Ser Ala Leu
385                 390                 395                 400
Glu Met Gly Phe Asn Arg Asp Leu Val Lys Gln Thr Val Leu Ser Lys
                405                 410                 415
Ile Leu Thr Thr Gly Glu Asn Tyr Lys Thr Val Asn Asp Ile Val Ser
            420                 425                 430
Ala Leu Leu Asn Ala Glu Asp Glu Lys Arg Glu Glu Glu Lys Glu Lys
        435                 440                 445
Gln Ala Glu Glu Met Ala Ser Asp Asp Leu Ser Leu Ile Arg Lys Asn
    450                 455                 460
Arg Met Ala Leu Phe Gln Gln Leu Thr Cys Val Leu Pro Ile Leu Asp
465                 470                 475                 480
Asn Leu Leu Lys Ala Asn Val Ile Asn Lys Gln Glu His Asp Ile Ile
                485                 490                 495
Lys Gln Lys Thr Gln Ile Pro Leu Gln Ala Arg Glu Leu Ile Asp Thr
            500                 505                 510
Ile Trp Val Lys Gly Asn Ala Ala Ala Asn Ile Phe Lys Asn Cys Leu
        515                 520                 525
Lys Glu Ile Asp Ser Thr Leu Tyr Lys Asn Leu Phe Val Asp Lys Asn
    530                 535                 540
Met Lys Tyr Ile Pro Thr Glu Asp Val Ser Gly Leu Ser Leu Glu Glu
545                 550                 555                 560
Gln Leu Arg Arg Leu Gln Glu Glu Arg Thr Cys Lys Val Cys Met Asp
                565                 570                 575
Lys Glu Val Ser Val Val Phe Ile Pro Cys Gly His Leu Val Val Cys
            580                 585                 590
Gln Glu Cys Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg Gly Ile
        595                 600                 605
Ile Lys Gly Thr Val Arg Thr Phe Leu Ser
    610                 615
```

<210> 224
<211> 2100
<212> DNA

<213> Mus musculus

<400> 224
gacactctgc tgggcggcgg gccgccctcc tccgggacct cccctcggga accgtcgccc 60
gcggcgctta gttaggactg gagtgcttgg cgcgaaaagg tggacaagtc ctattttcca 120
gagaagatga cttttaacag ttttgaagga actagaactt ttgtacttgc agacaccaat 180
aaggatgaag aatttgtaga agagtttaat agattaaaaa catttgctaa cttcccaagt 240
agtagtcctg tttcagcatc aacattggcg cgagctgggt ttctttatac cggtgaagga 300
gacaccgtgc aatgtttcag ttgtcatgcg gcaatagata gatggcagta tggagactca 360
gctgttggaa gacacaggag aatatcccca aattgcagat ttatcaatgg tttttatttt 420
gaaaatggtg ctgcacagtc tacaaatcct ggtatccaaa atggccagta caaatctgaa 480
aactgtgtgg gaaatagaaa tccttttgcc cctgacaggc cacctgagac tcatgctgat 540
tatctcttga gaactggaca ggttgtagat atttcagaca ccatataccc gaggaaccct 600
gccatgtgta gtgaagaagc cagattgaag tcatttcaga actggccgga ctatgctcat 660
ttaaccccca gagagttagc tagtgctggc ctctactaca caggggctga tgatcaagtg 720
caatgctttt gttgtggggg aaaactgaaa aattgggaac cctgtgatcg tgcctggtca 780
gaacacagga gacactttcc caattgcttt tttgttttgg gccggaacgt taatgttcga 840
agtgaatctg gtgtgagttc tgataggaat ttcccaaatt caacaaactc tccaagaaat 900
ccagccatgg cagaatatga agcacggatc gttacttttg gaacatggat atactcagtt 960
aacaaggagc agcttgcaag agctggattt tatgctttag gtgaaggcga taaagtgaag 1020
tgcttccact gtggaggagg gctcacggat tggaagccaa gtgaagaccc ctgggaccag 1080
catgctaagt gctacccagg gtgcaaatac ctattggatg agaaggggca agaatatata 1140
aataatattc atttaaccca tccacttgag gaatctttgg gaagaactgc tgaaaaaaca 1200
ccaccgctaa ctaaaaaaat cgatgatacc atcttccaga atcctatggt gcaagaagct 1260
atacgaatgg gatttagctt caaggacctt aagaaaacaa tggaagaaaa aatccaaaca 1320
tccgggagca gctatctatc acttgaggtc ctgattgcag atcttgtgag tgctcagaaa 1380
gataatacgg aggatgagtc aagtcaaact tcattgcaga aagacattag tactgaagag 1440
cagctaaggc gcctacaaga ggagaagctt tccaaaatct gtatggatag aaatattgct 1500
atcgtttttt ttccttgtgg acatctggcc acttgtaaac agtgtgcaga agcagttgac 1560
aaatgtccca tgtgctacac cgtcattacg ttcaaccaaa aaatttttat gtcttagtgg 1620
ggcaccacat gttatgttct tcttgctcta attgaatgtg taatgggagc gaactttaag 1680
taatcctgca tttgcattcc attagcatcc tgctgtttcc aaatggagac caatgctaac 1740
agcactgttt ccgtctaaac attcaatttc tggatctttc gagttatcag ctgtatcatt 1800
tagccagtgt tttactcgat tgaaacctta gacagagaag cattttatag cttttcacat 1860
gtatattggt agtacactga cttgatttct atatgtaagt gaattcatca cctgcatgtt 1920
tcatgccttt tgcataagct taacaaatgg agtgttctgt ataagcatgg agatgtgatg 1980
gaatctgccc aatgacttta attggcttat tgtaaacacg gaaagaactg ccccacgctg 2040
ctgggaggat aaagattgtt ttagatgctc acttctgtgt tttaggattc tgcccattta 2100

<210> 225
<211> 496
<212> PRT
<213> Mus musculus

<400> 225
Met Thr Phe Asn Ser Phe Glu Gly Thr Arg Thr Phe Val Leu Ala Asp
 1               5                  10                  15
Thr Asn Lys Asp Glu Glu Phe Val Glu Glu Phe Asn Arg Leu Lys Thr
            20                  25                  30
Phe Ala Asn Phe Pro Ser Ser Ser Pro Val Ser Ala Ser Thr Leu Ala
        35                  40                  45
Arg Ala Gly Phe Leu Tyr Thr Gly Glu Gly Asp Thr Val Gln Cys Phe
    50                  55                  60
Ser Cys His Ala Ala Ile Asp Arg Trp Gln Tyr Gly Asp Ser Ala Val
65                  70                  75                  80
Gly Arg His Arg Arg Ile Ser Pro Asn Cys Arg Phe Ile Asn Gly Phe
                85                  90                  95

```
Tyr Phe Glu Asn Gly Ala Ala Gln Ser Thr Asn Pro Gly Ile Gln Asn
            100                 105                 110
Gly Gln Tyr Lys Ser Glu Asn Cys Val Gly Asn Arg Asn Pro Phe Ala
        115                 120                 125
Pro Asp Arg Pro Pro Glu Thr His Ala Asp Tyr Leu Leu Arg Thr Gly
    130                 135                 140
Gln Val Val Asp Ile Ser Asp Thr Ile Tyr Pro Arg Asn Pro Ala Met
145                 150                 155                 160
Cys Ser Glu Glu Ala Arg Leu Lys Ser Phe Gln Asn Trp Pro Asp Tyr
                165                 170                 175
Ala His Leu Thr Pro Arg Glu Leu Ala Ser Ala Gly Leu Tyr Tyr Thr
            180                 185                 190
Gly Ala Asp Asp Gln Val Gln Cys Phe Cys Cys Gly Gly Lys Leu Lys
        195                 200                 205
Asn Trp Glu Pro Cys Asp Arg Ala Trp Ser Glu His Arg Arg His Phe
    210                 215                 220
Pro Asn Cys Phe Phe Val Leu Gly Arg Asn Val Asn Val Arg Ser Glu
225                 230                 235                 240
Ser Gly Val Ser Ser Asp Arg Asn Phe Pro Asn Ser Thr Asn Ser Pro
                245                 250                 255
Arg Asn Pro Ala Met Ala Glu Tyr Glu Ala Arg Ile Val Thr Phe Gly
            260                 265                 270
Thr Trp Ile Tyr Ser Val Asn Lys Glu Gln Leu Ala Arg Ala Gly Phe
        275                 280                 285
Tyr Ala Leu Gly Glu Gly Asp Lys Val Lys Cys Phe His Cys Gly Gly
    290                 295                 300
Gly Leu Thr Asp Trp Lys Pro Ser Glu Asp Pro Trp Asp Gln His Ala
305                 310                 315                 320
Lys Cys Tyr Pro Gly Cys Lys Tyr Leu Leu Asp Glu Lys Gly Gln Glu
                325                 330                 335
Tyr Ile Asn Asn Ile His Leu Thr His Pro Leu Glu Glu Ser Leu Gly
            340                 345                 350
Arg Thr Ala Glu Lys Thr Pro Pro Leu Thr Lys Lys Ile Asp Asp Thr
        355                 360                 365
Ile Phe Gln Asn Pro Met Val Gln Glu Ala Ile Arg Met Gly Phe Ser
    370                 375                 380
Phe Lys Asp Leu Lys Lys Thr Met Glu Glu Lys Ile Gln Thr Ser Gly
385                 390                 395                 400
Ser Ser Tyr Leu Ser Leu Glu Val Leu Ile Ala Asp Leu Val Ser Ala
                405                 410                 415
Gln Lys Asp Asn Thr Glu Asp Glu Ser Ser Gln Thr Ser Leu Gln Lys
            420                 425                 430
Asp Ile Ser Thr Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Lys Leu
        435                 440                 445
Ser Lys Ile Cys Met Asp Arg Asn Ile Ala Ile Val Phe Phe Pro Cys
    450                 455                 460
Gly His Leu Ala Thr Cys Lys Gln Cys Ala Glu Ala Val Asp Lys Cys
465                 470                 475                 480
Pro Met Cys Tyr Thr Val Ile Thr Phe Asn Gln Lys Ile Phe Met Ser
                485                 490                 495
```

<210> 226
<211> 2474
<212> DNA
<213> Mus musculus

<400> 226

```
gaattccggg agacctacac ccccggagat cagaggtcat tgctggcgtt cagagcctag 60
gaagtgggct gcggtatcag cctagcagta aaaccgacca gaagccatgc acaaaactac 120
atccccagag aaagacttgt cccttccccc ccctgtcatc tcaccatgaa catggttcaa 180
gacagcgcct ttctagccaa gctgatgaag agtgctgaca cctttgagtt gaagtatgac 240
ttttcctgtg agctgtaccg attgtccacg tattcagctt ttcccagggg agttcctgtg 300
tcagaaagga gtctggctcg tgctggcttt tactacactg gtgccaatga caaggtcaag 360
tgcttctgct gtggcctgat gctagacaac tggaaacaag gggacagtcc catggagaag 420
cacagaaagt tgtaccccag ctgcaacttt gtacagactt tgaatccagc caacagtctg 480
gaagctagtc ctcggccttc tcttccttcc acggcgatga gcaccatgcc tttgagcttt 540
gcaagttctg agaatactgg ctatttcagt ggctcttact cgagctttcc ctcagaccct 600
gtgaacttcc gagcaaatca agattgtcct gctttgagca caagtcccta ccactttgca 660
atgaacacag agaaggccag attactcacc tatgaaacat ggccattgtc ttttctgtca 720
ccagcaaagc tggccaaagc aggcttctac tacataggac ctggagatag agtggcctgc 780
tttgcgtgcg atgggaaact gagcaactgg gaacgtaagg atgatgctat gtcagagcac 840
cagaggcatt tccccagctg tccgttctta aaagacttgg gtcagtctgc ttcgagatac 900
actgtctcta acctgagcat gcagacacac gcagcccgta ttagaacatt ctctaactgg 960
ccttctagtg cactagttca ttcccaggaa cttgcaagtg cgggctttta ttatacagga 1020
cacagtgatg atgtcaagtg tttatgctgt gatggtgggc tgaggtgctg ggaatctgga 1080
gatgacccct gggtggaaca tgccaagtgg tttccaaggt gtgagtactt gctcagaatc 1140
aaaggccaag aatttgtcag ccaagttcaa gctggctatc ctcatctact tgagcagcta 1200
ttatctacgt cagactcccc agaagatgag aatgcagacg cagcaatcgt gcattttggc 1260
cctggagaaa gttcggaaga tgtcgtcatg atgagcacgc ctgtggttaa agcagccttg 1320
gaaatgggct tcagtaggag cctggtgaga cagacggttc agtggcagat cctggccact 1380
ggtgagaact acaggaccgt cagtgacctc gttataggct tactcgatgc agaagacgag 1440
atgagagagg agcagatgga gcaggcggcc gaggaggagg agtcagatga tctagcacta 1500
atccggaaga acaaaatggt gcttttccaa catttgacgt gtgtgacacc aatgctgtat 1560
tgcctcctaa gtgcaagggc catcactgaa caggagtgca atgctgtgaa acagaaacca 1620
cacaccttac aagcaagcac actgattgat actgtgttag caaaaggaaa cactgcagca 1680
acctcattca gaaactccct tcgggaaatt gaccctgcgt tatacagaga tatatttgtg 1740
caacaggaca ttaggagtct tcccacagat gacattgcag ctctaccaat ggaagaacag 1800
ttgcggcccc tcccggagga cagaatgtgt aaagtgtgta tggaccgaga ggtatccatc 1860
gtgttcattc cctgtggcca tctggtcgtg tgcaaagact gcgctccctc tctgaggaag 1920
tgtcccatct gtagagggac catcaagggc acagtgcgca catttctctc ctgaacaaga 1980
ctaatggtcc atggctgcaa cttcagccag gaggaagttc actgtcactc ccagttccat 2040
tcggaacttg aggccagcct ggatagcacg agacaccgcc aaacacacaa atataaacat 2100
gaaaaacttt tgtctgaagt caagaatgaa tgaattactt atataataat tttaattggt 2160
ttccttaaaa gtgctatttg ttcccaactc agaaaattgt tttctgtaaa catatttaca 2220
tactacctgc atctaaagta ttcatatatt catatattca gatgtcatga gagagggttt 2280
tgttcttgtt cctgaaaagc tggtttatca tctgatcagc atatactgcg caacgggcag 2340
ggctagaatc catgaaccaa gctgcaaaga tctcacgcta aataaggcgg aaagatttgg 2400
agaaacgaaa ggaaattctt tcctgtccaa tgtatactct tcagactaat gacctcttcc 2460
tatcaagcct tcta                                                   2474

<210> 227
<211> 602
<212> PRT
<213> Mus musculus

<400> 227
Met Asn Met Val Gln Asp Ser Ala Phe Leu Ala Lys Leu Met Lys Ser
 1               5                  10                  15
Ala Asp Thr Phe Glu Leu Lys Tyr Asp Phe Ser Cys Glu Leu Tyr Arg
            20                  25                  30
Leu Ser Thr Tyr Ser Ala Phe Pro Arg Gly Val Pro Val Ser Glu Arg
        35                  40                  45
Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Ala Asn Asp Lys Val
    50                  55                  60
Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Gln Gly Asp
```

```
65                  70                  75                  80
Ser Pro Met Glu Lys His Arg Lys Leu Tyr Pro Ser Cys Asn Phe Val
                85                  90                  95
Gln Thr Leu Asn Pro Ala Asn Ser Leu Glu Ala Ser Pro Arg Pro Ser
            100                 105                 110
Leu Pro Ser Thr Ala Met Ser Thr Met Pro Leu Ser Phe Ala Ser Ser
        115                 120                 125
Glu Asn Thr Gly Tyr Phe Ser Gly Ser Tyr Ser Ser Phe Pro Ser Asp
    130                 135                 140
Pro Val Asn Phe Arg Ala Asn Gln Asp Cys Pro Ala Leu Ser Thr Ser
145                 150                 155                 160
Pro Tyr His Phe Ala Met Asn Thr Glu Lys Ala Arg Leu Leu Thr Tyr
                165                 170                 175
Glu Thr Trp Pro Leu Ser Phe Leu Ser Pro Ala Lys Leu Ala Lys Ala
            180                 185                 190
Gly Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys
        195                 200                 205
Asp Gly Lys Leu Ser Asn Trp Glu Arg Lys Asp Asp Ala Met Ser Glu
    210                 215                 220
His Gln Arg His Phe Pro Ser Cys Pro Phe Leu Lys Asp Leu Gly Gln
225                 230                 235                 240
Ser Ala Ser Arg Tyr Thr Val Ser Asn Leu Ser Met Gln Thr His Ala
                245                 250                 255
Ala Arg Ile Arg Thr Phe Ser Asn Trp Pro Ser Ser Ala Leu Val His
            260                 265                 270
Ser Gln Glu Leu Ala Ser Ala Gly Phe Tyr Tyr Thr Gly His Ser Asp
        275                 280                 285
Asp Val Lys Cys Leu Cys Cys Asp Gly Gly Leu Arg Cys Trp Glu Ser
    290                 295                 300
Gly Asp Asp Pro Trp Val Glu His Ala Lys Trp Phe Pro Arg Cys Glu
305                 310                 315                 320
Tyr Leu Leu Arg Ile Lys Gly Gln Glu Phe Val Ser Gln Val Gln Ala
                325                 330                 335
Gly Tyr Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp Ser Pro
            340                 345                 350
Glu Asp Glu Asn Ala Asp Ala Ala Ile Val His Phe Gly Pro Gly Glu
        355                 360                 365
Ser Ser Glu Asp Val Val Met Met Ser Thr Pro Val Val Lys Ala Ala
    370                 375                 380
Leu Glu Met Gly Phe Ser Arg Ser Leu Val Arg Gln Thr Val Gln Trp
385                 390                 395                 400
Gln Ile Leu Ala Thr Gly Glu Asn Tyr Arg Thr Val Ser Asp Leu Val
                405                 410                 415
Ile Gly Leu Leu Asp Ala Glu Asp Glu Met Arg Glu Glu Gln Met Glu
            420                 425                 430
Gln Ala Ala Glu Glu Glu Glu Ser Asp Asp Leu Ala Leu Ile Arg Lys
        435                 440                 445
Asn Lys Met Val Leu Phe Gln His Leu Thr Cys Val Thr Pro Met Leu
    450                 455                 460
Tyr Cys Leu Leu Ser Ala Arg Ala Ile Thr Glu Gln Glu Cys Asn Ala
465                 470                 475                 480
Val Lys Gln Lys Pro His Thr Leu Gln Ala Ser Thr Leu Ile Asp Thr
                485                 490                 495
Val Leu Ala Lys Gly Asn Thr Ala Ala Thr Ser Phe Arg Asn Ser Leu
            500                 505                 510
Arg Glu Ile Asp Pro Ala Leu Tyr Arg Asp Ile Phe Val Gln Gln Asp
        515                 520                 525
Ile Arg Ser Leu Pro Thr Asp Asp Ile Ala Ala Leu Pro Met Glu Glu
```

```
    530                 535                 540
Gln Leu Arg Pro Leu Pro Glu Asp Arg Met Cys Lys Val Cys Met Asp
545                 550                 555                 560
Arg Glu Val Ser Ile Val Phe Ile Pro Cys Gly His Leu Val Val Cys
                565                 570                 575
Lys Asp Cys Ala Pro Ser Leu Arg Lys Cys Pro Ile Cys Arg Gly Thr
            580                 585                 590
Ile Lys Gly Thr Val Arg Thr Phe Leu Ser
        595                 600
```

<210> 228
<211> 2416
<212> DNA
<213> Mus musculus

<400> 228

```
ctgtggtgga gatctattgt ccaagtggtg agaaacttca tctggaagtt taagcggtca 60
gaaatactat tactactcat ggacaaaact gtctcccaga gactcgccca aggtacctta 120
cacccaaaaa cttaaacgta taatggagaa gagcacaatc ttgtcaaatt ggacaaagga 180
gagcgaagaa aaaatgaagt ttgacttttc gtgtgaactc taccgaatgt ctacatattc 240
agcttttccc aggggagttc ctgtctcaga gaggagtctg gctcgtgctg gcttttatta 300
tacaggtgtg aatgacaaag tcaagtgctt ctgctgtggc ctgatgttgg ataactggaa 360
acaaggggac agtcctgttg aaaagcacag acagttctat cccagctgca gctttgtaca 420
gactctgctt tcagccagtc tgcagtctcc atctaagaat atgtctcctg tgaaaagtag 480
atttgcacat tcgtcacctc tggaacgagg tggcattcac tccaacctgt gctctagccc 540
tcttaattct agagcagtgg aagacttctc atcaaggatg gatccctgca gctatgccat 600
gagtacagaa gaggccagat ttcttactta cagtatgtgg cctttaagtt ttctgtcacc 660
agcagagctg gccagagctg gcttctatta catagggcct ggagacaggg tggcctgttt 720
tgcctgtggt gggaaactga gcaactggga accaaaggat tatgctatgt cagagcaccg 780
cagacatttt ccccactgtc catttctgga aaatacttca gaaacacaga ggtttagtat 840
atcaaatcta agtatgcaga cacactctgc tcgattgagg acatttctgt actggccacc 900
tagtgttcct gttcagcccg agcagcttgc aagtgctgga ttctattacg tggatcgcaa 960
tgatgatgtc aagtgccttt gttgtgatgg tggcttgaga tgttgggaac ctggagatga 1020
cccctggata gaacacgcca aatggtttcc aaggtgtgag ttcttgatac ggatgaaggg 1080
tcaggagttt gttgatgaga ttcaagctag atatcctcat cttcttgagc agctgttgtc 1140
cacttcagac accccaggag aagaaaatgc tgaccctaca gagacagtgg tgcattttgg 1200
ccctggagaa agttcgaaag atgtcgtcat gatgagcacg cctgtggtta aagcagcctt 1260
ggaaatgggc ttcagtagga gcctggtgag acagacggtt cagcggcaga tcctggccac 1320
tggtgagaac tacaggaccg tcaatgatat tgtctcagta cttttgaatg ctgaagatga 1380
gagaagagaa gaggagaagg aaagacagac tgaagagatg gcatcaggtg acttatcact 1440
gattcggaag aatagaatgg ccctctttca acagttgaca catgtccttc ctatcctgga 1500
taatcttctt gaggccagtg taattacaaa acaggaacat gatattatta gacagaaaac 1560
acagataccc ttacaagcaa gagagcttat tgacaccgtt ttagtcaagg gaaatgctgc 1620
agccaacatc ttcaaaaact ctctgaaggg aattgactcc acgttatatg aaaacttatt 1680
tgtggaaaag aatatgaagt atattccaac agaagacgtt tcaggcttgt cattggaaga 1740
gcagttgcgg agattacaag aagaacgaac ttgcaaagtg tgtatggaca gagaggtttc 1800
tattgtgttc attccgtgtg gtcatctagt agtctgccag gaatgtgccc cttctctaag 1860
gaagtgcccc atctgcaggg ggacaatcaa ggggactgtg cgcacatttc tctcatgagt 1920
gaagaatggt ctgaaagtat tgttggacat cagaagctgt cagaacaaag aatgaactac 1980
tgatttcagc tcttcagcag gacattctac tctctttcaa gattagtaat cttgctttat 2040
gaagggtagc attgtatatt taagcttagt ctgttgcaag ggaaggtcta tgctgttgag 2100
ctacaggact gtgtctgttc cagagcagga gttgggatgc ttgctgtatg tccttcagga 2160
cttcttggga tttgggaatt tggggaaagc tttggaatcc agtgatgtgg agctcagaaa 2220
tcctggaacc agtgactctg gtactcagta gatagggtac cctgtacttc ttggtgcttt 2280
tccagtctgg gaaataagga ggaatctgct gctggtaaaa atttgctgga tgtgagaaat 2340
agatgaaagt gtttcgggtg ggggcgtgca tcagtgtagt gtgtgcaggg atgtatgcag 2400
gccaaacact gtgtag                                                  2416
```

<210> 229
<211> 591
<212> PRT
<213> Mus musculus

<400> 229

```
Met Glu Lys Ser Thr Ile Leu Ser Asn Trp Thr Lys Glu Ser Glu Glu
 1               5                  10                  15
Lys Met Lys Phe Asp Phe Ser Cys Glu Leu Tyr Arg Met Ser Thr Tyr
            20                  25                  30
Ser Ala Phe Pro Arg Gly Val Pro Val Ser Glu Arg Ser Leu Ala Arg
        35                  40                  45
Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys Val Lys Cys Phe Cys
    50                  55                  60
Cys Gly Leu Met Leu Asp Asn Trp Lys Gln Gly Asp Ser Pro Val Glu
65                  70                  75                  80
Lys His Arg Gln Phe Tyr Pro Ser Cys Ser Phe Val Gln Thr Leu Leu
                85                  90                  95
Ser Ala Ser Leu Gln Ser Pro Ser Lys Asn Met Ser Pro Val Lys Ser
            100                 105                 110
Arg Phe Ala His Ser Ser Pro Leu Glu Arg Gly Gly Ile His Ser Asn
        115                 120                 125
Leu Cys Ser Ser Pro Leu Asn Ser Arg Ala Val Glu Asp Phe Ser Ser
    130                 135                 140
Arg Met Asp Pro Cys Ser Tyr Ala Met Ser Thr Glu Glu Ala Arg Phe
145                 150                 155                 160
Leu Thr Tyr Ser Met Trp Pro Leu Ser Phe Leu Ser Pro Ala Glu Leu
                165                 170                 175
Ala Arg Ala Gly Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys
            180                 185                 190
Phe Ala Cys Gly Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Tyr Ala
        195                 200                 205
Met Ser Glu His Arg Arg His Phe Pro His Cys Pro Phe Leu Glu Asn
    210                 215                 220
Thr Ser Glu Thr Gln Arg Phe Ser Ile Ser Asn Leu Ser Met Gln Thr
225                 230                 235                 240
His Ser Ala Arg Leu Arg Thr Phe Leu Tyr Trp Pro Pro Ser Val Pro
                245                 250                 255
Val Gln Pro Glu Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Asp Arg
            260                 265                 270
Asn Asp Asp Val Lys Cys Leu Cys Cys Asp Gly Gly Leu Arg Cys Trp
        275                 280                 285
Glu Pro Gly Asp Asp Pro Trp Ile Glu His Ala Lys Trp Phe Pro Arg
    290                 295                 300
Cys Glu Phe Leu Ile Arg Met Lys Gly Gln Glu Phe Val Asp Glu Ile
305                 310                 315                 320
Gln Ala Arg Tyr Pro His Leu Leu Glu Gln Leu Leu Ser Thr Ser Asp
                325                 330                 335
Thr Pro Gly Glu Glu Asn Ala Asp Pro Thr Glu Thr Val Val His Phe
            340                 345                 350
Gly Pro Gly Glu Ser Ser Lys Asp Val Val Met Met Ser Thr Pro Val
        355                 360                 365
Val Lys Ala Ala Leu Glu Met Gly Phe Ser Arg Ser Leu Val Arg Gln
    370                 375                 380
Thr Val Gln Arg Gln Ile Leu Ala Thr Gly Glu Asn Tyr Arg Thr Val
385                 390                 395                 400
Asn Asp Ile Val Ser Val Leu Leu Asn Ala Glu Asp Glu Arg Arg Glu
                405                 410                 415
```

```
Glu Glu Lys Glu Arg Gln Thr Glu Glu Met Ala Ser Gly Asp Leu Ser
            420                 425                 430
Leu Ile Arg Lys Asn Arg Met Ala Leu Phe Gln Gln Leu Thr His Val
        435                 440                 445
Leu Pro Ile Leu Asp Asn Leu Leu Glu Ala Ser Val Ile Thr Lys Gln
    450                 455                 460
Glu His Asp Ile Ile Arg Gln Lys Thr Gln Ile Pro Leu Gln Ala Arg
465                 470                 475                 480
Glu Leu Ile Asp Thr Val Leu Val Lys Gly Asn Ala Ala Ala Asn Ile
                485                 490                 495
Phe Lys Asn Ser Leu Lys Gly Ile Asp Ser Thr Leu Tyr Glu Asn Leu
            500                 505                 510
Phe Val Glu Lys Asn Met Lys Tyr Ile Pro Thr Glu Asp Val Ser Gly
        515                 520                 525
Leu Ser Leu Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Arg Thr Cys
    530                 535                 540
Lys Val Cys Met Asp Arg Glu Val Ser Ile Val Phe Ile Pro Cys Gly
545                 550                 555                 560
His Leu Val Val Cys Gln Glu Cys Ala Pro Ser Leu Arg Lys Cys Pro
                565                 570                 575
Ile Cys Arg Gly Thr Ile Lys Gly Thr Val Arg Thr Phe Leu Ser
            580                 585                 590
```

<210> 230
<211> 6669
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1)...(6669)
<223> n=a,t,c, or g

<400> 230

```
ttgctctgtc acccagtttg gagtgcagtt atgcagtctc acactgcaag ctctgcctca 60
tgggctcaag tgaacctcct gcctcagcct ctcaagtagc tgggaccaca ggcaggtgcc 120
accatgtctg gctaattttt gagtttcttt gtagagatgg tgttttgcca agtcacccag 180
tttgaggctg gtctcaaaca cctgggctca agcaatccat ctacctcagc ctcccaaagt 240
gctgggatta caggagtgag ccatggcatg aggccttgtg gggtgtctct tttaaatgaa 300
agcatactct gtttacgtat ttgatatgaa ggaatatcct tcctttccac aaagacaaaa 360
attatcctat ttttctcaaa acatatgtcc tttttctcta cttttcattt ttgttacttt 420
tgatggacac atgtgttaca ttgatttcac tttctcataa ttctgctgta agaaaaacaa 480
tagtgccagt tcaatgacaa atagcaacag tctgttattg ctagactgtt actgttagtg 540
gagactacca gaacagtcag tcccagtgtc agggaatcaa agagaacatg ttccctctct 600
aaagggcaca gctgctgctc agctttagct gattgctgcc ctgcaggact ataggcccag 660
tgttgctaga tcttttgatg tttcaagaga agcttggaat ctagaatgtg atgggaagtc 720
tcttacattt aaacatgttg gcaattaatg gtaagattta aaaatactgt ggtccaagaa 780
aaaaatggat ttggaaactg gattaaattc aaatgaggca tgcagattaa tctacagcat 840
ggtacaatgt gaattttctg gtttctttaa ttgcactgta attaggtaag atgttagctt 900
tggggaagct aagtgcagag tatgcagaaa ctattatttt tgtaagtttt ctctaagtat 960
aaataaattt caaaataaaa ataaaaactt agtaaagaac tataatgcaa ttctatgtaa 1020
gccaaacata atatgtcttc cagtttgaaa cctctgggtt ttattttatt ttattttatt 1080
tttgagacag agtcttgctg tgtcacccag gctggagtgt agtggcacta tttcggccca 1140
ctgcaacctc cacctcccag gctcaaatga ttctcctgcc tcagcctccg gagtagctgg 1200
gattacaggc gcgtaccacc acacccagct aatttttgta tttttagtag agatggggtt 1260
tcaccatttt ggccaggctg gttttgaact cctgacctca agtgatccac ttgtcttggc 1320
ctcccaaaat gctgggatta caggcgtgag ccactgcacc aggcagaggc ctctgttttt 1380
```

tatctctttt tggcctctac agtgcctagt aaagcacctg atacatggta aacgatcagt 1440
aattactagt actctatttt ggagaaaatg attttttaaa aagtcattgt gttccatcca 1500
tgagtcgttt gagttttaaa actgtctttt tgtttgtttt tgaacaggtt tacaaaggag 1560
gaaaacgact tcttctagat tttttttca gtttcttcta taaatcaaaa catctcaaaa 1620
tggagaccta aaatccttaa agggacttag tctaatctcg ggaggtagtt ttgtgcatgg 1680
gtaaacaaat taagtattaa ctggtgtttt actatccaaa gaatgctaat tttataaaca 1740
tgatcgagtt atataaggta taccataatg agtttgattt tgaatttgat ttgtggaaat 1800
aaaggaaaag tgattctagc tggggcatat tgttaaagca tttttttcag agttggccag 1860
gcagtctcct actggcacat tctcccatta tgtagaatag aaatagtacc tgtgtttggg 1920
aaagatttta aaatgagtga cagttatttg gaacaaagag ctaataatca atccactgca 1980
aattaaagaa acatgcagat gaaagttttg acacattaaa atacttctac agtgacaaag 2040
aaaaatcaag aacaaagctt tttgatatgt gcaacaaatt tagaggaagt aaaaagataa 2100
atgtgatgat tggtcaagaa attatccagt tatttacaag gccactgata ttttaaacgt 2160
ccaaaagttt gtttaaatgg gctgttaccg ctgagaatga tgaggatgag aatgatggtt 2220
gaaggttaca ttttaggaaa tgaagaaact tagaaaatta atataaagac agtgatgaat 2280
acaaagaaga tttttataac aatgtgtaaa atttttggcc agggaaagga atattgaagt 2340
tagatacaat tacttacctt tgagggaaat aattgttggt aatgagatgt gatgtttctc 2400
ctgccacctg gaaacaaagc attgaagtct gcagttgaaa agcccaacgt ctgtgagatc 2460
caggaaacca tgcttgcaaa ccactggtaa aaaaaaaaaa aaaaaaaaaa aaagccacag 2520
tgacttgctt attggtcatt gctagtatta tcgactcaga acctctttac taatggctag 2580
taaatcataa ttgagaaatt ctgaattttg acaaggtctc tgctgttgaa atggtaaatt 2640
tattattttt tttgtcatga taaattctgg ttcaaggtat gctatccatg aaataatttc 2700
tgaccaaaac taaattgatg caatttgatt atccatctta gcctacagat ggcatctggt 2760
aacttttgac tgttttaaaa aataaatcca ctatcagagt agatttgatg ttggcttcag 2820
aaacatttag aaaaacaaaa gttcaaaaat gttttcagga ggtgataagt tgaataactc 2880
tacaatgtta gttctttgag ggggacaaaa aatttaaaat ctttgaaagg tcttatttta 2940
cagccatatc taaattatct taagaaaatt tttaacaaag ggaatgaaat atatatcatg 3000
attctgtttt tccaaaagta acctgaatat agcaatgaag ttcagttttg ttattggtag 3060
tttgggcaga gtctcttttt gcagcacctg ttgtctacca taattacaga ggacatttcc 3120
atgttctagc caagtatact attagaataa aaaaacttaa cattgagttg cttcaacagc 3180
atgaaactga gtccaaaaga ccaaatgaac aaacacatta atctctgatt atttatttta 3240
aatagaatat ttaattgtgt aagatctaat agtatcatta tacttaagca atcatattcc 3300
tgatgatcta tgggaaataa ctattattta attaatattg aaaccaggtt ttaagatgtg 3360
ttagccagtc ctgttactag taaatctctt tatttggaga gaaattttag attgttttgt 3420
tctccttatt agaaggattg tagaaagaaa aaaatgacta attggagaaa aattggggat 3480
atatcatatt tcactgaatt caaaatgtct tcagttgtaa atcttaccat tattttacgt 3540
acctctaaga aataaaagtg cttctaatta aaatatgatg tcattaatta tgaaatactt 3600
cttgataaca gaagttttaa aatagccatc ttagaatcag tgaaatatgg taatgtatta 3660
ttttcctcct ttgagtnagg tcttgtgctt tttnttcctg gccactaaat ntcaccatnt 3720
ccaanaagca aantaaacct attctgaata tttttgctgt gaaacacttg ncagcagagc 3780
tttcccncca tgnnagaagc ttcatgagtc acacattaca tctttgggtt gattgaatgc 3840
cactgaaaca tttctagtag cctggagnag ttgacctacc tgtggagatg cctgccatta 3900
aatggcatcc tgatggctta atacacatca ctcttctgtg nagggtttta attttcaaca 3960
cagcttactc tgtagcatca tgtttacatt gtatgtataa agattatacn aaggtgcaat 4020
tgtgtatttc ttccttaaaa tgtatcagta taggatttag aatctccatg ttgaaactct 4080
aaatgcatag aaataaaaat aataaaaaat ttttcatttt ggcttttcag cctagtatta 4140
aaactgataa aagcaaagcc atgcacaaaa ctacctccct agagaaaggc tagtcccttt 4200
tcttccccat tcatttcatt atgaacatag tagaaaacag catattctta tcaaatttga 4260
tgaaaagcgc caacacgttt gaactgaaat acgacttgtc atgtgaactg taccgaatgt 4320
ctacgtattc cacttttcct gctggggttc ctgtctcaga aaggagtctt gctcgtgctg 4380
gtttctatta cactggtgtg aatgacaagg tcaaatgctt ctgttgtggc ctgatgctgg 4440
ataactggaa aagaggagac agtcctactg aaaagcataa aaagttgtat cctagctgca 4500
gattcgttca gagtctaaat tccgttaaca acttggaagc tacctctcag cctacttttc 4560
cttcttcagt aacacattcc acacactcat tacttccggg tacagaaaac agtggatatt 4620
tccgtggctc ttattcaaac tctccatcaa atcctgtaaa ctccagagca aatcaagaat 4680
tttctgcctt gatgagaagt tcctacccct gtccaatgaa taacgaaaat gccagattac 4740
ttacttttca gacatggcca ttgacttttc tgtcgccaac agatctggca cgagcaggct 4800
tttactacat aggacctgga gacagagtgg cttgctttgc ctgtggtgga aaattgagca 4860

attgggaacc gaaggataat gctatgtcag aacacctgag acattttccc aaatgcccat 4920
ttatagaaaa tcagcttcaa gacacttcaa gatacacagt ttctaatctg agcatgcaga 4980
cacatgcagc ccgctttaaa acattcttta actggccctc tagtgttcta gttaatcctg 5040
agcagcttgc aagtgcgggt ttttattatg tgggtaacag tgatgatgtc aaatgctttt 5100
gctgtgatgg tggactcagg tgttgggaat ctggagatga tccatgggtt caacatgcca 5160
agtggtttcc aaggtgtgag tacttgataa gaattaaagg acaggagttc atccgtcaag 5220
ttcaagccag ttaccctcat ctacttgaac agctgctatc cacatcagac agcccaggag 5280
atgaaaatgc agagtcatca attatccatt ttgaacctgg agaagaccat tcagaagatg 5340
caatcatgat gaatactcct gtgattaatg ctgccgtgga aatgggcttt agtagaagcc 5400
tggtaaaaca gacagttcag agaaaaatcc tagcaactgg agagaattat agactagtca 5460
atgatcttgt gttagactta ctcaatgcag aagatgaaat aagggaagag gagagagaaa 5520
gagcaactga ggaaaaagaa tcaaatgatt tattattaat ccggaagaat agaatggcac 5580
tttttcaaca tttgacttgt gtaattccaa tcctggatag tctactaact gccggaatta 5640
ttaatgaaca agaacatgat gttattaaac agaagacaca gacgtcttta caagcaagag 5700
aactgattga tacgatttta gtaaaaggaa atattgcagc cactgtattc agaaactctc 5760
tgcaagaagc tgaagctgtg ttatatgagc atttatttgt gcaacaggac ataaaatata 5820
ttcccacaga agatgtttca gatctaccag tggaagaaca attgcggaga ctacaagaag 5880
aaagaacatg taaagtgtgt atggacaaag aagtgtccat agtgtttatt ccttgtggtc 5940
atctagtagt atgcaaagat tgtgctcctt ctttaagaaa gtgtcctatt tgtaggagta 6000
caatcaaggg tacagttcgt acatttcttt catgaagaag aaccaaaaca tcgtctaaac 6060
tttagaatta atttattaaa tgtattataa ctttaacttt tatcctaatt tggtttcctt 6120
aaaatttttа tttatttaca actcaaaaaa cattgttttg tgtaacatat ttatatatgt 6180
atctaaacca tatgaacata tatttttag aaactaagag aatgataggc ttttgttctt 6240
atgaacgaaa aagaggtagc actacaaaca caatattcaa tcaaaatttc agcattattg 6300
aaattgtaag tgaagtaaaa cttaagatat ttgagttaac ctttaagaat tttaaatatt 6360
ttggcattgt actaataccg ggaacatgaa gccaggtgtg gtggtatgtg cctgtagtcc 6420
caggctgagg caagagaatt acttgagccc aggagtttga atccatcctg ggcagcatac 6480
tgagaccctg cctttaaaaa caaacagaac aaaaacaaaa caccagggac acatttctct 6540
gtctttttg atcagtgtcc tatacatcga aggtgtgcat atatgttgaa tcacatttta 6600
gggacatggt gtttttataa agaattctgt gagaaaaaat ttaataaagc aaccaaaaaa 6660
aaaaaaaaa 6669

<210> 231
<211> 3000
<212> DNA
<213> Homo sapiens

<400> 231
ttgcaggtac ttagaatttt tcctgagcca ccctctagag ggcagtgtta catatatatc 60
tgtaattatc cagttacaac aaaaaaaggg ctctcattca tgcatgaaaa tcagaaatat 120
ttcatactct taaagaacac attggaacca atattatgat taaaacatat tttgctaagc 180
aaagagatat taaaaattaa ttcattaaca ttctgaacat tttttaactt gtaaaaacaa 240
ctttgatgcc ttgaatatat aatgattcat tataacaatt atgcatagat tttaataatc 300
tgcatatttt atgctttcat gtttttccta attaatgatt tgacatggtt aataattata 360
atatattctg catcacagtt tacatattta tgtaaaataa gcatttaaaa attattagtt 420
ttattctgcc tgcttaaata ttactttcct caaaaagaga aaacaaaaat gctagatttt 480
actttatgac ttgaatgatg tggtaatgtc gaactctagt atttagaatt agaatgtttc 540
ttagcggtcg tgtagttatt tttatgtcat aagtggataa tttgttagct cctataacaa 600
aagtctgttg cttgtgtttc acattttgga tttcctaata taatgttctc tttttagaaa 660
aggtggacaa gtcctatttt caagagaaga tgacttttaa cagttttgaa ggatctaaaa 720
cttgtgtacc tgcagacatc aataaggaag aagaatttgt agaagagttt aatagattaa 780
aaacttttgc taattttcca agtggtagtc ctgtttcagc atcaacactg gcacgagcag 840
ggtttcttta tactggtgaa ggagataccg tgcggtgctt tagttgtcat gcagctgtag 900
atagatggca atatggagac tcagcagttg gaagacacag gaaagtatcc ccaaattgca 960
gatttatcaa cggcttttat cttgaaaata gtgccacgca gtctacaaat tctggtatcc 1020
agaatggtca gtacaaagtt gaaaactatc tgggaagcag agatcatttt gccttagaca 1080

ggccatctga gacacatgca gactatcttt tgagaactgg gcaggttgta gatatatcag 1140
acaccatata cccgaggaac cctgccatgt attgtgaaga agctagatta aagtcctttc 1200
agaactggcc agactatgct cacctaaccc caagagagtt agcaagtgct ggactctact 1260
acacaggtat tggtgaccaa gtgcagtgct tttgttgtgg tggaaaactg aaaaattggg 1320
aaccttgtga tcgtgcctgg tcagaacaca ggcgacactt tcctaattgc ttctttgttt 1380
tgggccggaa tcttaatatt cgaagtgaat ctgatgctgt gagttctgat aggaatttcc 1440
caaattcaac aaatcttcca agaaatccat ccatggcaga ttatgaagca cggatcttta 1500
cttttgggac atggatatac tcagttaaca aggagcagct tgcaagagct ggattttatg 1560
ctttaggtga aggtgataaa gtaaagtgct ttcactgtgg aggagggcta actgattgga 1620
agcccagtga agacccttgg gaacaacatg ctaaatggta tccagggtgc aaatatctgt 1680
tagaacagaa gggacaagaa tatataaaca atattcattt aactcattca cttgaggagt 1740
gtctggtaag aactactgag aaaacaccat cactaactag aagaattgat gataccatct 1800
tccaaaatcc tatggtacaa gaagctatac gaatggggtt cagtttcaag gacattaaga 1860
aaataatgga ggaaaaaatt cagatatctg ggagcaacta taaatcactt gaggttctgg 1920
ttgcagatct agtgaatgct cagaaagaca gtatgcaaga tgagtcaagt cagacttcat 1980
tacagaaaga gattagtact gaagagcagc taaggcgcct gcaagaggag aagctttgca 2040
aaatctgtat ggatagaaat attgctatcg tttttgttcc ttgtggacat ctagtcactt 2100
gtaaacaatg tgctgaagca gttgacaagt gtcccatgtg ctacacagtc attactttca 2160
agcaaaaaat ttttatgtct taatctaact ctatagtagg catgttatgt tgttcttatt 2220
accctgattg aatgtgtgat gtgaactgac tttaagtaat caggattgaa ttccattagc 2280
atttgctacc aagtaggaaa aaaaatgtac atggcagtgt tttagttggc aatataatct 2340
ttgaatttct tgatttttca gggtattagc tgtattatcc atttttttta ctgttattta 2400
attgaaacca tagactaaga ataagaagca tcatactata actgaacaca atgtgtattc 2460
atagtatact gatttaattt ctaagtgtaa gtgaattaat catctggatt ttttattctt 2520
ttcagatagg cttaacaaat ggagctttct gtatataaat gtggagatta gagttaatct 2580
ccccaatcac ataatttgtt ttgtgtgaaa aaggaataaa ttgttccatg ctggtggaaa 2640
gatagagatt gtttttagag gttggttgtt gtgttttagg attctgtcca ttttctttta 2700
aagttataaa cacgtacttg tgcgaattat ttttttaaag tgatttgcca tttttgaaag 2760
cgtatttaat gatagaatac tatcgagcca acatgtactg acatggaaag atgtcaaaga 2820
tatgttaagt gtaaaatgca agtggcaaaa cactatgtat agtctgagcc agatcaaagt 2880
atgtatgttt ttaatatgca tagaacaaaa gatttggaaa gatatacacc aaactgttaa 2940
atgtggtttc tcttcgggga ggggggggatt gggggagggg ccccataggg gttttatagg 3000